



RAPID SEQUENCE TANDEM TRANSPLANT FOR CHILDREN WITH
METASTATIC SARCOMA
Adams, R.H.1; Smith, L.1; Grier, H.E.3; Bunin, N.J.2; Gorlin, J.B.3;
Diller, L.3; Grupp, S.A.2 1. University of Utah, Salt Lake City, UT; 2.
Children’s Hospital of Philadelphia, Philadelphia, PA; 3. Dana Farber
Cancer Institute, Boston, MA
Patients with metastatic sarcoma have a poor prognosis, with
disease-free survival (DFS) of 10-25%. We have piloted an inten-
sive protocol with 5 cycles of induction chemotherapy, followed
by tandem stem cell transplant, 4-6 weeks apart. Stem cell collec-
tion was performed after the third or fourth cycle of induction
chemotherapy. Local control was managed with either surgery or
local radiation therapy.
Results: 28 patients were enrolled: 16 patients-Ewing′s sarcoma
(ES); 8 patients- rhabdomyosarcoma (RMS); 2 patients-undiffer-
entiated sarcoma (UDS); 2 patients-synovial sarcoma (SS). Except
for 3 ES early in therapy, all other patients are > 1 year beyond
transplant. Mean follow-up is 32.5 months after completion of the
second transplant. 25/28 patients demonstrated adequate initial
response, qualifying to proceed to transplant. Three patients
showed evidence of progressive disease through the induction
cycles and did not proceed. All patients undergoing transplant tol-
erated the first transplant without undue toxicity. One patient
with RMS developed progressive disease after HD#1, and did not
proceed to HD#2. 24/28 patients proceeded to the second trans-
plant within 42 days. Engraftment occurred rapidly in both trans-
plants with a median time to neutrophil engraftment of 11 days
after HD #1 and 12 days after HD#2. DFS was 30% at 3 years for
all patients (90%CI, 14-46%) (n=28). Patients with ES had a sig-
niﬁcantly better outcome compared with non-ES patients (56%vs
8% p<.013).
Conclusion: Using an intensive tandem transplant approach to
patients with metastatic sarcomas is feasible and well tolerated,
even in very young children. Patients with ES have a signiﬁcantly
better outcome than patients with non-ES.
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TREATMENT WITH HIGH DOSE PULSE STEROID IN CHRONIC GRAFT-
VERSUS-HOST DISEASE
Akpek, G.; Lee, S.; Anders, V.; Ratkoff, D.J.; Vogelsang, G.B. The
Johns Hopkins University School of Medicine, Baltimore, MD
Corticosteroids remain essential for the initial treatment of
active chronic graft-versus-host disease (cGVHD). However, the
optimum dose and schedule is unknown. We have reviewed our
results on 41 patients treated with a high-dose pulse steroid regi-
men (PST) at a dose of 10 mg/kg/day for 4 consecutive days. After
4 days, all patients received a course of systemic immunosuppres-
sive therapy. Thirty-four patients (85%) had failed a median of 2
(1-5) treatment regimens prior to the PST. Twenty-two of 41
(54%) patients evaluable for response showed a major improve-
ment in all cGVHD manifestations including softening of the
skin, increased range of motion, and improved performance status
while 9 (22%) showed a minor improvement, deﬁned as improve-
ment in cGVHD in some sites but not in all. According to uni-
variate analysis, only the donor type was associated with response.
Twenty-four (86%) patients who had marrow transplant from a
sibling donor including one antigen mismatch and 7 of 13 (54%)
patients who had matched unrelated donor or allogeneic blood
stem cell transplant responded to PST (p=0.049). Three patients
developed acute hypertension (n=1) and infection (n=3) following
therapy. Eighteen (58%) patients who responded to PST and a
subsequent immunosuppressive regimen did not progress after a
median follow-up of 25 months (0.3-52). For the PST-responsive
group, the median progression free survival (PFS) was 46 months.
Univariate analysis revealed that the dose of prednisone that
patients receiving prior to PST (<0.5 vs. ≥0.5 mg/kg) [Hazard
Ratio (HR)=4.8, p=0.004] and the type of onset of cGVHD (pro-
gressive vs. denovo/quiescent) (HR=3.5, p=0.08) were associated
with PFS. The 2-year probability of PFS was 77% (50-91%) and
75% (31-93%) for patients who had major and minor improve-
ment after PST, respectively. Our results indicate that PST is an
effective and well-tolerated regimen for controlling active
cGVHD in patients who failed on previous therapies.
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HIGH-DOSE SAMARIUM WITH AUTOLOGOUS STEM CELL SUPPORT, A
NOVEL TREATMENT OF METASTATIC OR LOCALLY RECURRING
OSTEOSARCOMA AND OSTEOBLASTIC BONE METASTASES
Anderson, P.M.; Wiseman, G.A. Mayo Clinic, Rochester, MN
We performed a phase I dose escalation trial using peripheral
blood progenitor cell support following high-dose 153Sm-
EDTMP in patients with advanced osteosarcoma or osteoblastic
bone metastases (N=6); we also report on 5 additional patients
after the completion of the study. Total body radioactivity was
monitored on day 13 after 153Sm-EDTMP infusion and was
always <3600 microCi, a safe level for stem cell infusion. Autolo-
gous peripheral blood progenitor cells were given on day 14 after
153Sm-EDTMP. Patients were monitored as outpatients. Trans-
fusion support was required but non-hematologic side effects were
not seen until the maximally tolerated dose (MTD)was reached at
30 mCi/kg. At this dose hypocalcemia was seen with the 30 min
153Sm-EDTMP infusion. Lung lesions did not tend to respond
to this therapy; responses seemed “bone-specific”. Two patients
with osteosarcoma had major responses at 6 mCi/kg. One received
an estimated dose of 22,000 cGy to an osteoblastic lesion of the
left mandible and remains in CR without additional bone metas-
tases >28 months after 153Sm-EDTMP. Another osteogenic sar-
coma patient at the 6.0 mCi/kg level had an estimated absorbed
radiation dose of 19,300 cGy to a lesion in the left humerus; this
patient remains in CR >18 months. At 30 mCi/kg another
osteosarcoma patient had dose estimates of 23,800 and 24,100
cGy in two skull metastases. Representative scintographic images
will be presented.
Thus, by using autologous peripheral blood progenitor cell sup-
port, high-dose 153Sm-EDTMP (with or without external beam
radiation) may provide a new means to more effectively provide
very high and potentially curative doses of radiation to solid
tumors involving bone, especially osteosarcoma. A phase II study
of 153Sm-EDTMP at 30 mCi/kg in locally recurring and
metastatic osteosarcoma is planned.
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THE EFFECTS OF TOTAL OUTPATIENT AUTOLOGOUS STEM CELL
TRANSPLANTATION FOR BREAST CANCER ON RESOURCE UTILIZATION
Andrey, J.1; Burian, C.1; Ferran, K.2; Hollenbach, K.2; McMillan, R.1;
Miller, W.1; Meisenberg, B.3; Mason, J.1 1. Scripps Clinic Blood and
Marrow Transplantation Program, La Jolla, CA; 2. University of Cali-
fornia San Diego, Division of Family and Preventive Medicine, San
Diego, CA; 3. Greenbaum Cancer Center, University of Maryland,
Baltimore, MD
Introduction: 48 patients who received autologous stem cell
transplantation for breast cancer at Scripps Clinic between June
1997 and February 1999 participated in a longitudinal study of
total outpatient transplantation. This abstract focuses on outcome
measures and reasons and rates of readmission.
Patients: 45/48 had sufﬁcient data for analysis. Inpatient status
was reserved for patients without an available caregiver. Local
accomodations were arranged for patients who desired outpatient
therapy yet lived greater than 30 minutes from the BMT unit.
Terminology: Graduation Date = date at which care was
returned to the referring oncologist; Total Program Days = num-
ber of days between the ﬁrst date of high-dose chemotherapy and
the graduation date; Outpatient days also included days between
inpatient discharge date and graduation date.
Results: For all 45 patients, the average number of total program
days was 36. The average total number of days of antibiotic use
was 12. There was no regimen or disease related mortality while
they were on the program. 35/45 patients on study (77%) were
treated as outpatients. 11/35 outpatients (31%) had to be readmit-
ted; 1 for social reasons, 1 for neutropenic fever, 2 for bacteremia,
and 7 for regimen-related toxicity. Only 1/21 outpatients who
developed neutropenic fever was admitted. Even with readmis-
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sions, the outpatient group had signiﬁcantly fewer (p = 0.02) aver-
age total program days (34) than the initial inpatient group (42).
The readmitted outpatient group had signiﬁcantly fewer (p = 0.03)
average inpatient days (8) than the initial inpatient group (14).
Antibiotic usage patterns were not signiﬁcantly different between
groups.
Discussion: Patients who began their transplantation therapy as
outpatients had less average total program days and inpatient days
than their inpatient counterparts. Neutropenic fever in this popu-
lation could be effectively managed on an outpatient basis. Inter-
group comparisons of economics and quality of life are underway.
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TRASTUZUMAB FOLLOWING HIGH DOSE CHEMOTHERAPY WITH STEM
CELL RESCUE FOR PATIENTS WITH METASTATIC BREAST CANCER
Avigan, D.1; Borges, V.1; Richardson, P.2; Lazarus, H.3; Baynes, R.4;
Bihraray, R.5; Hurd, D.6; Holland, K.7; Raptis, A.8; Pecora, A.9 1. Beth
Israel Deaconess Medical Center, Boston, MA; 2. Dana Farber Cancer
Institute, Boston, MA; 3. University of Ireland Cancer Center, Cleve-
land, OH; 4. Karmanos Cancer Institute, Detroit, MI; 5. Marshﬁeld
Cancer Center, Marshfield, WI; 6. Comprehensive Cancer Center of
Wake Forest University, Winston-Salem, NC; 7. The Blood and Mar-
row Transplant Group of Georgia, Atlanta, GA; 8. Rush Presbyterian
St. Luke’s Medical Center, Chicago, IL; 9. Hackensack Unviersity Med-
ical Center, Hackensack, NJ
The use of high dose chemotherapy with stem cell rescue for
treatment of metastatic breast cancer has been effective in gener-
ating high rates of response but the large majority of patients sub-
sequently relapse from sites of minimal residual disease. A focus of
investigation has been the incorporation of immunotherapeutic
strategies in an effort to eliminate persistent chemotherapy resist-
ant disease. In the present study, we are examining the impact of
Trastuzumab therapy given weekly for 1 year following stem cell
transplantation. 15 patients, who demonstrated response to pri-
mary chemotherapy for metastatic disease, have been enrolled
between 6/99 and 7/00. At time of transplant, 6 patients had vis-
ceral disease involving lung and/or liver, 2 patients had bone only
disease and 3 patients achieved complete remission in response to
pre-transplant induction chemotherapy. The high dose
chemotherapy regimen consisted of cyclophosphamide, thiotepa,
or carboplatin (STAMP 5) for 13 patients and cyclophosphamide,
BCNU, cisplatin (STAMP 1) for 2 patients. To date, 13 patients
have initiated Trastuzumab therapy at a median of 40 days follow-
ing stem cell infusion. No treatment related mortality has been
observed. Trastuzumab was well tolerated with no clinically sig-
niﬁcant treatment related toxicity noted. Transient anemia, lym-
phopenia and leukopenia was seen in 2, 3 and 3 patients respec-
tively. No signiﬁcant cardiac events were noted and the median
ejection fraction remained stable following transplant and after 1
and 3 months of Trastuzumab therapy. Of 11 evaluable patients, 7
patients remain free of disease progression with a median of 7
months of follow up and 4 patients have experienced disease pro-
gression at a median of 3.5 months following initiation of
Trastuzumab. The use of Trastuzumab following high dose
hemotherapy has been well tolerated without significant cardiac
toxicity. Longer follow up is needed to assess the impact of this
treatment strategy on progression free survival.
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SUCCESSFUL ENGRAFTMENT WITH DISEASE RESPONSE FOLLOWING
SIBLING ALLOGRAFT WITH REDUCED CONDITIONING,T-CELL DEPLE-
TION AND DELAYED INCREMENTAL DLI IN CML AND MM
Bardy, P.; Grigg, A.P.; Szer, J.; Roberts, A.; Schwarer, A.P.;
Spencer, A.; Arthur, C.; Bradstock, K.; Mrongovius, R.; Hughes, T.
The Australasian Leukaemia and Lymphoma Study Group, Mel-
bourne, Australia
Stable allogeneic engraftment is achievable following reduced
conditioning. We are investigating the engraftment kinetics and
Graft versus Host Disease (GVHD) incidence following Fludara-
bine(Flu) and Melphalan(Mel) conditioning with T depletion of
stem cell grafts from matched sibling donors in patients with
CML and MM . Twenty three patients (17 MM and 6 CML)
median age 53yrs have been enrolled in two cohorts.Cohort I
received Flu 150mg/m2, Mel 140mg/m2 and at least 4x106
CD34+/kg Isolex 300i separated ﬁlgrastim mobilised blood cells.
Cyclosporin 3mg/kg/day IV started on day -5. Four incremental
doses of DLI (3x106/kg to 1x108/kg CD3+ cells) were scheduled at
2,4,6 and 8 mths. Cohort II received a lower Mel dose
(100mg/m2) and higher day zero T-cell dose (1x106 /kg CD3+
cells). Eleven patients were enrolled to Cohort I, twelve to cohort
II. Mobilisation failed in 3 donors. 20/23 patients were transplant-
ed with a median 4.2x106 CD34 cells/kg. 17/20 patients are
analysable. Prompt hematopoietic recovery occurred in 16/17.
9/17 are analysable beyond 6mths. 5/17 died prior to 6mths and
3/17 are alive with <6mths follow up. Two of 5 early deaths fol-
lowed graft failure in patients with MM hence the protocol modi-
fications. Analysis of sorted myeloid (CD13+) and lymphoid
(CD3+) cells has shown high levels of donor myeloid and lym-
phoid chimerism beyond 6mths in 6/9,low levels in 2/9 and 1/9
has mixed chimerism. Acute GVHD has occurred in 6/17, three
prior to ( patients in cohort II one dying of Grade 4 GVHD) and
three following DLI ( all steroid responsive). High level donor T-
cell chimerism has been associated with disease response however
three patients progressed ( 2 MM,1 CML) following initial
responses. This study using a uniform protocol of T-cell depletion
and delayed T-cell add-back confirms that stable engraftment
with disease response is achievable using this strategy.
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ATG DURING CONDITIONING FOR MUD BMT IN ADULTS: PHARMA-
COKINETICS AND IMMUNE RECONSTITUTION
Baurmann, H.1; Baumann, P.1; Bonnefoy-Berard, N.2; Revillard, J.2;
Schwerdtfeger, R.1 1. Deutsche Klinik für Diagnostik, Wiesbaden, Ger-
many; 2. CERVI Inserm U503, Lyon, France
We prospectively studied the pharmacokinetics of ATG and
immune reconstitution in 37 adult recipients of MUD BMT. 18
males, 19 females, median age 39 years, were grafted with unmanip-
ulated bone marrow after standard conditioning complemented by
4 doses of Thymoglobuline(R) 2.5 mg/kg BW days -5 to -2. Resid-
ual serum rabbit IgG (RIG) (ELISA), speciﬁc anti-lymphocyte-anti-
bodies (ATGeq) (FACS) and lymphocyte subpopulations (FACS)
were monitored serially with a median observation time of 526 days.
Serum RIG peaks day 0 at a median of 65 µg/mL, and is measured
at 10 µg/mL week 8. ATGeq rises to a median of 7.4 µg/mL and is
detected at 0.3 µg/mL week 4 after BMT. Rapid and profound lym-
phocyte depletion is seen during ATG infusion. Whereas NK-cell
restoration is achieved within 4 weeks, T- and B-cells are deeply
and durably depressed. A first wave of CD3- and CD8-cells
emerges around day 100 (median of 114 and 65 /µL), a second
around month 9 when CD3- and CD8-cells reach twice those after
fully in vitro T-cell-depleted (TCD) BMT (median of 952 and
518/µL) (1). CD4-cell reconstitution is particularly impaired (35/µL
day 100) and parallels that after TCD until month 9 when counts
increase to a median of 194/µL. CD4/CD45RA/CD45R0-ratio at
that timepoint is still as low as after TCD (0.08) and only increases
to a relative maximum of 1.3 more than 1.5 years after BMT. At day
100 a median of 77% of CD3-positive and 23% of CD3-negative
cells are coated by RIG. Conclusions: Residual ATG circulates for
weeks after grafting. Lymphocytes covered with ATG can be
detected even longer. During the first year T-cells reconstitute
almost completely by peripheral expansion, including CD4-cells. In
adults a limited thymic rebound is only seen during the second year
after MUD BMT and ATG.
(1) Blood 93, 1999: 467.
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INVOLVED FIELD RADIOTHERAPY (IF-RT) AND BVAC WITH AUTOLO-
GOUS STEM CELL TRANSPLANTATION FOR REFRACTORY OR
RELAPSED NHL
Begaz, T.; Scigliano, E.; Fruchtman, S.; Shank, B.; Mandell, L.; Isola,
L. Mount Sinai Medical Center, New York, NY
Several HDC regimens with autologous SCT have been shown
to be effective for NHL in chemosensitive relapse and CR2.
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Between 8/87 and 4/99, 71 patients with primary refractory or
relapsed NHL received BCNU 600 mg/m2, VP16 400 mg/m2 x 4,
Ara-C 3 g/m2 x 8, cyclophosphamide 90 mg/kg and autologous
SCT. Patients with adenopathy >2.5 cm received IF-RT (2000
cGy) to bulk disease. Our patients were a particularly poor risk
group. Median age was 52 (21%>60 year old), 55% had induction
failure, 7% CR at time of SCT, 56% refractory disease, 73% ≥2
regimens before SCT and 84% intermediate or high grade NHL.
Thirty-two (45%) patients received IF-RT. There was no differ-
ence in high-risk patients and those receiving >1 prior regimen
between the groups that received IF-RT and no IF-RT. Median
follow-up is 699 days. Transplant mortality (d100) was 25%
(mostly VOD or pulmonary) and not inﬂuenced by age±60. Five
year OS and EFS were 44%±13% and 35%±13%. Age ≥60
adversely influenced OS (p=.023) and EFS (p=.006). Histology,
disease status at transplant (ABMTR defined), number of regi-
mens and CR1 duration didn’t affect OS or EFS. Patients in IF-
RT group had improved OS 49%±21% vs. 33%±17% (p<.015)
and marginally better EFS 39%±20% vs. 30%±15% (p=.06).
Overall relapse rate in 53 evaluable patients was 40%. Time to lat-
est relapse was 2048 days (5.6 years). BVAC/IF-RT was highly
effective even in patients deemed poor candidates for autologous
SCT. Toxicities of BVAC IF-RT limit its application for patients
with liver and lung co-morbidities and may not justify its use in
patients with good prognostic indicators i.e. ﬁrst chemosensitive
relapse, low LDH and low tumor burden. Further studies using
BVAC IF-RT for patients with poor prognostic indicators seem
warranted.
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HEMATOPOIETIC CELL TRANSPLANTATION FOR AUTOIMMUNE DIS-
EASES: STUDIES IN NOD MICE
Beilhack, G.F.; Shizuru, J.A. Stanford University, Department of
Medicine, Division of Bone Marrow Transplantation Room H1353
MC5623, Stanford, CA 94305, CA
It has been shown that transplantation of MHC-mismatched
allogeneic whole bone marrow cells can block the pathogenesis of
autoimmune diseases. However, little data exist that demonstrate
the effects of clinically relevant hematopoietic cell grafts on
autoimmune disease outcome. These grafts include
autologous/syngeneic, haploidentical and MHC-matched (mHC
mismatched) sources. The goal of our studies is to ﬁnd the opti-
mal graft composition for hematopoietic cell transplantation
(HCT), which blocks the autoimmune process and prohibits
recurrence of disease after transplantation with limited morbidity
and mortality.
In prior studies we showed that transplantation of MHC-mis-
matched puriﬁed hematopoietic stem cells from AKR/J mice pre-
vents the onset of autoimmune diabetes in prediabetic non-obese
diabetic (NOD) mice. Here, we show that HCT of (pseudo)autol-
ogous NOD.Thy1.1 and haploidentical donor cells (NODx-
AKR)F1 do not block the onset of diabetes in prediabetic NOD
mice, whereas transplantation of MHC-matched unrelated donor
hematopoietic cells, C57BL/6.H-2g7 confer protection. These
ﬁndings are surprising given that the (NODxAKR)F1 cells express
(at a one gene dose) a presumably protective MHC allele, whereas
cells from the C57BL/6.H-2g7 donors express the disease associ-
ated MHC allele. The data suggest non-MHC background genes
expressed in donor derived hematopoietic cells can block autoim-
mune disease pathogenesis. The human correlates of these studies
are matched unrelated donor transplants, which are routinely per-
formed in patients with malignancies and bone marrow failure
states.
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PROTECTION AGAINST OPPORTUNISTIC PATHOGENS IN A MURINE
MODEL OF HEMATOPOIETIC CELL TRANSPLANTATION USING
NEWLY CHARACTERIZED MYELOID PROGENITORS
BitMansour, A.; Burns, S.M.; Weissman, I.L.; Contag, C.H.; Brown,
J.M. Stanford University, Stanford, CA
Infectious complications in the early posttransplant period
remain a significant challenge. Two pathogens associated with
neutropenia and share high mortality rates are the fungus
Aspergillus fumigatus and the virulent gram-negative bacteria,
Pseudomonas aeruginosa. Weissman, et al, recently identiﬁed line-
age-restricted progenitors. Two of these, the common myeloid
progenitor (CMP) and the further restricted granulocyte-mono-
cyte progenitor (GMP) differentiate into their mature progeny as
early as day 6 posttransplant (D+6). We postulated that accelerat-
ing reconstitution of functional neutropenia by the inclusion of
newly identiﬁed myelomonocytic progenitors would signiﬁcantly
reduce morbidity and mortality from these as related pathogens.
We established a murine model of infection following HSC
transplantation. Groups of mice received syngeneic grafts con-
taining : (1) 200 HSC only or (2) 200 HSC + 1x104 CMP and
2x104 GMP.
Protection against invasive aspergillosis. Following lethal chal-
lenge with 100 conidia of Aspergillus fumigatus i.v. on D+3, none of
the animals survived. However, 75% of the HSC+CMP/GMP
animals survived compared to 0% in the HSC group if challenged
on D+7. Fungal colonies were routinely cultured from homoge-
nized organs of moribund mice, whereas cultures from healthy
animals yielded no colonies. In an attempt to further shorten the
period of susceptibility to A. fumigatus, hG-CSF (250 µg/kg) was
administered to both groups for ﬁve days beginning on D+1. Fol-
lowing a D+3 infection, the survival rate of animals cotransplanted
with CMP/GMP was 50% while none of the HSC only group
survived.
Protection against Pseudomonas aeruginosa. Mice were injected
with 300 CFU of Pseudomonas aeruginosa i.p on D+7. 75% of the
HSC+CMP/GMP group survived compared to 10% survival in
the HSC only group. Bacterial load as determined by biolumines-
cence imaging and culture of homogenized organs correlated with
clinically apparent illness and survival.
Therefore, cotransplantation of myeloid progenitors protects
against lethal challenge with virulent opportunistic pathogens.
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INCREASED RISK OF GRAFT-FAILURE AFTER NONMYELOABLATIVE
CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION
FROM UNRELATED DONORS
Bornhaeuser, M.; Thiede, C.; Roellig, C.; Jenke, A.; Babatz, J.;
Geissler, G.; Platzbecker, U.; Freiberg-Richter, J.; Helwig, A.;
Ehninger, G. Med. Klinik und Poliklinik I, Dresden, Germany
A ﬂudarabine-based nonmyeloablative preparative regimen was
investigated in 42 patients with hematologic malignancies receiv-
ing blood stem cell grafts from unrelated volunteer donors. Recip-
ient conditioning consisted of ﬂudarabine 30 mg/sqm on days -6
to -2 and intravenous busulfan 3.3 mg/kg on days -6- to -5.
Antithymocyte globuline was added at 2.5 mg/kg i.v. on days -5 to
-2. The patients were grafted with bone marrow (n=13) or periph-
eral blood stem cells either unmanipulated (n=20) or CD34+
selected (n=9). Graft-versus-Host disease prophylaxis was per-
formed with cyclosporin A (CsA, n=12), CsA/methotrexate (n=12)
or CsA/mycophenolate mofetil (n=18).
With a median follow-up of 13 months (range, 5-26 months)
the actuarial disease-free survival is 64% and 41% for patients
with lymphoid malignancies and standard-risk leukemia com-
pared to only 14% for patients with high-risk disease. The main
cause of treatment-failure was relapse of disease in high-risk
patients (14/42). The rate of primary (n=1) or secondary graft-
failure (n=8) was higher after unrelated transplants (21%) com-
pared to the experience with related donors. Univariate analysis
indicates a higher rate of graft-failure in patients with chronic
myeloid leukemia (p=0.08) and in transplants with one or more
HLA mismatches (p=0.09). Chimerism analysis of peripheral
blood cell subsets showed an impaired increase of donor NK cell
chimerism in patients without sustained engraftment.
Unrelated transplants after dosed reduced conditioning are asso-
ciated with a higher risk of graft-failure. Pretransplant host
immunosuppression has to be optimized to overcome resistance to
grafts from unrelated donors after nonmyeloablative conditioning
therapy.
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HIGH DOSE THERAPY WITH CD34 SELECTED STEM CELL RESCUE
FOR MULTIPLE MYELOMA RESULTS IN PROLONGED PLATELET
RECOVERY
Broun, E.R.1; Essell, J.1; Sigmund, D.1; DeVoe, M.1; Tierney, C.1;
Sorensen, S.2; Crouch, T.J.2 1. Jewish Hospital/University of Cincin-
nati Stem Cell Transplant Program, Cincinnati, OH; 2. Hoxworth
Blood Center, Cincinnati, OH
We have treated 20 patients with multiple myeloma (19) or
amyloidosis (1) with high dose melphalan +/-XRT and CD34
selected stem cell rescue. Patients with disease responsive to con-
ventional dose induction therapy underwent chemomobilization
with Cytoxan 2 gm/m2/d x 2 alone(16 pts) or with etoposide
100mg/m2/d x 3 (4 pts); followed byG-CSF/GM-CSF (9 pts) or
G-CSF (11 pts). Patients underwent apheresis when the WBC
exceeded 1000/uL with a target collection of 6.5 x 106 CD34+
cells/kg (1.5 x 106 for backup and 5.0 x 106 for selection). CD34+
cells were isolated using the Isolex® 300i device (Version 1.12,
Nexell, Inc). Median age was 57 yrs (41-67 yrs), male/female
10/10. Median number of phereses: 2 (1-7), median CD34 cells
collected 18.3 x 106, median CD34 frozen for backup:1.5 x 106/kg;
median CD34+ cells/kg infused post selection: 7.65 x 106 (range
0.7-37.2). Median % recovery of CD34+ cells was 51% (14-77%).
Patients received melphalan 200 mg/m2 plus TBI (7pts). One pt
was not treated due to rapidly progressive disease. 19 pts complet-
ed high dose therapy with CD34 selected stem cell reinfusion.
There was one treatment related death (aspiration
pneumonia/sepsis). Median follow-up is 12 mos (2-20 mos), 16 pts
are alive, 4 expired: pneumonia (1), progressive disease (2), TRM
(1). Days to AGC 500/uL: 17 (6-50 days), days to platelet transfu-
sion independence: 55 (22-230 d) for the 14 pts who have recov-
ered plts (too early-2, expired-3, not treated-1). These pts
required an average of 20 plt transfusions in the 100 days post
transplant. 3 have relapsed, 15/20 are alive relapse-free. This
treatment approach is well tolerated but results in prolonged plt
recovery despite adequate numbers of CD34+ cells infused.
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HIGH DOSE THERAPY WITH CD34 SELECTED STEM CELL RESCUE
FOR NON-HODGKIN’S LYMPHOMA, SLOW RECOVERY OF GRANULO-
CYTES AND PLATELETS
Broun, E.R.1; Essell, J.1; Sigmund, D.1; DeVoe, M.1; Tierney, C.1;
Sorensen, S.2; Crouch, T.J.2 1. Jewish Hospital/University of Cincin-
nati Stem Cell Transplant Program, Cincinnati, OH; 2. Hoxworth
Blood Center, Cincinnati, OH
We have treated 20 patients with non-Hodgkin’s lymphoma
(NHL) with high dose chemotherapy +/-XRT and CD34 selected
stem cell rescue. Patients with disease responsive to conventional
dose induction therapy underwent chemomobilization with
Cytoxan 2 gm/m2/d x 2 alone(13 pts) or with etoposide
100mg/m2/d x 3 (3 pts); followed byG-CSF/GM-CSF (9 pts) or
G-CSF (11 pts). Patients underwent apheresis when the WBC
exceeded 1000/uL with a target collection of 6.5 x 106 CD34+
cells/kg (1.5 x 106 for backup and 5.0 x 106 for selection). CD34+
cells were isolated using the Isolex® 300i device (Version 1.12,
Nexell, Inc). Median age was 48 yrs (21-68 yrs), male/female 12/8.
Median number of phereses: 4 (1-9), median CD34 cells collected:
8.6 x 106/kg (5.7-67.4); median CD34 frozen for backup: 1.5 x
106/kg; median CD34+ cells/kg infused post selection 3.3 x 106/kg
(2.0-20.6). Median % recovery of CD34+ cells was 51% (30-87).
One patient required a bone marrow harvest as well as stem cell
collection and nine required 2 selection procedures. Patients
received BEAM (11 pts) or Cytoxan/VP-16 plus TBI (8 pts).
19/20 pts completed high dose therapy with CD34 selected stem
cell reinfusion. There were no treatment related deaths. Median
follow-up is 12 mos (1-19 mos), 14/20 pts are alive, 6 expired: all
from PD. Days to AGC 500/uL: 20d (14-102d), days to platelet
transfusion independence: 33 (18-101) for the pts who recovered
plts (3 exp-ired without plt receovery). 9 have relapsed, 11 are
alive relapse-free. This treatment approach is well tolerated with
no treatment related mortality but recovery of granulocytes and
platelets appears delayed in comparison to unmanipulated stem
cell transplants.
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TRANSIENT HYPERBILIRUBINEMIA FOLLOWING PACKED RED BLOOD
CELL TRANSFUSIONS (PRBCT) IN PATIENTS UNDERGOING HIGH
DOSE CHEMOTHERAPY (HDC) ± AUTOLOGOUS HEMATOPOIETIC
STEM CELL TRANSPLANT (HSCT)
Bunner, P.; Weisenborn, R.; Ericson, S. West Virginia University,
Morgantown, WV
Background: Total bilirubin (TB) is measured in HDC ± HSCT
patients to detect complications such as VOD, gall bladder dis-
ease, drug effects and disease progression. Unexpected hyper-
bilirubinemia in patients receiving PRBCT following HDC con-
founds the assessment of potentially serious complications.
Methods: A retrospective chart review was performed for patients
receiving HDC ± autologous HSCT during 1999. Sixty-one (61)
patients were evaluated, 35 (57%) had received HDC with HSCT,
26 (43%) had received HDC only. Median age was 43 (range 21-
63) with 36 females and 25 males. Results: Increases in TB to
above the upper limit of normal the day following PRBCT were
observed in 27 (44%) of the patients evaluated. Doubling of the
TB occurred in 14 (23%) of the patients with 6 experiencing
greater than one episode of hyperbilirubinemia. TB normalized
prior to the next PRBCT in 25 (93%) of patients. The median dif-
ference in TB (pre to post PRBCT) for those experiencing hyper-
bilirubinemia was 0.7 gm/dl (range 0.5-2.4). Median days from
last chemotherapy to ﬁrst hyperbilirubinemia following PRBCT
was 9 (range 3-30). Co-existing medical events possibly related to
hyperbilirubinemia were seen in 11 (41%) of patients. Continuous
infusion narcotics were in use at the time of hyperbilirubinemia in
11 (41%) of the patients.
Conclusion: The normalization of TB following post transfusion
hyperbilirubinemia in 93% of these patients coupled with the lack
of other proven causes for the hyperbilirubinemia suggests that
PRBCT may cause transient hyperbilirubinemia. No significant
differences were noted between the two populations in regard to
age, gender, days from HDC to ﬁrst PRBCT, hemoglobin level at
PRBCT, HSCT source or disease. Transient hyperbilirubinemia
following PRBCT appears to be common in this setting. For clin-
ically stable patients, 24 - 48 hours should be allowed for normal-
ization of TB prior to extensive investigation of other causes.
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ACYCLOVIR VERSUS GANCICLOVIR FOR PREVENTION OF
CYTOMEGALOVIRUS ANTIGENEMIA AND DISEASE AFTER ALLOGENE-
IC TRANSPLANTATION: SIMILAR EFFICACY AND TOXICITY
Burns, L.J.; Miller, W.J.; Kandaswamy, C.; Defor, T.E.; MacMillan,
M.L.; van Burik, J.; Weisdorf, D.J. University of Minnesota, Min-
neapolis, MN
The aim of this prospective, randomized trial was to compare
the effectiveness of acyclovir (ACV) versus ganciclovir (GCV) in
preventing CMV antigenemia and disease, and to determine toxic-
ity. From 1995-1999, 91 CMV seropositive recipients of related
and unrelated donor transplants were enrolled. All received GCV
5 mg/kg IV every 12 hrs days -7 to -2, then ACV 10 mg/kg IV
every 8 hrs day -1 until ANC ≥ 750/ul. Patients were then ran-
domly assigned to ACV 800 mg (adults)/18 mg/kg (children) oral-
ly 5 times a day (n=46) or GCV 5 mg/kg IV weekdays (n=45) until
day 100. Any degree of antigenemia was treated with GCV 5
mg/kg IV twice a day for 2 weeks, then 5 mg/kg IV weekdays for 6
weeks. At twelve months, the cumulative incidence of antigenemia
was 43% (95% C.I. 28-58%) and 33% (95% C.I. 19-49%) for
ACV and GCV prophylaxis, respectively (P=0.24). Adjusted multi-
variate regression conﬁrmed similar prophylactic efﬁcacy. In the
ACV group, 8/46 (11%, 95% C.I. 2-20%) patients developed
CMV disease, compared to 5/45 (7%, 95% C.I .0-14%) in the
GCV group (P=0.39); time to development of disease was similar.
Multiple regression analysis identiﬁed ANC ≤ 1500/ul at random-
ization (P<0.01) and grade II-IV aGVHD (P=0.06), but not the
assigned prophylaxis (P=0.50), as independent risk factors for
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CMV disease. Increased neutopenia from baseline was experi-
enced by 19/46 (39%) patients who received ACV, versus 28/45
(62%) who received GCV (P=0.03). The one year estimate of OS
was 54% (95% C.I. 40-68%) for ACV and 64% (95% C.I. 50-
78%) (P=0.38) for the GCV group. Our data do not support the
use of GCV at engraftment for prophylaxis of CMV antigene-
mia/disease, as high dose oral ACV in the setting of preemptive
antiviral therapy results in similar outcomes with lower cost, ease
of administration, and without additional toxicity.
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LIPOSOMAL AMPHOTERICIN (AMBISOME®) COMPARED TO AMPHO-
TERICIN B ± ADDITIONAL FMLP IS ASSOCIATED WITH SIGNIFICANT-
LY DECREASED PMN AGGREGATION FROM G-CSF/DEXAMETHASONE
MOBILIZED ALLOGENEIC (DONOR) PMNS
Cairo, M.S.; Anderson, L.; Sulis, M.; van de Ven, C. Columbia Uni-
versity, New York, NY
Recently, Price et al demonstrated the success of collecting 5-
fold more neutrophils by leukopheresis from allogeneic donors
(AD) mobilized with G-CSF and dexamethasone (G/D) (Price et
al, Blood 95:3302, 2000). The concomitant use of both AD PMN
transfusions and amphotericin B in febrile neutropenic transplant
recipients is limited in part by the increased incidence of PMN
aggregation, pulmonary sequestration, and respiratory distress.
New liposomal formulations of amphotericin B (Ambisome®)
have been demonstrated to be associated with decreased infusion-
al and systemic toxicity in febrile neutropenic transplant patients
compared to amphotericin B (Walsh et al, NEJM 340:764, 1999).
We compared the in-vitro effect of amphotericn B versus Ambi-
some® on PMN aggregation from PMNs isolated from G/D
mobilized AD. Briefly, following informed consent and screen-
ing, 6 AD were mobilized with G (600 mcg SQ) and D (8 mg
PO) 16 hours prior to leukopheresis for neutropenic and septic
ABO compatible transplant recipients. PMNs (1 x 107/ml) were
incubated with amphotericin B (10-100 mcg/ml) and Ambi-
some® (10-100 mcg/ml) ± FMLP (2x107 M) and aggregation was
evaluated by ∆ light transmission (%T) in 5 minutes by standard
aggregometry. Ambisome® compared to amphotericin B was
associated with signiﬁcantly less PMN aggregation at 50 mcg/ml
(0.5 ± 0.5 vs 26.33 ± 8.33%, n=3, P<0.01) and 100 mcg/ml (0.33 ±
0.33 vs 54.33 ± 5.82 %, n=3, P<0.001). Furthermore, with the
PMN agonist, FMLP, Ambisome® was also associated with sig-
nificantly less aggregation compared to amphotericin B at 100
mcg/ml (18.67 ± 1.45 vs 54.67 ± 2.4%, n=3, P<0.001). In summa-
ry, these studies demonstrate that liposomal amphotericin (Ambi-
some®) compared to amphotericin B is associated with signifi-
cantly less in vitro PMN aggregation and could possibly be
administered concomitantly with mobilized AD PMN transfu-
sions. Future prospective controlled clinical trials will be required
to conﬁrm this hypothesis.
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IMPROVED SURVIVAL OF EXTRAOCULAR RETINOBLASTOMA FOLL-
LOWING COMBINED INTENSIVE THERAPY
Calderwood, S.1; Doyle, J.J.2; Saunders, E.F.2; Gallie, B.L.2; Heon, E.2;
Budning, A.2; Chan, H.L.2 1. City of Hope National Medical Center,
Duarte, CA; 2. The Hospital For Sick Children, Toronto, ON, Canada
Purpose: Most extraocular retinoblastoma patients manifest
mutidrug resistance (MDR) due to p-glycoprotein, and few sur-
vive beyond a year when treated with conventional chemotherapy
and radiation. We evaluated the use of combined MDR reversal
chemotherapy consolidated by high dose therapy with autologous
stem cell rescue.
Method: Three patients with retinoblastoma who presented with
extensive optic nerve involvement (two with tumor at the resection
margin of the optic nerve and one with 9 mm optic nerve involve-
ment beyond the lamina cribrosa) were treated with enucleation,
orbital irradiation, 6 cycles of carboplatin, vincristine, and teniposide
with cyclosporin (33 mg/ kg) to reverse MDR, intrathecal cytarabine
and high dose carboplatin, etoposide and cyclophosphamide with
autologous stem cell rescue. Stem cells were obtained from periph-
eral blood, and were CD34 selected as a de facto tumor depletion.
Results: The therapy was associated with acceptable acute toxici-
ties, and no treatment related deaths. All three patients are surviv-
ing event-free at 28, 23 and 14 months following diagnosis.
Conclusions: Children with extensive extraocular retinoblastoma
that would have died in the past, may achieve long-term event-
free survival with intensive multi-modal therapy.
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COULD DIMETHYL SULFOXIDE (DMSO) BE HARMFUL TO NURSING
STAFF DURING PBSC REINFUSION?
Canepa, M.1; Barbieri, S.1; Gini, S.2; Giovannini, N.3 1. San Martino
Hospital, Genova, Italy; 2. Az.Osp.Pisana, Pisa, Italy; 3. Osp. Forlani-
ni, Forli, Italy
In the last years PBPC reinfusion has become progressively uti-
lized, when PBPC are cryopreserved in DMSO at a concentration
5-10%, which is added before the freezing procedure to prevent
ice crystal formation in the cells. DMSO is subsequently eliminat-
ed by the patients during and after reinfusion mostly via respirato-
ry mucosa and skin, causing the characteristic smell.
In March 2000 we made a survey within BMT centres of
GITMO group to evaluate the following: awareness by the staff
about potential side effects, protection procedure and possible
toxicity to the nursing staff. A questionnaire was sent to 67 centres
of GITMO.
The questions were:
1-whether symptoms were recorded during and after reinfusion
2-whether the nurse was aware of protection procedures
3-whether protections devised were put in place
4-characteristics of aeration of rooms in which the procedure
was performed
5-modalities of clearance of waste material after reinfusion
34 questionnaires were appropriately ﬁlled out; 7 out of 34 (20.5%)
centres apply protocols for the reinfusion and procedures for the
protection of the nurse; 12 out of 34 (35.2%)centres apply individual
devices for protection; 10 out of 34 (29.5%) have the possibility to
aerate the room; 13 out of 34 (38.2)have recorded symptoms during
reinfusion (11 headache, 9 nausea, 3 vomiting, 1 dyspnea, 1 ocular
symptoms);15 out of 34 (44.1%) centres have a speciﬁc procedure
for the clearance of waste material. The results indicate the lack of
appropriate information for the personnel involved in the procedure.
Literature data do not show evidence of toxicity for the person-
nel performing or attending the procedure. On the other hand,
DMSO is classified as teratogen and mutagenic drug based on
mice studies. These data suggest that the utilization of general and
individual safety procedures is strongly advised.
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A PILOT STUDY OF THE ORAL ABSORPTION OF ITRACONAZOLE
SOLUTION IN BONE MARROW TRANSPLANT (BMT) PATIENTS
Capozzi, D.L.; Horan, J.L.; Avery, R.; Curtis, J.; Seraﬁn, M.; Bolwell,
B. The Cleveland Clinic Foundation, Cleveland, OH
Background: Itraconazole is a reasonable choice for antifungal
prophylaxis in allogeneic BMT recipients given its spectrum of
activity and its availability as an oral formulation. The absorption
of this agent in BMT patients has been questioned. Peak concen-
trations of itraconazole greater than 250 ng/ml and itraconazole
plus hydroxyitraconazole (OHI) greater than 1000 ng/ml via
reverse-phase high performance liquid chromatography (HPLC)
have been correlated with maximum efﬁcacy. Case reports suggest
suboptimal absorption in BMT patients. Objective: To evaluate
the bioavailability of itraconazole in a population of allogeneic
BMT recipients that would include patients with GVHD. Meth-
ods: Patients were instructed to begin itraconazole solution at a
dose of 200 mg daily on an empty stomach. Itraconazole and OHI
serum concentrations were assayed using reverse-phase HPLC
and were obtained 2 hours after the itraconazole dose. Patients
with subtherapeutic concentrations had their itraconazole dose
increased by 100 mg. Patients were interviewed to determine any
adverse experiences with the drug. Results: Eight allogeneic BMT
patients were included in the pilot analysis. At least one itracona-
zole level was obtained on all eight patients. Four of the eight
patients were subsequently withdrawn from the study for the fol-
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lowing reasons: elevated liver enzymes, engraftment failure, nau-
sea/intolerability and start of amphotericin therapy with only nau-
sea in one patient felt to be an effect of the itraconazole. Three
patients had biopsy conﬁrmed GVHD of the gut. Mean concen-
trations of itraconazole were 2411 ng/ml(range 1252-4807 ng/ml)
and OHI were 5305 ng/ml (range 2067-8407 ng/ml). All concen-
trations achieved the desired target levels and no dosage adjust-
ments were required. The presence of GVHD did not affect
serum concentrations of either itraconazole or OHI. Conclusions:
Allogeneic BMT patients both with and without GVHD appear to
adequately absorb itraconazole after administration of the oral
solution. Further study of itraconazole in BMT prophylaxis
appears warranted.
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AUTOLOGOUS CD34+ SELECTED HEMATOPOIETIC STEM CELL
TRANSPLANTATION (CD34+/HSCT) FOR MULTIPLE SCLEROSIS:
UPDATE OF A SINGLE CENTER EXPERIENCE IN 10 PATIENTS
Carreras, E.; Saiz, A.; Graus, F.; Marín, P.; Martínez, C.; Rovira,
M.; Urbano-Ispizua, A.; Mazzara, R.; Tolosa, E.; Montserrat, E. Hos-
pital Clínic, Barcelona, Spain
We analyzed the outcome of the ﬁrst 10 patients with multiple
sclerosis (MS) included in a phase II trial of CD34+/HSCT.
Blood stem cells were mobilized with cyclophosphamide (Cy) (3
g/sqm) and G-CSF (5 ug/kg/d). CD34+ selection was performed
by means Isolex 300 or Clinimacs system. Conditioning included
BCNU (300 mg/sqm), Cy (150 mg/kg) and ATG (Merieux) (60
mg/kg). Patients were assisted in LAF rooms, received low micro-
bial diet, oral ciprofloxacin, fluconazole and acyclovir, inhaled
pentamidine, IgIV, and G-CSF.
Between April 1998 and October 2000, 10 patients with second-
ary progressive (6 cases) or relapsing/remitting (4 cases) MS
underwent HSCT. Their median (range) age, Kurtzke EDSS and
Karnofsky score were 30 years (23-45), 6.25 (5-6.5) and 60 (40-80),
respectively. The grafts contained a mean (+/-SD) of 4.8 (+/-1.7)
x106 /kg CD34+ cells. Clinimacs selection (8 cases) resulted in a
mean of 0.4 (+/-0.19) x104 /kg CD3+ cells; being 30 and 7 x104 /kg,
respectively in two Isolex procedures. Conditioning-related toxici-
ties were grade I mucositis in all patients and grade II liver toxicity
in one. WBC >500/uL and platelet >20.000/uL were achieved
after a median of 10.5 (9-18) and 12 (9-15) days, respectively. One
patient had two episodes of CMV infection that responded to gan-
ciclovir. After a median follow-up of 18 (6-32) months, three
patients have shown an improvement of EDSS (1, 1.5, and 1.5,
respectively), two have worsened (0.5 and 1) 30 and 12 months
after HSCT, and ﬁve have remained stable (including one patient
that worsened during HSCT). Two patients had relapses after
HSCT. All episodes were subjective sensory symptoms that lasted
a few days and did not require treatment. No patients needed
additional immunosuppressive therapy after HSCT.
In conclusion, CD34+/HSCT is a feasible approach in MS.
Whether CD34+/HSCT inﬂuences the clinical course of patients
remains to be seen.
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A SINGLE CENTER EXPERIENCE OF UMBILICAL CORD BLOOD
TRANSPLANTATION IN CHILDREN IN HONG KONG
Chik, K.; Li, C.; Shing, M.M.; Lee, V.; Yuen, P.M. Department of
Paediatrics, Prince of Wales Hospital, The Chinese University of Hong
Kong, Hong Kong, China
From August 1994 to November 2000, 10 children, aged 2.1 to
12.1 years (median: 6.2 years) with thalassemia (3), leukemias
(5)and metabolic conditions (2), received allogeneic umbilical
cord blood transplant following myeloablative conditioning ther-
apy in our center. The graft source was derived from five sib-
lings, four HLA-identical, one HLA mismatched at two loci.
Unrelated cord blood mismatched for 1 to 2 antigens were also
used, 3 from local cord blood bank, 2 from cord blood banks
elsewhere. Median recipient body weight was 16.9 kg (range:
11.7 - 38.6). Median volume of the cord blood harvested was 93
ml (range: 44 - 130). There were two subjects receiving neonatal
blood and bone marrow in addition respectively as supplement
to the cord blood with low cell count. Median values of cells in
the remaining umbilical cord blood graft were: nucleated cells
5.07•107/kg (2.90•107 - 1.12•108); mononuclear cells
2.03•107/kg (4.50•106 - 4.72•107); CFU-GM 4.59•104/kg
(5.96•103 - 1.80•105); CD34 1.34•105/kg (2.93•104 - 1.03•106).
For non-malignant conditions, the pre-transplant conditioning
regime was busulphan and cyclophosphamide. For malignant
conditions, the pre-transplant conditioning regime varied with
total body irradiation based(2), and chemotherapy based(3).
GVHD prophylaxis included combinations of cyclosporin,
methotrexate and methylprednisolone. 2 patients died within
100 days post-transplant due to sepsis. The median time for neu-
trophil engraftment was 19 days (13 - 32) and 38.5 days (22 - 50)
for platelet. The median follow-up period was 20.4 months
(range, 0.03 to 6.23)with overall survival of 60%. There were
three subjects failed to develop donor engraftment, three had
mixed chimerism and four with complete donor chimerism. No
GVHD was observed among HLA-identical sibling transplant.
One mismatched related and three unrelated transplant subjects
had acute GVHD grade II - III. In conclusion, umbilical cord
blood transplant is a feasible alternative haematopoietic cell
source for transplant.
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CONDITIONING REGIMEN AND GRAFT-VERSUS-HOST DISEASE
(GVHD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT): INTRAVENOUS BUSULFAN/CYCLOPHOSPHAMIDE (BU/CY) VS
TOTAL BODY IRRADIATION (TBI)
Couriel, D.R.; Hartzog, M.G.; Sadeghi, T.H.; Esfandiary, N.; Cohen, A.I.;
de Lima, M.; Giralt, S.A.; Gajewski, J.L.; Champlin, R.E.; Andersson,
B.S. The University of Texas M. D. Anderson Cancer Center, Houston, TX
Objective: To compare the impact of IV Bu/Cy vs TBI on acute
and chronic GVHD. Methods: We evaluated a total of 84 patients
with CML in chronic or accelerated phase who received grafts
from HLA-matched related donors. Thirty-two patients had Cy,
Thiotepa, TBI and antithymocyte globulin (ATG) as their condi-
tioning (Group 1) and 52 received IV Bu (0.8 mg/kg) and Cy (60
mg/kg) (Group 2). Patients in Group 1 had CD8-depleted grafts
(BM=21, PBSC=11) and cyclosporin/methylprednisolone prophy-
laxis. Patients in Group 2 had unmanipulated transplants (BM=32,
PBSC=20), with tracolimus/methotrexate prophylaxis. Results:
The overall incidence of acute GVHD Grade II-IV was 47%
(n=15) and 17% (n=9) for Groups 1 and 2, respectively (p=0.0036).
Skin was the organ most commonly involved in both groups
(1=73%, 2=66%), followed by upper and lower GI tract (1=33%,
2=55% and liver (1=13%, 2=33%). Chronic GVHD was observed
in 31% of patients in Group 1 and 25% of patients in Group 2
(p=0.53). Mortality for the TBI-treated group is 50% (n=16),
compared to 23% (n=12) in Group 2 (p=0.01). The majority of
deaths in Group 1 were GVHD-related (68.5%) while they repre-
sented only 33% of the deaths in Group 2. The relapse rate rate
was 9% (n=3) for Group 1 and 21% (n=11) for Group 2
(p=0.1595). Two patients who relapsed (Group 1) had acute
GVHD, and only 3 of 14 relapses in both groups had extensive
chronic GVHD. Relapse accounted for 6% of deaths in Group 1
(n=1) and 33% in Group 2 (n=4). Conclusions: In this study, the
group of patients receiving TBI had a higher incidence of acute
GVHD, higher mortality and higher GVHD-related mortality
than patients treated with IV Bu/Cy. The conditioning regimen
does not affect the clinical features of acute GVHD or incidence
of chronic GVHD.
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A PROSPECTIVE STUDY OF LOW-DOSE ABELCET IN THE TREATMENT
OF NEUTROPENIC PATIENTS FAILING OR EXPERIENCING TOXICITY
WITH CONVENTIONAL AMPHOTERICIN-B
Devaney, M.1; Cook, G.2; Franklin, I.2; Tansey, P.3; Sharp, S.3; John-
son, P.1 1. Western General Hospital, Edinburgh, United Kingdom; 2.
Glasgow Royal Inﬁrmary, Glasgow, United Kingdom; 3. Victoria Inﬁr-
mary, Glasgow, United Kingdom
The mainstay of anti-fungal therapy is Amphotericin-B.
Ampho-B is, however, toxic.Liposomal/lipid-associated prepara-
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tions of Ampho-B have been developed to minimise toxicity, but
cost is significantly higher. Abelcet is a lipid-complexed prepara-
tion of Ampho-B. Recommended dose is 5mg/kg/day, however
lower doses are effective. This study investigated the use of low-
dose Abelcet (2mg/kg/day) in neutropenic patients failing treat-
ment, or experiencing toxicity with Ampho-B. Antifungal treat-
ment with Ampho-B was initiated in patients who continued to
be pyrexial after 72-96 hours of 1st/2nd line antibiotics. Patients
failing to respond to Ampho-B, or who developed toxicity
received Abelcet 2mg/kg/day. Forty-one patients were recruited
(median age 46). Haematological diagnoses were as follows:
AML 22 (allograft 7, autograft 2), NHL 5 (autograft 3), myelo-
ma 5 (autograft 4), others 9 (allograft 5, autograft 1). Response
endpoints - complete response if pyrexia resolved to <37°C on 3
consecutive days; failure if Abelcet dose was increased, if addi-
tional antifungal therapy was required, or if fever persisted
despite resolution of neutropenia. CR occurred in 27(66%);
fever resolved in a median 14 days (range 1-22). Neutrophil
counts remained <0.5x109/L for median 14 days, but did resolve
in 73% of patients. 11 treatment failures - 4 continuing fever
(though in 2 neutrophil counts did not recover), 6 dose of Abel-
cet increased, and 1 because additional antifungal treatment
required. 1 patient died in whom there was no evidence of deep-
seated fungal infection. Mean creatinine level at start of Abelcet
was 139 (range 47-450 umol/l), and at end of treatment was 136
(range 47-390). 2 patients had increasing creatinine levels on
Abelcet; both were also receiving concurrent nephrotoxic drugs.
Infusion-related reactions were mainly rigors (n=8) or fever(n=4)
and responded to treatment with chlorpheniramine/pethidine.
Study demonstrates that Abelcet 2mg/kg/day is effective and
well tolerated in neutropenic patients, including transplant
patients, failing treatment or experiencing toxicity with
AmphoB.
24
ROUTINE VS RISK-ADAPTED ADMINISTRATION OF COLONY STIMU-
LATING FACTORS (CSF) FOLLOWING AUTOLOGOUS PERIPHERAL
BLOOD STEM CELL TRANSPLANT (AUTOPBSCT)
Dix, S.P.; McGuirk, J.P.; Barnhart, C.S.; Belt, R.J. Hematology and
Associates and Saint Luke’s Hospital, Kansas City, MO
Various trials report no benefit of CSF therapy following
autoPBSCT; others report modest acceleration in neutrophil
recovery and decreases in hospitalization among patients (pts)
undergoing autoPBSCT as inpatients. Prior to Oct 99, pts ini-
tiated CSF therapy on Day 0 following infusion of autoPBSC
(Group 1, n=141). After Oct 99, pts initiated CSF therapy on
day 7 following autoPBSC infusion only if the CD34+ cell dose
was less than 2.5 x 106 /kg (Group 2, n=38). Median age,
CD34+ cell doses infused, disease and number of PBSCTs per-
formed in the outpatient setting were similar for both groups.
In group 1, 82% of pts received GM-CSF following autoPB-
SCT, 14% G-CSF, 2% both (not simultaneously), and 2% no
CSF therapy. In group 2, 8% of pts received GM-CSF, 3% G-
CSF, 3% both (not simultaneously), and 86% no CSF therapy.
For pts receiving CSF therapy, the mean number of days of
CSF therapy was reduced in group 2 (8 days) compared to
group 1 (13 days), p<0.05. Pts in group 1 achieved an
ANC>500/ul on median d12 vs d14 for pts in group 2, p=0.01.
Platelet recovery to 20,000/ul occurred on d18 vs d17 for
groups 1 and 2, respectively, p=NS. For groups 1 and 2, the
incidence of hospitalization in outpatients was 30% vs 25%
(p=NS), respectively, and the duration of hospitalization for
inpatients was 21d vs 20d (p=NS), respectively. Documented
infections occurred in 23% of pts in group 1 vs 24% in group 2
(p=NS). The median days of IV antibiotics for groups 1 and 2
was 8 and 7 days, respectively, p=NS. Administration of CSFs
following autoPBSCT accelerated neutrophil recovery, but did
not decrease infection, days of IV antibiotics, or hospitaliza-
tion. Risk-adapted administration of CSFs following autoPB-
SCT did not significantly affect clinical outcomes and resulted
in an approximate savings of $2000/pt.
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CYTOKINES AND POSTNATAL BOOSTS IMPROVE HEMATOLOGICAL
PARAMETERS FOLLOWING IN UTERO TRANSPLANTATION IN β-THA-
LASSEMIC MICE
Donahue, J.; Gilpin, E.; Young, D.; Carrier, E. University of Califor-
nia San Diego, La Jolla, CA
We have developed a murine model of allogeneic in utero trans-
plantation in B-thalassemic mice to study chimerism, tolerance,
and hematological parameters. We have documented that survival
of homozygous fetuses receiving allogeneic fetal liver cells
improved by 40% as compared to controls. The percent of reticu-
locytes in peripheral blood was decreased by a mean of 52.8%
(p=0.04), and ektacytometry (osmotic fragility) shift toward nor-
mal was observed in 30% of the transplanted animals. Mass spec-
trometry detected up to 5% of donor α and β globin in trans-
planted mice, which correlated with hemoglobin chimerism.
Hemoglobin levels improved with postnatal SCF/GCSF/EPO
injection as compared to control mice (11.58±4.03 transplanted,
and 9.92±0.39 controls, p=0.13). Chimerism was tested by FACS
analysis over the lifetime of the animals. Donor cells were detect-
ed in CD45, CD3, and TER 119 populations. The percent of
donor cells varied from 0.01-1.6% and persisted throughout life.
In mixed lymphocyte cultures, the response of control mice to
donor cells increased 30-40% (as compared to pre-boost response,
while the response of transplanted animals remained stable. The
percent of donor cells signiﬁcantly increased following postnatal
boosts with donor cells (0.3-6%). Cytotoxicity assays demonstrat-
ed higher responses to donor cells in control mice as compared to
in utero transplanted animals (at 50:1 effector to target ratios,
transplanted animals showed 8.66% target lysis, and controls
showed 51.85% target lysis, p=0.0003). This experiment demon-
strates that even very low levels of donor chimerism may be sufﬁ-
cient for improvement in hematological parameters. The level of
chimerism can increase following the postnatal boosts with donor
cells in tolerant animals.This possibility of tolerance induction
may allow development of successful non-myeloablative transplant
regimens in β-Thalassemic patients.
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MICROCHIMERISM SUSTAINS ACTIVE POSTNATAL IMMUNITY IN
MICE PRIMED IN UTERO TO ALLOGENEIC CELLS
Donahue, J.; Tzong-Hae, L.; Michael, B.; Elisabeth, G.; Carrier, E.
University of California San Diego, La Jolla, CA
Induction of a high degree of tolerance following prenatal trans-
plantation with allogeneic cells is an ultimate goal which may lead
to successful prenatal treatment of congenital disorders. This
however was not achieved so far and prenatal transplants are only
successful in hosts with defective immune systems, such as severe
combined immunodeficiency disorders, but not in hemoglo-
binopathies and inborn errors of metabolism We have previously
demonstrated evidence of postnatal immunity to allogeneic c-kit+
cells from cytokine stimulated peripheral blood stem cells follow-
ing prenatal transplantation with this cells (manuscript submitted).
In order to further study this new phenomenon, we have per-
formed experiment in which puriﬁed murine Sca-1+/lin- cells and
c-kit+/Lin- cells of C57Bl/6 mice(H-2b,I-E-) mice were injected
into Balb/c (H-2d,I-E+) fetal recipients. It was previously demon-
strated that the transplantation of I-E+ donor cells into I-E- recip-
ient strains results in microchimerism only and lack of tolerance.
We found that in both groups only microchimerism (<1% donor
cells ) was observed, but it persisted up to 23 weeks in mice trans-
planted with sca-1+ cells and only up to 3 weeks in mice which
received c-kit+ cells. This difference in longevity of chimerism
was related to different level of in vivo and in vitro responses to
donor tissues/cells: mice that had prolonged chimerism, hypere-
jected donor skin grafts as compared to non-transplanted controls
and showed evidence of immune rejection of donor cells in cyto-
toxicity assay. In contrast, mice with short lived chimerism reject-
ed donor skin grafts at a time similar to controls and showed only
minimal immune responses to donor cells in cytotoxicity culture.
This results support that active immunity to allogeneic cells may
be induced by prenatal transplantation and enhanced by the per-
ASBMT Poster Presentations
71B B & M T
sistence of microchimerism. This new ﬁnding may explain lack of
successes in prenatal transplantation in hosts with intact immune
system.
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AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
IN DE NOVO AML PATIENTS ≤ 60 YEARS WITH INTERMEDIATE RISK
CYTOGENETICS
Ehninger, G.; Schaekel, U.; Soucek, S.; Bornhäuser, M.; Schaich, M.
Med. Klinik und Poliklinik I, Dresden, Germany
401 de novo AML patients ≤ 60 years were included in the
ongoing trial of the German SHG AML96 study group. Patients
were stratiﬁed according to cytogenetic risk. After double induc-
tion therapy they received risk adapted and priority based post-
remission therapy. 304 patients were treated within the largest
group of intermediate cytogenetic risk. First priority for post-
remission therapy was related allogeneic peripheral blood stem
cell transplantation (PBSCT), second priority autologous PBSCT
after one course of conventional post-remission chemotherapy
and third priority two courses of conventional Ara-C containing
chemotherapy. The autologous stem cell harvest obtained after
the ﬁrst course of conventional post-remission therapy was taken
for transplantation. The conditioning regimen for the autologous
PBSCT consisted of either TBI and cyclophosphamide or a com-
bination of busulfan, VP-16 and cyclophosphamide. 71% of de
novo AML patients ≤ 60 years with intermediate risk cytogenetics
reached CR criteria after double induction therapy. These inter-
mediate risk patients had favorable survival with autologous
PBSCT. Median OS was 27 months for conventional chemother-
apy as post-remission therapy, whereas the median survival for
autologous PBSCT or allogeneic PBSCT was not reached yet.
Finally, DFS after 54 months was 63% for autologous PBSCT
compared to 59% for allogeneic PBSCT. DFS for conventional
post-remission chemotherapy was as low as 40% after 32 months.
In conclusion, autologous PBSCT for second post-remisson ther-
apy is a well tolerated procedure with favorable outcome and last-
ing remissions in de novo AML patients ≤60 years with intermedi-
ate cytogentic risk.
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ADOPTIVE T-CELL THERAPY FOR PERSISTENT HCMV INFECTION
Einsele, H.1; Rufer, N.3; Hebart, H.1; Loeffler, J.1; Grigoleit, U.1;
Bruemmendorf, T.1; Riegler, S.2; Sinzger, C.2; Jahn, G.2; Roosnek, E.3
1. Department of Hematology and Oncology, University of Tuebingen,
Tuebingen, Germany; 2. Institute of Virology, University of Tuebingen,
Tuebingen, Germany; 3. Hopital Cantonal Universitaire de Geneve,
Geneva, Switzerland
Late HCMV disease remains a major concern after allo-SCT.
Delayed HCMV-specific T-cell reconstitution and persistent
HCMV infection have been described as major risk factors. Adop-
tive transfer of HCMV-speciﬁc T-cells was shown to restore pro-
tective immunity to HCMV. Thus, HCMV-infected patients not
responding to antiviral chemotherapy for >4 weeks and lacking
HCMV-specific T-cell responses were offered adoptive
immunotherapy. T-cell lines were generated by repetitive stimu-
lation of PBLs with HCMV-antigen. Following 3 speciﬁc restim-
ulations the frequency of HCMV-speciﬁc T-cells (predominantly
CD4+ T-cells) could be increased and alloreactive T-cells deplet-
ed in 14/20 donors. 6/14 patients did not receive T-cell therapy
(clearance of HCMV-DNAemia, n=5; refractory acute GvHD,
n=1). Thus, 8 patients received 107 /m2 T-cells a median of 120
(79-479) days post transplant. At the time of T-cell therapy
patients had received a median of 8 (4-10) weeks of antiviral
chemotherapy and the median viral load determined by quantita-
tive PCR was 1x104 (0.8x103-105) genomes/ml blood. T-cell lines
were transferred even in a patient receiving a graft from a 3 anti-
gen-mismatched donor. Two weeks following transfer HCMV-
specific T-cell proliferation was demonstrated in all 7 evaluable
patients, in 5 of them ELISPOT and/or intracellular cytokine
staining revealed 0.1-2.1% HCMV-specific CD4+ T-cells. In 2
HLA-A*0201 and 1 HLA-A*0101 positive patients tetrameric
HLA/peptide complex and/or intracellular cytokine staining
revealed 0.5-1% of CD8+ T-cells being HCMV-peptide-speciﬁc
30 days post-transfer. HCMV load signiﬁcantly dropped in spite
of cessation of antiviral chemotherapy in 7 evaluable patients,
with maximal reduction of viral load after a median of 23 (14-42)
days. In 5 patients HCMV infection was persistently controlled,
in 2 patients with high viral load the antiviral effect was only tran-
sient. A decrease in telomer length of HCMV-specific T-cells,
following ex-vivo expansion as demonstrated by Flow-FISH tech-
nology could be one reason for short term persistence of trans-
ferred T-cells.
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EVALUATION OF SAFETY, EFFICACY AND PHARMACOKINETICS OF
ADMINISTERING TWICE DAILY IV BUSULFAN (BUSULFEX®) IN
PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES UNDER-
GOING STEM CELL TRANSPLANT (SCT)
Fernandez, H.F.1; Tran, H.T.2; Albrecht, F.1; Caldera, H.1; Goodman,
M.S.1 1. University of Miami, Miami, FL; 2. UT-MD Anderson Can-
cer Center, Houston, TX
Intravenous busulfan(IVBU) has demonstrated safety and efﬁcacy
when administered at 0.8 mg/kg/dose IV Q6H x 16 doses. We evalu-
ated the efﬁcacy, safety and pharmacokinetics(PK) of giving the same
total daily dose in a twice-daily schedule. Six patients with hemato-
logic malignancies were treated. The preparative regimen consisted
of IVBU 1.6mg/kg/dose over 4 hours Q12H x 4 days, followed by
cyclophosphamide(CY) 60mg/kg IV QD x 2 days. Blood specimens
were collected on 1st and 5th and 7th dose to determine the disposi-
tion of IVBU. Peripheral blood stem cells were given two days after
completion of CY. G-CSF 5 mcg/kg was started on the day 0.
GVHD prophylaxis consisted of tacrolimus plus methotrexate for
allogeneic recipients. One patient developed a presumed fungal
pneumonia and died of sepsis and MSOF on day +21. The remaining
patients engrafted (ANC>500/µL) at a median of 10 days and sus-
tained platelet counts>20,000/µL at 12 days. Signiﬁcant RRT (grade
III-IV) toxicity was limited to catheter infection(2), mucositis(1),
hyperglycemia(1), pneumonia(1) and sepsis(1). Patient data and
results are summarized below. First dose AUC was predictive of later
doses. Despite higher AUCs, in the early post-transplant period there
was no evidence of VOD, nor signiﬁcant CNS, pulmonary or other
end-organ toxicity. Conclusion: Twice daily dosing of IVBU is safe,
efﬁcacious and tolerable for patients undergoing hematopoietic SCT.
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QUALITY OF LIFE (QOL) IN WOMEN WITH BREAST CANCER (BC)
AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION (ABMT)
Flam, R.; Donovan, D.; Frederick, D.; Vahdat, L.; Papadopoulos, K.;
Savage, D.; Tierston, A.; Nichols, G.; Wiener, I.; Hesdorffer, C.
Department of Medical Oncology, The Herbert Irving Comprehensive
Cancer Center of Columbia University, New York, NY
We conducted a prospective analysis of BC patients undergoing
ABMT to assess how quickly and completely QOL is recovered.
All women enrolling in three ABMT protocols (stages 2-4 BC)
were invited to complete pre-validated, self-administered ques-
tionnaires (FAC-Br) at intake, discharge, and multiple points post-
discharge. The questionnaire measured physical, social, emotion-
al, functional, and general well-being, plus breast cancer-speciﬁc
issues. At 1.5 years of accrual, 25 women were eligible; 1 refused,
7 expired during participation, and 1 withdrew. Nineteen had data
for 3 months; 8 for one year. The mean age was 48, 62% were
married, and 67% worked outside the home. For physical, func-
tional, and general well-being, patients showed a nadir at dis-
charge, with recovery beginning by thirty days, and back to base-
line at 90 days (p=.05). For social and emotional well-being, no
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change was observed from baseline through to one year. Compari-
son of general well-being by survival showed a lower baseline
QOL for women who ultimately died, with a discharge nadir pro-
portionate to their surviving counterparts but a swifter, more dra-
matic recovery (NS). Survival did not affect the lack of trend
observed in social and emotional domains. Conclusions: The
observed nadir in QOL at discharge in our sample is consistent
with published reports, but subsequent recovery was even more
rapidly complete than previously demonstrated. This may indicate
that women undergoing ABMT for BC do not experience signiﬁ-
cant debilitation as has been suggested. The observed lack of vari-
ability in social/emotional domains also deviates from previous
reports, and may reﬂect the intense family/social/medical support
characteristic of our patient group. Poorer baseline QOL and
ampliﬁed rate of recovery in patients who expired within one year
suggest that these patients are not only sicker at outset, but may
also be resistent to, or fast metabolizers of chemotherapy, explain-
ing both diminished toxicity and decreased efﬁcacy.
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REPERTOIRE ANALYSIS OF CD8+ AND CD4+ T CELL RESPONSES TO
MINOR HISTOCOMPATIBILITY ANTIGENS INVOLVED IN THE DEVEL-
OPMENT OF GRAFT-VERSUS-HOST DISEASE
Friedman, T.M.; Caster, D.E.; Jones, S.C.; Korngold, R. Jefferson
Medical College, Philadelphia, PA
Graft-versus-host disease(GVHD) is a major complication of
allogeneic hematopoietic-stem-cell transplantation. GVHD can
be induced between MHC-matched murine strains expressing
multiple minor-histocompatibility antigen(miHA) differences.
Lethally irradiated C.B10-H2b/LiMcdJ(BALB.B) mice were
transplanted with C57BL/6By(B6) T-cells and positively-selected
miHA T-cell blasts were collected 5 days later from the thoracic-
duct-lymphocyte(TDL) pool. T-cell receptor(TCR) CDR3-size-
spectratyping analysis was used to examine the repertoire of the
responding CD8+ and CD4+ TDL subsets at a single time point
early in the development of GVHD. Spectratype analysis of the
CD8+ TDL indicated that Vβ1,4,6,8-11 and 14 exhibited biased
CDR3-size skewing. The CD4+ TDL exhibited biased CDR3-
size skewing in the Vβ2,4 and 6-14 TCR families. Positively-
selected TCR Vβ-skewed CD4+ and CD8+ T-cell subsets injected
into irradiated BALB.B recipients were capable of inducing lethal
GVHD. BALB.B mice transplanted with non-skewed Vβ CD4+
T-cells survived with minimal symptoms of GVHD. Given that
GVHD is a dynamic process, we extended these studies to exam-
ine the T-cell repertoire responses during the course of disease.
For this evaluation, lethally irradiated BALB.B recipients were
transplanted with either host-presensitized B6 CD4+ or CD8+ T-
cells. Spleens from transplanted mice were harvested at various
time points and spectratyping was used to examine the TCR Vβ
repertoire of the responding GVH-reactive T-cells. The results
demonstrated only a few constant size skewings within any Vβ
family throughout the course of GVHD. In the CD8+ responding
T-cell population, Vβ5 and 16 exhibited the most consistent
skewing at every time point examined. In the CD4+ T-cell popu-
lation, Vβ3, 6, 10 and 11 demonstrated the most consistent skew-
ing at every time point examined. The ﬂuctuations of the CDR3-
size skewing of the T-cell subsets could be a reflection of the
increased processing, frequency and presentation of miHA as
GVHD progresses in conjunction with the constant trafﬁcking of
T-cells through the splenic lymphoid compartment.
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HIGH DOSES OF CD34+ CELLS AND CHEMOMOBILIZATION ARE
ASSOCIATED WITH A REDUCED PROGRESSION RATE AFTER AUTOLO-
GOUS PBSC TRANSPLANTATION FOR BREAST CANCER IN A PHASE
III TRIAL
Gajewski, J.L.; Saliba, R.; Korbling, M.; Rondon, G.; McMannis, J.;
Ueno, N.; Donato, M.L.; Anderlini, P.; Hortobagyi, G.; Champlin,
R.E. UT-MD Anderson Cancer Center, Houston, TX
We hypothesized that intensive chemotherapy would improve
PBSC mobilization and disease control in a randomized con-
trolled trial of 141 patients comparing results of chemomobiliza-
tion with cisplatin 135 mg/m2, etoposide 1200 mg/m2, and
cyclophosphamide 4.5 g/m2 over 3 days plus G-CSF (6mcg/kg
q12h) (CVP-G), with G-CSF alone with the collection goal
>3x106 CD34+ cells/kg. Patients received cyclophosphamide 6
g/m2, thiotepa 750 mg/m2 and BCNU 450 mg/m2 over 3 days
with PBSC transplantation for treatment of breast cancer. Strati-
ﬁed by stage, 71 were randomized to the CVP-G group, 70 to G-
CSF alone. 74 patients were high-risk stage II-III, 67 were stage
IV. The CVP-G group had improved mobilization with a collec-
tion median of 18(range 3-141)x106 CD34+ cells/kg compared
with 4(1-8)x106/kg for the G-CSF group. The median CD34+
dose infused was 11(2-89) vs 3.5(.7-7.2)x106/kg, respectively.
Granulocyte and platelet recovery post-transplant was 9 and 9
days for the CVP-G mobilized group, 10 and 11 days for the G-
CSF group (p<0.001). Breast cancer progression at 3 years was
reduced in patients mobilized with CVP+G-CSF 34±6% vs.
59±7% for G-CSF alone (p=0.02). Progression was reduced in
patients receiving CD34+ cell doses >7x106/kg (25±7% vs. 62±6%,
p=0.0006), independent of the effects of CVP and disease stage.
Among patients receiving CD34+ doses <7x106/kg, the progres-
sion rate was 61±12% in the CVP-G group and 62±7% in the G-
CSF group. The CVP-G patients receiving CD34+ cell doses
>7x106/kg had a progression rate of 24±7%; only one G-CSF
patient received a dose >7x106/kg. For stage II-III patients, disease
progression rates were 11±7% for CD34+ doses >7x106/kg vs.
60±9% for doses <7x106/kg (p=0.002), and 41±12% vs. 62±8%
(p=0.08) respectively for stage IV. Use of CVP mobilizing
chemotherapy and higher doses of CD34+ cells transplanted are
associated with a lower risk of disease progression. The mecha-
nism of this cell dose effect is uncertain.
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ADENOVIRUS INFECTIONS IN PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANT (HSCT) RECIPIENTS: PROBABLE EFFECTIVENESS
OF ANTIVIRAL THERAPY WITH CIDOFOVIR
Giller, R.1,2; Shin, Y.1; Quinones, R.1,2; Robinson, C.2; Schissel, D.1,2;
Hild, E.2; Malcolm, J.2; Levin, M.1,2 1. Univ of Colorado School of
Medicine, Denver, CO; 2. The Children’s Hospital, Denver, CO
Adenovirus is a common, potentially life-threatening pathogen
in HSCT patients. Effective antiviral therapy has not been clearly
identiﬁed. Recent in vitro studies in our laboratory show that Cid-
ofovir inhibits adenovirus growth at levels achievable in vivo.
Between February 1994 and October 2000, post-transplant aden-
ovirus infections occurred in 19 of 140 patients, including 17 of 77
allografted patients and 2 of 63 patients receiving autografts.
Median patient age at HSCT was 6 years (range, 8m − 17y). Initial
infection occurred at a median of 48 days post-transplant (range,
day +7 - 1119). Sites of infection included the upper respiratory
tract (N=9), lower respiratory tract (N=2), gut (N=15), bladder
(N=5), and blood (N=1). Nine patients had multiple sites of infec-
tion. Autografted patients recovered without specific therapy.
Prior to January 1999, 7 allografted patients developed adenoviral
infections and were managed with supportive care alone. Five of
these patients had lifethreatening infections (pneumonia[2], hem-
orrhagic gastroenteritis[2], disseminated[3]). In 3 cases, dissemi-
nated adenovirus infection was a cause of death. Since January
1999, patients with progressive adenoviral infections have been
offered treatment with Cidofovir (5mg/kg IV q.week x 4, then
q.2weeks x 2 and discontinued dependent on tolerance and symp-
tomatic improvement). To date, 5 patients have received Cido-
fovir therapy, all for progressive gastroenteritis. Each patient
experienced symptomatic improvement with Cidofovir; 5/5 had
treatment-associated clearance of culturable virus from infected
site(s). No serious Cidofovir toxicity occurred. An additional 5
allografted patients with milder adenoviral infections after January
1999 were managed without Cidofovir and recovered with sup-
portive care. Viral isolates from 4 Cidofovir-treated patients were
studied for in vitro sensitivity. Cidofovir concentrations inhibiting
virus plaque formation by 50% (IC50) ranged from 0.6 − 2.3
micrograms/ml, levels consistent with clinical efﬁcacy. Based upon
these preliminary laboratory and clinical ﬁndings, Cidofovir mer-
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its further investigation for adenovirus treatment in immunocom-
promised patients.
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NUCLEATED CELL DOSE IN UNRELATED CORD BLOOD UNITS COR-
RELATES WITH ENGRAFTMENT IN ADULT RECIPIENTS
Goldberg, S.L.1; Rowley, S.D.1; Preti, R.A.2; Pecora, A.L.1,2 1. Hacken-
sack University Medical Center, Hackensack, NJ; 2. Progenitor Cell
Therapy, Hackensack, NJ
Nucleated cell dose (TNC) in unrelated cord blood (UCB) units
may be a key feature in neutrophil engraftment, thus limiting
applicability in larger adults. We have performed 21 UCB trans-
plants in adult patients with acute myeloid leukemia (PIF n=1,
CR1 n=2, REL1 n=3, CR2 n=1, advanced n=3), chronic myeloge-
nous leukemia (CP n=2, AP n=2, BC n=2), myelodysplasia
(RAEBT n=1), multiple myeloma (REL1 n=3), and NHL (REL2
n=1). Median age was 48 (range 20-59); median weight 70 kg
(range 52-126 kg). Conditioning regimens: cyclophosphamide/
TBI/ATG (n=15), melphalan/TBI/ATG (n=4), busulfan/cyclo-
phosphamide (n=2). Graft-vs-host prophylaxis consisted of pred-
nisone with either cyclosporin (n=13), or tacrolimus (n=8).
Degree of HLA match was 6/6 in 4, 5/6 in 9, and 4/6 in 8. Medi-
an infused TNC/kg was 1.8 X 107 (range 0.4-5.3). Ten patients
received ex-vivo expanded UCB (Aastrom Bioscience, Inc). Medi-
an time to ANC > 500/mm3 was 30 days (Kaplan-Meier estimates)
including 24% non-engraftment by day 60. Among recipients of
UCB containing less than 2 X 107 TNC/kg the median time to
ANC > 500/mm3 was 35 days including all non-engrafting
patients. By contrast, recipients of > 2 X 107 TNC/kg achieved
engraftment at 18 days (p=0.126). This TNC/kg correlation is
similar to adult Eurocord experience (>1.7 X 107 TNC/kg; ASH
2000) We found no evidence that HLA disparity adversely affect-
ed engraftment. Median time to platelets > 50,000/mm3 was 56
days. Toxic deaths before day 30 occurred in 4 (19%) (MOF n=2,
sepsis n=1, DAH n=1). Toxic death between day 31-100 occurred
in 9 (43%) (GVHD n=2, sepsis n=6, adenovirus n=1, CNS hem-
orrhage n=1) with one late infectious death. (VZV at day 425).
Our experience suggests that delayed engraftment remains an
issue in adult recipients of UCB, especially when the TNC/kg is
below 2 X 107. We have added prophylactic granulocyte transfu-
sions to our protocol.
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PREEMPTIVE GANCICLOVIR AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION BASED ON THE DIGENE HYBRID CAPTURE® CMV
DNA ASSAY
Goldstein, S.; Sandin, R.; Field, T.; Partyka, J.; Burroughs, S.; Greene,
J.; Quilitz, R.; Fields, K. H. Lee Mofﬁtt Cancer Center and Research
Institute at the University of South Florida, Tampa, FL
Although cytomegalovirus (CMV) remains a major source of
morbidity and mortality after allogeneic transplantation, a consen-
sus for the optimal detection, surveillance, and intervention for
CMV has not been reached. In January 99, our center changed its
detection assay and interventional strategy from shell vial and uni-
versal prophylaxis, respectively, to a nucleic acid amplification
method (“signal ampliﬁcation”) utilizing the Digene Hybrid Cap-
ture®(HC) Assay Version 2.0. The advantages of this qualitiative
system, one of only 2 commercially available assays with FDA
approval for CMV detection, include that it: 1) does not require
viable cells, 2) is signiﬁcantly more sensitive than the shell vial or
antigenemia assay, approximating the sensitivity of PCR-based
assays, 3) is less labor-intensive, and 4) allows rapid turnover time
(5h). These features enabled the conversion to a preemptive gan-
ciclovir strategy based on the initial positive Hybrid Capture assay
obtained as part of weekly blood (culture) surveillance after
engraftment through D+90. Of the 49 consecutive evaluable
patients (pts) screened (13 MUD, 36 related): 2 of 15 (13%) pts
who had both seronegative recipient (R) and donor (D) status (low
risk group) had a positive assay post-transplant (2 sib); of the 34
pts with either seropositive R or D status (high risk group), 19
(56%) developed CMV HC positivity on one or more episodes
(R/D +/+ 13/20; +/- 4/7; -/+ 2/7). One pt had documented CMV
colitis in the setting of Grade 4 aGVHD; the remaining pts had
viremia only without associated evidence for CMV infection.
Using this assay as a trigger for pre-emptive ganciclovir spared
15/34 (44%) high risk pts the complications and costs (eg., neu-
tropenia, thrombocytopenia, transfusions, growth factors) associ-
ated with anti-viral therapy in this population.
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HUMAN CYTOMEGALOVIRUS EFFICIENTLY INFECTS DENDRITIC CELLS
AND SUPPRESSES DC FUNCTION AND CELL-MEDIATED IMMUNITY
Grigoleit, U.1; Hebart, H.1; Jahn, G.2; Sinzger, C.2; Riegler, S.2;
Gruenebach, F.1; Einsele, H.1 1. Department of Hematology and Oncol-
ogy, University of Tuebingen, Tuebingen, Germany; 2. Institute of
Medical Virology, University of Tuebingen, Tuebingen, Germany
Human cytomegalovirus (HCMV) infection is one of the most
important and life threatening infections in patients undergoing
allogeneic stem cell transplantation (SCT). In addition, HCMV
infection seems to induce severe immunosuppression and is often
followed by other life-threatening infectious complications, e.g.
invasive aspergillosis. To better understand the effects of HCMV
on dendritic cells (DC), the most professional antigen presenting
cells, DC of healthy HCMV sero-negative donors were infected
with endothelotropic HCMV strains in vitro. Twenty-four hours
after virus infection, the efﬁciency of infection was determined by
immunocytochemical staining of immediate early antigen (IEA). In
addition, the cytokines IL-1β, IL-6, IL-10, IL-15, IL-18 and TNF-
α were analysed in the DC culture supernatant. Furthermore the
expression of CD1a and CD83, MHC class I and II as well as the
co-stimulating molecules CD80, CD86 and CD40 were determined
on infected and uninfected DC by flow cytometry. For their
immunostimulatory function, the DC were tested in a mixed lym-
phocyte reaction (MLR). As a negative control mock infected DC of
each donor were cultured and analysed under the same conditions.
After 24 h of infection 60%-80% of the DC infected with
endothelotropic HCMV strains expressed HCMV specific pro-
tein, e.g. IEA. Whereas the expression of CD1a, CD83 and MHC
II was not signiﬁcantly different between non-infected and infect-
ed DC, MHC class I, CD80 and CD40 were signiﬁcantly reduced
in surface expression as demonstrated by ﬂow cytometry analysis.
The proliferation rate with infected DC as stimulator cells in the
MLR was 2-3 fold lower compared to the one with non infected
DC as stimulator cells.
In conclusion, endothelotropic HCMV strains efﬁciently infect
dendritic cells, reduce the expression of MHC class I and costimu-
latory molecules and thus suppresses cell-mediated immunity. This
might be one explanation of HCMV mediated immunosuppression.
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RAPID SEQUENCE TANDEM STEM CELL TRANSPLANT FOR CHILDREN
WITH HIGH-RISK NEUROBLASTOMA
Grupp, S.A.1; Pierson, G.1; Grifﬁn, G.5; Nancarrow, C.2; Gorlin, J.4;
Stern, J.W.1; Adams, R.3; Diller, L.2 1. Children’s Hospital Philadel-
phia, Philadelphia, PA; 2. Dana Farber Cancer Institute, Boston, MA;
3. Primary Children’s Hospital, Salt Lake City, UT; 4. Memorial
Blood Center, Minneapolis, MN; 5. A.I. DuPont, Wilmington, DE
Autologous bone marrow transplantation has improved the
event-free survival (EFS) of children with high risk neuroblas-
toma. However, the majority of these patients still relapse. To
increase dose intensity during consolidation therapy, we have
designed a Phase II trial for children with advanced neuroblas-
toma utilizing induction chemotherapy followed by tandem high-
dose, myeloablative treatments with stem cell rescue (HDT/SCR)
in rapid sequence. Patients initially received induction chemother-
apy during which local control was completed and peripheral
blood stem/progenitor cells collected. Patients then received tan-
dem courses of HDT/SCR, 4 to 6 weeks apart. 55 patients are
evaluable, median age 3 yrs, and 94 cycles of HDT/SCR have
been completed to date. Pheresis has been possible for every
patient, despite the young age of these patients, with an average of
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7.2x106 CD34+ cells/kg available to support each HDT/SCR
cycle and no differences in numbers of cells collected in younger
or older patients. Patients experience rapid engraftment during
both HDT/SCR cycles, with a median time to neutrophil engraft-
ment of 11 days. Four patients who completed the first HDT
course did not complete the second, and there were four toxic
deaths. With a median follow-up of 22 months from diagnosis, 38
of 55 patients (3 year EFS 58%) remain event-free. A subset of the
patients received stem cells purged by CD34 selection. The
engraftment and EFS of these patients are similar to the overall
group. This work demonstrates that a tandem HDT/SCR regi-
men for high-risk neuroblastoma is a feasible treatment strategy in
children and may improve disease-free survival.
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SUCCESSFUL STEM CELL PURGING USING CD34 SELECTION IN
PATIENTS WITH NEUROBLASTOMA
Grupp, S.A.1; Ash, S.2; Donovan, J.2; Diller, L.2; Pierson, G.1; Fang,
J.1; Ross, A.3; Temel, J.2; Zuckerman, A.2; Gribben, J.2 1. Children’s
Hospital Philadelphia, Philadelphia, PA; 2. Dana Farber Cancer Insti-
tute, Boston, MA; 3. Nexell Inc, Irvine, CA
CD34 selection for purging tumor from peripheral blood pro-
genitor cells (PBPC) collected from patients with neuroblastoma
(NB) has been questioned because of reports of detection of low
levels of CD34 on the surface of some NB cells. We have used 3
approaches to address the issue of purging of NB from PBPC and
possible labeling of NB. 1) FACS detection of CD34 on NB cell
lines. We analyzed 6 NB lines for CD34 expression using the anti-
CD34 MoAbs 9C5 (used in the Isolex system), 12.8 (CellPro) and
QBend10 (CliniMACS), HPCA-1 and HPCA-2. Two of these
lines were previously reported to express CD34. Most MoAb/cell
line combinations showed no increase in labeling over control.
Minimal labeling with 9C5 and QBend10 was eliminated after
forward/side scatter gating to exclude debris. 2) Spiking experi-
ments with the Isolex 50 system. PBPC were spiked with NB cells
and the products puriﬁed using the Isolex 50. Purging of NB was
assessed by quantitative multiplex RT-PCR (Taqman system)
using primers to detect GAGE and normalizing to GAPDH
showing depletion of NB (>2 logs). 3) Analysis of clinical speci-
mens. PBPC pre and post CD34 selection were analyzed from
patients treated on a tandem transplant trial. 30 PBPC aliquots
were selected using the Ceprate LC CD34 selection system and
analyzed using high-sensitivity NB immunocytochemistry (ICC).
In 9/30 specimens where tumor was detectable, we again observed
>2 logs of NB purging. We then analyzed 23 PBPC aliquots from
products infused into tandem transplant patients, both pre and
post CD34 selection, by RT-PCR. 20/23 specimens showed
depletion of NB, although some level of GAGE message was
observed in most post-CD34 selection specimens. These data
show that purging of NB from PBPC specimens using CD34
selection is feasible, yielding infused products that are negative by
ICC but positive by RT-PCR.
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MIROSTIPEN (CKβ-8, MPIF-1) PROTECTS LONG-TERM REPOPULAT-
ING BONE MARROW HEMATOPOIETIC STEM CELLS FROM 5-FLUO-
ROURACIL (5-FU) INDUCED CYTOTOXICITY IN VIVO
Grzegorzewski, K.J.; Hirsch, J.; McCormick, K.; Zhang, L.; Patel,
V.P. Human Genome Sciences, Rockville, MD
Mirostipen, a novel human β-chemokine, inhibits colony forma-
tion by human and mouse myeloid progenitors in vitro and pro-
tects these progenitors from cytotoxic drugs and irradiation in
vivo. The present study examines the effect of mirostipen admin-
istration on the recovery of the long-term repopulating
hematopoietic stem cell following 5-FU administration. Donor
mice (C57BL/6-Ly 5.1) were administered with mirostipen or
vehicle i.p. twice daily for 6 consecutive days. On days 3 and 6,
these mice received i.v. bolus injection of 5-FU (100 mg/kg). Mice
were then sacriﬁced on day 7 and bone marrow cells from each
treatment group were pooled to assay for the presence of long-
term repopulating stem cells. For transplantation, 105 bone mar-
row cells from each of the treatment groups were injected intra-
venously into sublethally irradiated (2 x 4.0 Gy) recipient mice
(C57BL/6). After six months, bone marrow and spleen cells of the
recipient mice were analyzed by ﬂow cytometry to determine the
percentage of donor derived myeloid and lymphoid cells. Irradiat-
ed recipient mice that received bone marrow cells from mice
treated with mirostipen contained 4-fold higher donor derived
cells in both spleen and bone marrow compared to mice that
received bone marrow cells from the vehicle control ( p < 0.001).
Lineage analysis showed that bone marrow from mirostipen treat-
ed mice efﬁciently reconstituted both myeloid and T- and B-lym-
phoid compartments. These pre-clinical studies demonstrate that
mirostipen administration results in the protection of long-term
repopulating bone marrow hematopoietic stem cells, thereby mak-
ing mirostipen an attractive drug candidate for evaluation in bone
marrow autotransplant patients where the preservation of a func-
tionally intact stem cell compartment is desirable.
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ASSOCIATION OF BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMO-
NIA (BOOP) WITH ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE
Hackman, R.C.1,2; Freudenberger, T.D.2; Curtis, J.2; Storer, B.E.1,2;
Madtes, D.K.1,2 1. Fred Hutchinson Cancer Research Center, Seattle,
WA; 2. University of Washington School of Medicine, Seattle, WA
Fifty-one patients with histologic bronchiolitis obliterans organ-
izing pneumonia (BOOP) were identiﬁed by review of all open-
lung biopsies (n=817) from hematopoietic stem cell transplant
patients reported over a 22 year period. Two cases were subse-
quently excluded because they occurred following autologous
stem cell transplantation. The mean age of the remaining patients
was 30.1, and 78% were male. The primary disease was ANL in
41%, ALL in 22%, CML in 22%, lymphoma in 6%, MDS in 6%,
and other diagnoses in 3%. Onset at a median of day 108 after
transplantation was with fever (61%), dyspnea (45%), non-pro-
ductive cough (43%) and crackles (48%). BOOP remained stable
or resolved in 78% of patients. It progressed in 22%, and most of
these patients died of respiratory failure. The study design did not
allow assessment of whether corticosteroid therapy was beneﬁcial.
Microorganisms isolated from 7 of the cases included CMV alone
(3), CMV and parainﬂuenza 3 (1), RSV (2), and Candida parap-
silosis (1). Four allotransplant control subjects were matched to
each case according to year of transplant and age at transplant.
Case and control subjects differed in primary disease diagnosis and
pretransplant conditioning regimen. They did not differ in gen-
der, underlying disease activity, HLA matching with donor,
GVHD prophylaxis, or recipient or donor CMV antibody status.
Histological BOOP was associated with both acute (P=0.001) and
chronic (P=0.036) GVHD. By multivariate analysis, the odds ratio
(adjusted for other variables associated with BOOP) for acute
GVHD was 3.21 (95% CI, 1.15 to 8.99) and for chronic GVHD
was 8.68 (95% CI, 1.81 to 41.62). When the conditional logistic
regression model was adjusted for the presence of both acute and
chronic GVHD, no other variable was associated with BOOP.
Patients with BOOP were more likely to have acute GVHD
involving the skin (P=0.003) and liver (P=0.007).
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HIGH DOSE MELPHALAN(HDM) AND TOTAL BODY IRRADIATION(TBI)
WITH PERIPHERAL STEM CELL TRANSPLANTATION(PSCT) FOL-
LOWED BY INTERFERON (IFN) FOR MULTIPLE MYELOMA
Hamm, C.M.; Klein, J.; Dansey, R.; Baynes, R.; Abella, E.; Karanes,
C.; Varterasian, M.; Mohamed, A.; Aref, A.; Al-Katib, A. Wayne
State University, Detroit, MI
Fifty-nine patients with the established diagnosis of multiple
myeloma (MM) received HDM 140 mg/m2 with TBI(1200 cGy)
or HDM 200 mg/m2 if they had prior radiation. The fractionation
of the TBI was modiﬁed early in the study due to a high incidence
of pulmonary toxicity. All patients were mobilized with cyclophos-
phamide at 4 gm/m2 and G-CSF and were to receive IFN post
transplant. Median age was 54 years (38 - 71 years). The median
number of prior chemotherapy regimens is 2 (range 1- 3). Four-
teen of 40 patients evaluable for IFN therapy received IFN for
minimum of 6 months. The reasons for not receiving interferon
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are varied and will be presented. OS and RFS was 51.3% and
18.6% at 65.5 months with a median follow-up of 12.1 months.
Treatment related mortality was 3.3%. There was a significant
improvement in overall survival (OS) in patients who received
IFN (p=0.009) and a trend to improved relapse free survival (RFS)
(p=0.07) Treatment with TBI predicted for better RFS and OS.
Those receiving TBI had 25.7% RFS and 58.7% OS at 65 months
vs. 0% RFS and 35.2% OS at 31 months in those not receiving
TBI (p = 0.004). Those patients not receiving TBI may have been
a poorly selected group, with most having received prior radiation.
As well, patient selection may play a role in the IFN results, with
better results in the patients who tolerated the IFN. Abnormal
cytogenetics prior to PSCT were found in three patients(8%). All
3 relapsed and died by 30 months. In comparison, 53% of those
with normal cytogenetics were relapse-free at 30 months of fol-
low-up. Abnormal cytogenetics are a poor predictive factor and
alternative therapy such as allogeneic transplants should be con-
sidered in this high risk group.
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EARLY PREDICTION OF POOR HEMATOPOIETIC PROGENITOR CELL
(HPC) MOBILIZATION DURING APHERESIS
Herman, J.H.; Mullaney, M.T.; Klumpp, T.R.; Sabol, P.J.; Mangan,
K.F. Fox Chase-Temple University BMT Program, Philadelphia, PA
Failure of HPC mobilization (MOB) wastes resources and
causes clinical delay. Records of 64 consecutive autologous
HPC patients (PTS) were analyzed to determine whether poor
MOB could be identified early enough to allow salvage inter-
ventions (e.g. altered cytokine dose, changes in apheresis
parameters). Diagnoses included breast cancer (22), NHL (20),
myeloma (11), Hodgkins (5), CML (5), amyloid (2), CLL (1).
Two MOB regimens were used: 1) cyclophosphamide (CTX) 3
gm/m2 and G-CSF 10 mcg/kg/d followed by apheresis when
WBC >1000/mm3 or 2) G-CSF 10 mcg/kg/d for 4 days fol-
lowed by apheresis. Apheresis collections were performed for 5
days or until a target of >4.0x106 CD34+ cells/kg was reached.
G-CSF was given prior to each apheresis. RESULTS with
CTX/G-CSF (33 PTS): 25 PTS reached target after 1 or 2 col-
lections (76%). 3 PTS had >1.0x106/kg after 2 collections and
all reached target after 5 collections. 5 PTS had <1.0x106/kg
after 2 collections, and only 1 reached target after 5 collections
(p=0.0001). RESULTS with G-CSF alone (31 PTS): 8 PTS
reached target after 1 or 2 collections (27%). 15 PTS had
>1.0x106/kg after 2 collections but only 7 reached target after 5
collections, all 7 having >1.5x106/kg. 8 PTS had <1.0x106/kg
after 2 collections, and none reached target after 5 collections
(p=0.002). ANALYSIS: Using <1.0x106 CD34+ cells/kg after 2
days to define poor MOB, 15% (5/33) of CTX/G-CSF PTS and
26% (8/31) of G-CSF only PTS failed to mobilize HPC. Only 1
of these 13 combined poor MOB PTS reached target after 5
aphereses (p<0.0001). Subset analysis of G-CSF only PTS using
<1.5x106 CD34+ cells/kg to define poor MOB was also highly
predictive (p<0.0001). CONCLUSION: Interventions to sal-
vage MOB seem indicated for patients failing to achieve
>1.0x106 CD34+ cells/kg after 2 aphereses following CTX/G-
CSF, or >1.5x106 CD34+ cells/kg following G-CSF alone.
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QUANTITATION OF T CELL NEOGENESIS IN VIVO AFTER ALLOGENE-
IC BONE MARROW TRANSPLANTATION IN ADULTS
Hochberg, E.P.; Chillemi, A.C.; Wu, C.J.; Neuberg, D.; Alyea, E.P.;
Soiffer, R.J.; Ritz, J. Dana-Farber Cancer Institute, Boston, MA
Following myeloablative therapy, it is unknown to what extent
age-dependent thymic involution limits the generation of new T
cells with a diverse repertoire. Normal T cell receptor (TCR)
gene rearrangement in T cell progenitors results in the genera-
tion of T cell receptor rearrangement excision circles (TREC).
TREC are stable episomal DNA circles which are not replicated
and are therefore diluted with subsequent cellular divisions. In
this study we used a quantitative assay for TREC to measure T
cell neogenesis in 18 adult patients with CML who received mye-
loablative therapy followed by transplantation of T cell depleted
allogeneic hematopoietic stem cells. These patients offered an
opportunity to determine the kinetics of immune reconstitution
from normal hematopoietic stem cells in a setting devoid of addi-
tional immunosuppression. Although phenotypically mature T
cells had recovered by 1-2 months post BMT, TREC levels
remained low for 3 months after BMT. T cell neogenesis became
evident by 6 months and normal levels of adult thymic function
were restored at 6-12 months post-BMT. Subsequent leukemia
relapse in 13 patients was associated with reduced TREC levels
but infusion of mature donor CD4+ T cells resulted in rapid
increase of TREC levels indicating restoration of thymic func-
tion. The return of normal levels of TREC in patients after mye-
loablative therapy demonstrates that T cell neogenesis con-
tributes to immune reconstitution in adult patients. The low
levels of TREC detected at relapse suggest that relapse of
leukemia markedly affects the ability to maintain normal thymic
function and normal levels of T cell neogenesis. The rise in
TREC levels after DLI implies that thymic function in adults is
not static and can be manipulated in vivo. The quantitative meas-
urement of TREC offers a new method for assessment of T cell
neogenesis and the effects of different treatments on thymic func-
tion in vivo.
44
PERIPHERAL BLOOD PROGENITOR CELL (PBPC) PREPARATIONS
EXPRESS TISSUE FACTOR (TF) ANTIGEN AND ACTIVITY
Hoffman, M.1; Monroe, D.M.2; Gabriel, D.2 1. Durham VAMC,
Durham, NC; 2. Univeristy of North Carolina, Chapel Hill, NC
Patients undergoing peripheral blood progenitor cell (PBPC)
transplantation can develop laboratory and clinical evidence of a
coagulopathy. We hypothesized that PBPC contain procoagu-
lant activity that contributes to the deleterious effects of trans-
plantation, including coagulopathy and venoocclusive disease.
We assessed TF antigen and activity in PBPC collected for
autologous transplantation. Patients received Cytoxan (2 or 4
g/m2) on day 1, VP-16 (200 mg/m2) on days 1-3, then G-CSF
(10 µg/kg) daily from day 4 until collection of PBPC was com-
pleted. Most underwent three or more apheresis procedures.
Samples of the PBPC products were analyzed by flow cytometry
(12 samples, 8 patients) and TF activity assays (8 samples, 6
patients). The first collection from each patient was sampled, as
were additional collections from 3 patients. Fluorochrome
tagged antibodies to TF and surface antigens were used to deter-
mine the proportion of TF+ cells and correlate TF and lineage
specific marker expression. The number of TF + cells ranged
from 0.2% to 11%. Neither CD34+ cells, nor lymphoid cells
expressed TF antigen. A subpopulation of myeloid (CD33+) cells
were positive for TF, with most of TF+ cells also expressing
granulocytic markers (CD11b, CD15 and lactoferrin). However,
the TF+ cells did not have the light scattering characteristics of
mature granulocytes. They were larger and of lower granularity
than granulocytes. None of the samples with less than 1% TF+
cells (3 samples, all 2nd collections) had coagulant activity in a
prothrombin time-type assay. However, not every sample with
higher proportions of TF+ cells had procoagulant activity. Pro-
coagulant activity was due to TF since an inhibitory anti-TF
antibody abolished clot formation. Thus, PBPC preparations,
especially the first collection from a patient, contain myeloid
precursors that express variable amounts of TF antigen and
activity. This procoagulant activity may contribute to complica-
tions of PBPC transplantation.
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NON-ADHERENT MARROW CELLS GIVE RISE TO THE MARROW
STROMAL MICROENVIRONMENT AND MESENCHYMAL TISSUES AFTER
BMT IN ANIMAL MODELS—TOWARD A MESENCHYMAL STEM CELL
Horwitz, E.M.1; Marx, J.C.1; Brown, P.S.1; Kelly, P.F.1; Vanin, E.F.1;
Donahue, R.E.2; Allay, J.A.1; Persons, D.A.1 1. St. Jude Children’s
Research Hospital, Memphis, TN; 2. Hematolgoy Branch, NHLBI,
Rockville, MD
Although it is well established that hematopoietic stem cells
can be transplanted, it remains unclear whether the same holds
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true for the hematopoietic microenvironment. Recently, inves-
tigators have postulated the existence of a mesenchymal stem
cell whose identity many consider to be an adherent marrow
stromal cell. We specifically tested this hypothesis by studying
the fate of gene-marked adherent and non-adherent marrow
cells after BMT. Murine adherent marrow stromal cells were
isolated and transduced with a retroviral vector encoding the
green fluorescent protein (GFP). Gene transfer efficiency was
>85%, as determined by flow cytometry for GFP. Transduced
cells were infused intravenously after either lethal (1100 cGy)
or sub-lethal (400 cGy) irradiation. Lethally irradiated mice
were additionally given non-transduced, non-adherent marrow
(hematopoietic) cells for hematologic rescue. At 1 and 3
months after infusion, mice were sacrificed and the adherent
marrow cells were isolated. Flow cytometric analysis and PCR
failed to demonstrate GFP+ cells. In separate experiments,
non-adherent marrow cells were transduced with the same
retroviral vector and FACS-sorted cells (>95% GFP+) or
unsorted cells (~40% GFP+) were infused into lethally irradi-
ated recipients. After 6 months, recipient mice were sacrificed
and adherent marrow cells isolated. In contrast to our previous
results, fluorescence microscopy unequivocally demonstrated
GFP+ marrow stromal cells. Flow cytometry confirmed that
up to 80% of recipient stromal cells were GFP+ and lacked
hematopoietic cell antigen expression. Moreover, osteoblasts,
adipocytes, and muscle satellite cells also expressed GFP.
Finally, GFP+ marrow stromal cells (18%) were observed from
a macaque rhesus monkey that received an autologous BMT
with CD34+ PBSCs transduced with the GFP vector. Togeth-
er, these results suggest the existence of a mesenchymal stem
cell which resides within the non-adherent marrow compart-
ment. Ongoing studies are aimed at determining whether
there is a common ontogeny of hematopoietic and mesenchy-
mal tissues.
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MISMATCHED BMT AFTER NON-MYELOABLATIVE CONDITIONING
Isola, L.; Scigliano, E.; Rosina, O.; Najfeld, V.; Fruchtman, S. Mount
Sinai Medical Center, New York, NY
Most non-myeloablative transplants use HLA-matched, G-
CSF−primed PBSC. We performed 3 HLA-mismatched unma-
nipulated BMT’s after non-myeloablative conditioning with
rapid and complete donor engraftment. The patients had refrac-
tory NHL, ALL and AML. One donor was sex-matched sibling
mismatched at A-locus. One VUD was sex-matched (female)
DRβ1-locus mismatched with 9 qh+ chromosome polymor-
phism. The other VUD was sex-mismatched (male) and A-locus
mismatched. Conditioning was TBI 200 cGy, ATG, CSA and
MMF. Grafts contained 6.42, 7.34 and 8.648 TNC and 0.63,
4.68 and 5.52 CD34+ cells/kg. CSA and MMF were continued
post-transplant. Donor chimerism was assessed by cytogenet-
ics,FISH and molecular HLA typing. ANC 500 occurred on d+7
and +11(VUDs) and +11 (related). PLT >20,000/µL was not
reached by the related patient (expired d+29). VUD recipients
achieved PLT >20,000/µL d+17 and +18. In all cases 100%
donor chimerism was documented. By d+30, 2 patients with
leukemia had NED by microscopy and flow cytometry and the
NHL patient had reduction of bulky adenopathy. All three
patients expired with multiorgan failure and evidence of GvHD
of the liver. Graft rejection was not seen in this small group of
recipients with extensive previous chemotherapy. Marked
response to the transplant was seen in these patients who had
refractory disease. Severe GvHD occurred in all patients.
Although not unexpected, the presence of persistent malignant
disease or normal host hematopoiesis may contribute to GvHD
by displaying class II antigens. Mismatched stem cell transplan-
tation can be accomplished across HLA barriers using non-mye-
loablative conditioning. GvHD rather than rejection appears as a
limiting factor to the success of this transplants. Further refine-
ments in conditioning and/or graft manipulation may result in
improved outcomes.
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AN INTERIM LOOK: NON-MYELOABLATIVE CHEMOTHERAPY AND
ALLOGENEIC STEM CELL TRANSPLANT (ALLOSCT) FOR MULTIPLE
MYELOMA IS SAFE AND EFFECTIVE
Janakiraman, N.; Nath, R.; Chodimella, U.; Green, J.; Burt, S.; Vial,
I.; Ford-Cattaneo, C.; Fortney, C. Henry Ford Health Systems,
Detroit, MI
Multiple myeloma (MM) is often treated with autologous stem
cell transplant (AutoSCT), offering higher complete remission
rates and longer survival than conventional chemotherapy. Most
patients eventually relapse. AlloSCT is potentially curative (graft
versus myeloma effect) but is associated with unacceptable mortal-
ity. Non-Myeloablative AlloSCT seems to be a reasonable option
for myeloma patients. 4 patients with MM (IgG kappa, IgG lamb-
da, IgD Lambda, and kappa-light chain) and 1 with multiple plas-
macytoma were treated. There were 2 males and 3 females. Two
of the ﬁve had relapsed after prior AutoSCT. The non-myeloabla-
tive transplant regimen included Fludarabine (30mg/m2 x 5d),
Melphalan (140mg/m2) and Anti-thymocyte globulin (ATG at
10mg/kg x 4d: days -3, -1, +1, and +3). AlloSCT followed with
Cellcept (weeks 2, 3, & 4) and Cyclosporine being used for graft
versus host disease (GVHD) prophylaxis. Patients received a mean
of 8.81 x 106 CD34+ cells/kg and 3.60 x 108 CD3+ cells. Mean
time to neutrophil engraftment (ANC 500/µL) was day 18 (range
day 6 to 50). Mean time to platelet engraftment (>20,000/µL) was
day 42 (range day 14 to 78). Clinically signiﬁcant acute GVHD
(Grade II) occurred in one patient. Three others had grade 2 skin
GVHD. Extensive chronic GVHD occurred in 2/3 evaluable
patients. Mean follow-up is 8.5 months and 4 of 5 patients are
alive without disease progression. One patient died from myocar-
dial infarction secondary to co-morbid conditions. This patient
had IgD MM that had relapsed within 6 months of a prior
AutoSCT. At the time of death, the patient was in remission with
100% donor engraftment. 3/3 evaluable patients reached full
donor chimerism by the day 45-60 VNTR analysis and had disap-
pearance of their monoclonal proteins. The above regimen seems
to be well tolerated and effective. We plan to continue accrual.
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FASL AND PERFORIN CYTOTOXICALLY IMPARED DONOR T-CELLS
INDUCE GVHD IN TNF RECEPTOR 1 (P55) KNOCKOUT MHC I/II MIS-
MATCHED RECIPIENTS
Jiang, Z.; Jones, M.; Levy, R.B. University of Miami School of Medi-
cine, Miami, FL
To understand the involvement of donor T-cell cytotoxic func-
tion in GVHD induction following allogeneic BMT, we examined
GVHD development in the absence of three major cytotoxic
pathways: perforin, FasL and TNF receptor 1 (TNF-R1). In a
MHC I/II mismatched BMT model (H-2b → H-2d), 5•106 T-cell
depleted donor bone marrow cells and varying numbers of T cells
from FasL/perforin double deficient B6 donors (B6-cdd) were
transplanted into MHC mismatched recipients 24 hours after
lethal single dose TBI (8.5Gy). Compared to B6 wild type donor
T cells, we previously reported that 10-fold greater numbers of
B6-cdd T cells are required to induce a similar kinetic pattern of
GVHD onset (e.g. 2.5•106 B6-cdd vs. 2.5•105 B6-wt). In the pres-
ent studies, both TNF-R1 wild type and TNF-R1 deﬁcient recipi-
ents developed lethal GVHD after transplantation of B6-cdd
donor T-cells. The onset of recipients’ weight loss indicated that
both wild type and TNF-R1 deficient hosts developed GVHD
with the same kinetic pattern when 5•106 or 1•106 T-cells from
B6-cdd donors were injected. In addition, groups of recipients
exhibited clinical signs of acute GVHD, including diarrhea, skin
lesion, ruffled fur and haunched posture. Therefore, TNF-R1
deﬁciency did not protect recipients from skin and intestinal dam-
age. Finally, no signiﬁcant difference between mean survival times
(MST) of wild type and TNF-R1 deficient recipients receiving
B6-cdd donor T-cells was observed. In total, these results demon-
strate that TNF-R1 is not the primary pathway for GVHD induc-
tion by T cells which lack the capacity to effect donor-anti-host
cytotoxicity via perforin and FasL dependent signaling. Thus, we
conclude that GVHD can still occur in the simultaneous absence
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of perforin, FasL and TNF-R1 dependent cytotoxic function in
this model.
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DIFFERING NUMBERS OF CYTOTOXICALLY IMPAIRED CD4+ DONOR
T-CELLS IN RECIPIENT LYMPH NODES SUGGEST THAT FAS LIGAND
FUNCTION IS CRUCIAL PRIOR TO GVHD PATHOGENESIS IN MHC
CLASS I/II MISMATCHED BMT MODEL
Jiang, Z.; Jones, M.; Levy, R.B. University of Miami, Miami, FL
A number of allogeneic BMT models involving donor T-cells
with cytotoxic deﬁciencies (perforin/granzyme and/or Fas ligand)
have been examined to investigate the roles of donor T-cell cyto-
toxicity in GVHD. While these studies clearly demonstrated both
FasL and perforin/granzyme dependent effector mechanism con-
tribute to GVHD pathology, it remains unclear when and how
following transplant, each of these cytotoxic pathways are impor-
tant. In this study, we compared the GVHD induction efﬁcacy of
CD4+ T-cells from cytotoxic single (B6-gld faslgld/gld or B6-pko Pfp-
/-) and double deficient (B6-cdd, Faslgld/gldPfp-/-), with wild type
(B6-wt) donors (B6) in a MHC I/II fully mismatched BMT
(8.5Gy) model. The combined absence of perforin and FasL func-
tion in B6-cdd CD4+ T-cells did not prevent induction of GVHD
associated body weight loss, clinical changes and mortality. How-
ever, recipients of B6-cdd T-cells clearly showed a delayed disease
onset. Examination of donor cell numbers early post-BMT
revealed that the absence of perforin and fasL function resulted in
a marked decrease in B6-cdd donor CD4+ T-cell numbers vs. B6-
wt CD4+ numbers, which correlated with the former population′s
delayed ability to induce GVHD. Increasing the dose of TBI con-
ditioning abolished this difference as well as the delayed induction
of GVHD by B6-cdd CD4+ T-cells in the host, suggesting a role
of host resistance. To determine whether perforin and/or FasL
dependent cytotoxic function was responsible for these observa-
tions, individual cytotoxic single deficient and double deficient
CD4+ populations were transplanted. These studies demonstrated
that donor CD4+ T-cells in host LN is dependent primarily on
FasL function. Additionally, rapid weight loss and 100% lethality
occurred in recipients of all four CD4+ donor T cell populations.
Experiments in progress focus on the early mechanism by which
donor CD4+ T-cells overcome the host resistance and mediate
GVH response in the host.
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SUPPRESSION OF ALLOREACTIVITY IN VIVO BY DONOR-DERIVED
REGULATORY T CELLS MAY INVOLVE IL-10 AND FAS/FASL INTERAC-
TIONS BUT NOT IL-4 OR PERFORIN
Johnson, B.D.; Stankowski, M.C.; Hanke, C.A.; Truitt, R.L. Medical
College of Wisconsin, Milwaukee, WI
We previously demonstrated that donor marrow-derived
immunoregulatory T cells emerging from the host thymus sup-
press donor-anti-host alloreactivity induced by donor leukocyte
infusion (DLI) after BMT. The dominant population of regulato-
ry T cells were αβTCR+, Thy1+ and CD4+. Preliminary results
indicated that the regulatory T cells could be adoptively trans-
ferred to suppress alloreactivity in recipients depleted of regulato-
ry cells. We have investigated the mechanism of suppression
induced by these regulatory T cells. Lethally irradiated AKR mice
(H-2k, Thy1.1+) were given TCD BM from C57BL/6 donors (H-
2b, Thy1.2+) and infused 28 days later with spleen cells from
Thy1-congenic donors (H-2b, Thy1.1+) to simulate DLI therapy.
C57BL/6 mice deficient in FasL, perforin, IL-4 or IL-10 were
used as BM donors to examine the role of these molecules in regu-
latory T cell-mediated suppression of alloreactivity. Recipients of
marrow from IL-4 knockout or perforin knockout mice did not
develop acute GVHD after DLI, suggesting that these molecules
were not involved in regulatory cell activity. In contrast, recipients
of IL-10 knockout BM had a signiﬁcantly higher rate of GVH-
related mortality than the DLI controls, indicating that IL-10 may
be involved in the suppression of alloreactivity by regulatory T
cells. Similarly, recipients of FasL knockout BM had more severe
GVHD than chimeras given normal BM and DLI, suggesting that
Fas:FasL interactions were also involved in suppression of allore-
activity by regulatory cells. Notably, BM chimeras given DLI with
Fas-deﬁcient spleen cells did not develop GVHD after DLI, indi-
cating that FasL expressed on regulatory cells is involved in the
suppression of alloreactivity by a mechanism other than inducing
apoptosis of the infused donor T cells. Experiments are in
progress to determine whether other immunosuppressive mole-
cules, such as TGF-β, might also be involved in suppression of
alloreactivity by donor regulatory T cells.
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PREDICTIVE FACTORS FOR UNSUCCESSFUL MOBILIZATION OF
PERIPHERAL BLOOD STEM CELLS (PBSC) IN PATIENTS WITH NON-
HODGKIN′S LYMPHOMA (NHL) AND HODGKIN′S LYMPHOMA (HD)
Johnston, P.B.; Micallef, I.N.; Inwards, D.J.; Ansell, S.M.; Geyer,
S.M.; Iturria, N.L.; Gastineau, D.A.; Litzow, M.R. Mayo Clinic,
Rochester, MN
Introduction: PBSC transplant has become increasingly utilized
in patients with high risk NHL and HD. Factors have been iden-
tiﬁed which are associated with poor mobilization; however, their
importance remains unclear.
Patients and Methods: Between 10/97 and 6/00, 111 patients
were identiﬁed who underwent PBSC mobilization for NHL(90)
or HD(21). NHL histology was low grade(n=10), intermediate
grade(n=45), transformed(n=23) or other(n=12). The median age
at mobilization was 53.2 years (range 12.4−76.1); 64 male:47
female. Stage was early(I/II) in 42 and advanced(III/IV) in 69. The
median interval from diagnosis to mobilization was 18.4 months
(range 3.6−342.4). The median number of prior treatment
episodes was 3(range 1-6)and prior treatment cycles was 9(range
3-25). Bone marrow was positive at mobilization in 12. PBSC
mobilization was with G-CSF(10 mcg/kg/day) in the majority of
patients. The mobilization was considered successful if ≥ 2.0 x 106
CD34+ cells/kg were collected in three or less leukaphereses.
Results: 55 patients(49.5%) had a successful PBSC mobilization.
Unsuccessful mobilization was signiﬁcantly associated with female
gender(p=0.04, odds ratio[OR] 0.45), increasing number of prior
treatment regimens(p=0.04, OR=0.69) and increasing number of
prior therapy cycles(p=0.02, OR=0.87). Mobilization success was
not significantly associated with specific types of therapy. The
only potential exception was the use of purine analogs, where
none of the 9 patients who received this treatment had a successful
mobilization. In a multivariate logistic model for mobilization suc-
cess, gender and the number of prior therapy cycles were the two
signiﬁcant factors (p=0.035 and p=0.025, respectively).
Conclusion: Female gender and increased number of prior treat-
ment cycles are significantly associated with unsuccessful mobi-
lization in both univariate and multivariate analyses. These ﬁnd-
ings help to better deﬁne a population of patients with Hodgkin′s
and NHLs in which alternative regimens for stem cell collection
should be developed.
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FOCUSING ON A LIMITED NUMBER OF T-CELL SPECIFICITIES AS
POTENT INDUCERS OF GRAFT-VERSUS-HOST DISEASE ACROSS A
MULTIPLE MINOR HISTOCOMPATABILITY ANTIGEN BARRIER
Jones, S.C.1; Friedman, T.M.1; Murphy, G.2; Korngold, R.1 1. Thomas
Jefferson University, Department of Immunology and Microbiology,
Philadelphia, PA; 2. Jefferson Medical College, Department of Patholo-
gy, Anatomy and Cell Biology, Philadelphia, PA
CXBE recombinant inbred mice express a subset of the miHA
repertoire expressed by BALB.B mice. As lethally irradiated recip-
ients of naïve H2b-matched C57Bl/6 (B6) T-cells, both strains
succumb to acute GVHD. However, purified B6 CD4+ T-cells
can mediate severe GVHD only in BALB.B recipients, whereas
CXBE recipients develop a much milder form of disease. CDR3-
size spectratype analysis indicated a polyclonal, largely overlap-
ping T-cell response in both strains, as well as evidence for speci-
ficities directed against unique BALB.B miHA. Histological
analysis of GVHD target organs from both recipients revealed
ASBMT Poster Presentations
78
similar amounts of inﬁltration and injury in the lingual epitheli-
um, however significant differences were found in the crypt
epithelium of the small intestine. This contrasting pathology sug-
gested qualitative, rather than purely quantitative differences in
the B6 CD4+ T-cell response between the two recipient strains.
To investigate this notion, we transferred carboxy-fluorescein
diacetate succinimidyl ester (CFSE) labeled B6 T-cells into both
lethally irradiated recipient strains, and 4-5 days later analyzed the
size of the responding B6 CD4+ T-cell pool. The data revealed
that a similar percentage of labeled B6 CD4+ T-cells had under-
gone antigen driven division in both recipients, relative to a syn-
geneic B6->B6 control. To further study the pathological signiﬁ-
cance of the B6->BALB.B response, B6 CD4+ T-cells utilizing
Vbeta families found involved only in the BALB.B response
(Vbeta’s 2 and 11) were selectively transferred into lethally irradi-
ated BALB.B recipients. Both the Vbeta 2 and 11 only and whole
CD4 groups demonstrated similar disease severity until at least 30
days post-transplant. Signiﬁcantly, animals that received Vbeta 2
and 11 depleted CD4+ T-cells experienced slightly less severe
GVHD than the other two groups. This suggests that Vbeta 2
and/or 11+ CD4+ T-cells may be contributing to the more severe
GVHD observed in the BALB.B recipients.
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CHANGES IN LYMPHOCYTE SUBPOPULATIONS AFTER AUTOLOGOUS
PBSCT IN CHILDREN TREATED WITH LOW-DOSE IL-2
Kim, M.1; Lee, S.1; Cho, H.2; Lyu, C.2; Yang, C.2; Kim, H.4; Kang,
S.3; Kim, K.2 1. Ajou University Hospital, Suwon, South Korea; 2.
Yonsei University, College of Medicine, Seoul, South Korea; 3. Pochun
Cha Medical University, Sungnam, South Korea; 4. Yonsei University,
Wonju College of Medicine, Wonju, South Korea
Interleukin-2(IL-2) exerts anti-cancer effect when the tumor
burden is low. During immune reconstitution after stem cell
transplantation, there is a persistent CD4 depletion. To see the
effects of IL-2 on immune reconstitution in children, 14 patients
(9 neuroblastoma, 4 AML, 1 Ewing sarcoma, age 6.1±4.2yr) were
enrolled in this study from 1997 to 2000. IL-2 (Proleukin ®, Chi-
ron) was started subcutaneously after neutrophil engraftment with
the dose of 5MU/sqm for the ﬁrst 2 days, 1MU/sqm for the sub-
sequent 12 days, then followed by 14 days of rest. IL-2 was repeat-
ed more than 6 cycles. The CBC, total eosinophil count(TEC)
and T lymphocyte subsets were checked before and after IL-2
therapy. The interval from PBSCT to start IL-2 was
46.7±36.3days. The follow-up duration was 15.2±7.7(2-26)
months. Two of neuroblastoma patients relapsed 4, 11 months
after PBSCT, respectively. A total of 95 cycles of IL-2 therapy
was done without dose modiﬁcation. All parameters of T-lympho-
cyte subsets increased after IL-2(see table). After the ﬁrst cycle of
IL-2 therapy, CD4/CD8 ratio decreased but subsequent IL-2
therapy resulted in increase of CD4/CD8 ratio and remained <1
for months. Low-dose IL-2 is well tolerated in all patients and
there was marked increase in lymphocyte subpopulations. CD8+
increased prominently for the ﬁrst 2 cycles, however CD4/CD8
ratio increased gradually thereafter. NK cell increased after each
IL-2 therapy and sustained above normal range during follow-up
period. Taken together, IL-2 would have some anti-cancer effects
on early post-transplant period.
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NOVEL APPROACHES FOR THE GENERATION OF LEUKEMIA-REAC-
TIVE ALLOCYTOTOXIC DONOR T CELLS FOR PATIENTS WITH
RELAPSED ALL POST ALLOGENEIC MARROW TRANSPLANTATION.
Koehne, G.; Kernan, N.A.; Steinherz, P.; Doubrovina, E.; O’Reilly,
R.J. Memorial Sloan-Kettering Cancer Center, New York, NY
We have evaluated the capacity of host-derived EBV-trans-
formed B-lymphoblastic cell lines (BLCL), which express critical
costimulatory molecules, to stimulate the generation of cytotoxic
T cells against minor or major alloantigens expressed on host
pre-B ALL cells. Matched-unrelated (HLA-A, B, DR and DQ)
donor PBMC were stimulated weekly for 5 weeks with EBV
BLCL derived from PBMC obtained from the patient with pre-
B ALL during remission. Effector T cells tested in 51Cr-release
assay showed 39% and 28% lysis of the patient EBV BLCL and
patient B-ALL cells and 9% lysis of third party B-ALL cells. In a
second case haploidentical maternal T lymphocytes were stimu-
lated with EBV BLCL, derived from the patient during remis-
sion and their killing capacity determined in functional assays.
51Cr-release assay showed 30% lysis of both the patient’s EBV
BLCL and B-ALL cells, 15% lysis of patient PHA-blasts and
5% of third party B-ALL. In limiting dilution analysis we
obtained a CTLp frequency of 1/633 against patient EBV
BLCL, 1/10,253 against patient leukemia cells, 1/319,903 and
1/469,928 against patient PHA-blasts and third party B-ALL,
respectively. Intracellular cytokine staining of IFN-γ− producing
donor CD8+ cells displayed 18% of the donor CD8+ cells pro-
ducing IFN-γ in response to the EBV BLCL, 4.8% in response
to the patient’s leukemia cells and only 0.5% and 0.1% following
activation with PHA-blasts and third party B-ALL cells, respec-
tively. These studies suggest that EBV transformed BLCL
express alloantigens that are also displayed on patient B-ALL
cells which can be targeted by sensitized HLA matched-unrelat-
ed or HLA disparate alloresponsive T cells. Such cells, if modi-
fied to express a drug sensitive gene, such as herpes simplex
virus-thymidine kinase, could provide a more potent and con-
trolled population of effector cells for adoptive therapy of acute
lymphoblastic leukemia.
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CD8+ BARRIER T-CELLS ELICIT INTACT BARRIER ACTIVITY AGAINST
ALLOGENEIC MARROW TRANSPLANTS IN THE SIMULTANEOUS
ABSENCE OF PERFORIN, FAS-L AND TNFR1 OR R2 SIGNALING.
Komatsu, M.; Mammolenti, M.; Jones, M.; Zimmerman, Z.; Levy, R.
University of Miami, Miami, FL
Engraftment failure following allogeneic bone marrow trans-
plantation is of clinical concern using T-cell depleted innoculum
(BMT-TCD), particularly in aplastic anemia recipients. Immune
resistance by lymphoid and NK populations with “barrier” func-
tion is well established. We previously demonstrated that host
TCR+CD8+NK1.1- cells effectively resist MHC-matched marrow
allografts in B6 wild type (wt) recipients primed to donor BALB.B
MiHA. Immunodominant CTL deﬁned donor antigens appear to
dominate the speciﬁcity of this allograft resistance, consistent with
a response by MiHA-reactive CD8+ T-cells. Host CD4+ cells do
not function as effector cells in the resistance observed, but are
required for the generation of resistance activity, presumably sup-
porting the expansion of TCR+CD8+NK1.1- barrier cells. T-cell
lines generated from the B6-wt Spl and LN cells primed to
BALB.B MiHA were exclusively TCRαβ+CD8+NK1.1-Mac1-
cells. Transfer of these cells into naive B6 recipients conferred
resistance to BALB.B marrow allografts. Importantly, studies
using the cytotoxically double (perforin/FasL) deﬁcient (cdd) B6
mice primed to donor MiHA revealed that B6-cdd CD8+ cells are
capable of highly efﬁcient allograft resistance. Barrier activity in
B6-cdd against progenitor cells from TNFR1-/- or TNFR2-/-
donors demonstrated resistance in the simultaneous absence of
three major effector pathways. These findings indicate the
involvement of alternative effector pathway(s), which could
include ligands of other TNF-family members or non-cytotoxic
inhibitors (i.e. TGF-β) in resistance. Notably, MiHA reactive T-
cell lines recently generated from B6-cdd were predominantly
TCR+CD8+NK1.1-Mac1- cells, and also contained a high percent-
age of Vβ5 TCR+ cells, consistent with a limited response against
selected (i.e. immunodominant) donor antigens. In total, we pro-
pose that priming of host lymphoid populations to donor MiHA
leads to the expansion of TCR+CD8+ effector T-cells which can
exert potent barrier activity against MHC-matched marrow allo-
graft in the absence of well deﬁned, classic cytotoxic pathways.
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HIGH-DOSE BCNU, ETOPOSIDE, ARA-C, CYCLOPHOSPHAMIDE (BEAC)
IS FEASIBLE IN AN OUTPATIENT COMMUNITY SETTING FOR
PATIENTS (PTS) WITH RELAPSED AND HIGH-RISK NON-HODGKIN′S
LYMPHOMA (NHL)
Kritz, A.D.; Mandanas, R.A.; Cuasay, L.; Quiett, K.J.; Williams, L.A.;
Beveridge, R.; Spitzer, G.; Rifkin, R.M. U.S. Oncology, Houston, TX
Most studies of high-dose chemotherapy (HDC) and autologous
stem cell transplant (ASCT) for NHL have been reported from
university hospital inpatient settings. Between 1996 and 1999, US
Oncology’s network of community transplant centers (17 centers
in 13 states) treated 103 NHL pts (median age 54 (range 23 - 70),
sex: males-64, females-39) using an identical protocol (AOR-
NHL-9605). Status of disease at time of transplant: 70 relapsed,
23 failed to achieve a CR with ﬁrst line therapy, and 10 were in
ﬁrst CR. Pathology: 15 low grade, 68 intermediate grade, 3 high
grade, 12 mantle cell, 4 T-Cell, and 1 unclassiﬁed lymphoma. All
transplants were initiated in the outpatient setting with hospital-
ization only for complications. HDC consisted of bolus BEAC
given as Day -7: BCNU 300 mg/m2; and Day -6 to -3 : etoposide
100 mg/m2 bid, ara-C 100 mg/m2 bid, and cyclophosphamide 35
mg/kg qd. Median days to ANC > 500/µL was 10 (range: 7-29)
and to platelets > 20,000/µL was 16 (range: 6-29). 59 pts never
required hospitalization. Median days for 44 hospitalized pts was
10 (2-28). Four treatment-related deaths occurred prior to 100
days post-transplant. Median follow-up for 69 alive pts is 22
months (range 3-43).
High dose BEAC is a safe and effective regimen and that can be
used in a community and outpatient setting.
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PREDICTING RELAPSE AFTER ALLOGENEIC TRANSPLANT FOR ACUTE
MYELOGENOUS LEUKEMIA
Kumar, S.; Chen, M.G.; Gastineau, D.A.; Gertz, M.A.; Inwards, D.J.;
Lacy, M.Q.; Tefferi, A.; Litzow, M.R. Mayo Clinic, Rochester, MN
Background: Allogeneic BMT is potentially curative in patients
with AML.However,nearly 20-30% relapse within a year. There
are no reliable markers to predict relapse. Lymphocyte recovery in
early post-transplant period, development of acute GVHD
(aGVHD), cytogenetics pre-transplant and disease status
(advanced vs. non-advanced) have been shown to inﬂuence risk of
relapse. Hypothesis: A scoring system using these variables can
predict with more certainty the risk of relapse. Methods:A retro-
spective review of patients with AML who underwent matched
related allogeneic-BMT at our institution between 1982 and 1999
was done to examine this hypothesis. Patients surviving up to 30
days post-transplant and those for whom all the variables were
available were included for analysis. One point was assigned for
each of the four good prognostic variable namely; normal cytoge-
netics pre-transplant or good-risk abnormalities (t15:17,t8:21,inv
16), non-advanced disease (AML in ﬁrst remission), development
of any grade of aGVHD by day +30 and absolute lymphocyte
count (ALC) >175/µL at day 30 post-transplant. Results: Twenty-
one relapses occurred among the 54 eligible transplants (Table).
There was a continuous increase in the risk of relapse with
decreasing total score. The relapse free survival as estimated by
the Kaplan Meier product limit method demonstrated signiﬁcant
difference in the relapse survival between the groups (p <0.001,
log rank test). Conclusion: A scoring system utilizing these four
factors appears to be able to stratify patients according to increas-
ing risk of relapse. However, these results needs confirmation
using larger patient groups.
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CHARACTERISTICS OF CORD BLOOD COLLECTIONS: THE COBLT
STUDY CORD BLOOD BANK EXPERIENCE
Kurtzberg, J.1; Wagner, E.L.2; Gindy, L.3; Issitt, L.1; Carter, S.L.2;
Kernan, N.A.4; Jensen, L.5; Cairo, M.S.6; Fraser, J.K.3 1. Duke Uni-
versity, Durham, NC; 2. The EMMES Corporation, Potomac, MD; 3.
University of California - Los Angeles, Los Angeles, CA; 4. Memorial
Sloan-Kettering Cancer Center, New York, NY; 5. National Heart,
Lung, and Blood Institute, Bethesda, MD; 6. Georgetown University,
Washington, DC
In October 1997, recruitment for cord blood donors was initiat-
ed by the cord blood banks (CBBs) established as part of the
NHLBI-sponsored Cord Blood Transplantation (COBLT) Study.
After three years of recruitment at hospitals serving ethnically
diverse populations, 30709 donors have been screened for donor
eligibility. Of those screened, 18432 (60.0%) consented to donate
cord blood, 9074 (29.6%) were not approached, and 3203 (10.4%)
were approached but refused participation. As of November 1,
2000, 14609 cord blood units (CBUs) (38.9% White, 16.4%
Black, 11.2% Asian, 20.3% Hispanic, 13.1% Mixed/Other/
Unknown) have been collected from consented donors. The mean
CBU collection volume is 64.2 mL (SD ± 31.2). CBUs with a col-
lection volume ≥ 40 mL and ≥ 6 x 108 nucleated cells, or collection
volumes ≥ 60 mL are red cell depleted and volume reduced. Of
the collected CBUs, 9542 (65%) have been processed. The mean
pre- and post-processing total nucleated cell count is 11.7 x 108
(SD ± 5.3) and 9.1 x 108 (SD ± 4.1), respectively. The mean viable
nucleated cell recovery is 78.0% (SD ± 9.8). Flow cytometry char-
acterization and colony forming unit enumeration are also avail-
able for 82% of the processed CBUs (CD 34+ cells: mean=2.6 x
106, SD ± 3.0; CFU-GM: mean=9.6 x 105, SD ± 8.4). Overall,
6841 (46.8%) CBUs have been discarded. A total of 4853 (70.9%)
have been discarded prior to initiating processing, primarily for
insufficient volume (n=4290, 88.4%). The remaining 1988
(29.1%) CBUs have been discarded post-processing primarily for
a positive maternal infectious disease test (n=543, 27.3%). Of
note, an additional 496 CBUs, currently under review, have a pos-
itive Hepatitis B core antibody test. Sixty-five percent of these
CBUs are from Asian donors. Detailed data regarding donor
recruitment, delivery, collection, processing and cryopreservation
will be described.
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ROLE OF COSTIMULATORY AND CLASS I MHC MOLECULES IN THE
INDUCTION OF TUMOR IMMUNITY TO MURINE ACUTE MYELOGE-
NOUS LEUKEMIA
LaBelle, J.1; Blazar, B.2; Truitt, R.1 1. Medical College of Wisconsin,
Milwaukee, WI; 2. University of Minnesota Cancer Center, Minneapo-
lis, MN
Donor leukocyte infusions (DLI) have been used successfully to
treat CML relapse after BMT, but have been less effective against
AML. The inability of AML cells to induce leukemia-specific
immunity may be due in part to the lack of necessary costimulato-
ry molecules. In this study, we examined the effects of B7-1 and
B7-2 costimulatory molecules on induction of immunity to
C1498, a weakly immunogenic murine AML of C57BL/6 origin,
with the intent of identifying a vaccine that would enhance
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leukemia-speciﬁc immunity in donor/host-tolerant BM chimeras.
We found that subcutaneous inoculation of syngeneic B6 mice
with 106 viable C1498/B7-2 induced a strong CD8+ T-cell medi-
ated immune response and persistent immunity to parental C1498
AML. CD4+ T-cells did not appear to play a significant role.
C1498/B7-2 leukemia cells were sufﬁcient for inducing immunity
to C1498 since BM chimeras deficient in MHC class I+ APCs
(ß2m ko) were able to reject viable C1498/B7-2 AML cells and a
subsequent challenge with C1498. In contrast, inoculation of
viable C1498/B7-1 resulted in progressive and lethal tumor
growth. T-cells from mice inoculated with C1498/B7-1 leukemia
were nonresponsive to stimulation with C1498/B7-2 or C1498 in
vitro. When mixtures of B7-1+ and B7-2+ AML cells were coin-
jected subcutaneously, B7-2+ cells were rejected, while B7-1+ cells
grew progressively. Using BM chimeras in which host T-cells
lacked CTLA-4, we found that the failure of C1498/B7-1 cells to
induce CD8+ T-cell immunity to C1498 was due to the interac-
tion of CTLA-4 on the responding T-cells with B7-1 on the
leukemia. In this model, speciﬁc interaction of B7-1 and CTLA-4
appears to result in a dominant negative effect and T-cell anergy.
A differential effect of costimulatory molecules on induction of
tumor immunity in vivo has signiﬁcant implications for the design
of vaccine strategies both within and outside the context of
BMT/DLI therapy.
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QUANTIFICATION OF POLYOMA BK VIRURIA TO PREDICT THE
OCCURRENCE OF HEMORRHAGIC CYSTITIS IN BONE MARROW
TRANSPLANTATION PATIENTS
Leung, A.Y.; Suen, C.K.; Lie, A.K.; Liang, R.H.; Yuen, K.Y.; Kwong,
Y.L. Queen Mary Hospital, Hong Kong, China
Background. Polyoma BK virus is frequently identified in the
urine of bone marrow transplantation (BMT) patients with hem-
orrhagic cystitis (HC). However, viruria is common even in
asymptomatic patients, so that a direct causative role of BKV is
difﬁcult to establish. We tested the hypothesis that although qual-
itative testing of BK viruria is non-discriminating, quantiﬁcation
of BK viruria might be useful in predicting HC in BMT patients.
Methods. Prospective serial quantiﬁcation of BK viruria in 24-
hour urine and viremia was performed in ﬁfty patients at a median
of seven time points during BMT. A total of more than 800
patients samples were quantified for BKV VP-1 gene sequence
with a real-time quantitative Polymerase chain reaction (Q-PCR).
Results. Twenty patients (40%) developed HC, of whom six had
overt cystitis with gross hematuria (HC≥grade 2), and 14 had
microscopic hematuria (HC grade 1). Patients with HC, when
compared with asymptomatic patients, had significantly higher
peak BK viruria (6x1012 vs. 5.7 x 107 genome copies/day, p <
0.001) and larger total amount of BKV excreted during BMT
(4.9x1013 vs. 7.7x108genome copies, p < 0.001). HC of severity ≥
grade 2 occurred after engraftment, and was significantly later
than HC of grade 1 that usually occurred before engraftment (day
37 vs. day 4, p < 0.01). Multivariate analysis showed that HC was
not related to age, conditioning regimens (cyclophosphamide and
total body irradiation), type of BMT (allogeneic / autologous) and
graft versus host disease. BK viruria, both peak value and total
BKV excretion, was the only risk factor that predicted the occur-
rence of HC.
Conclusion. Quantification of BKV excreted in the urine of
BMT patients predicted the occurrence of HC.
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GM-CSF AS PREEMPTIVE THERAPY FOR POST-TRANSPLANT EBV
DISEASE
Loechelt, B.J.; Witte, D.P.; Vergamini, S.; Groen, P.; Wallace, C.;
Boyer, M.; Harris, R.E.; Filipovich, A.H.; Gross, T.G. Children’s Hos-
pital Medical Center, Cincinnati, OH
Successful treatment of post-transplant EBV disease requires the
control of B-cell proliferation and enhancement of EBV speciﬁc
cytotoxic T-cell (EBV-CTL) immunity. Since GM-CSF can aug-
ment primary CTL responses and enhance CTL responses as an
adjuvant to vaccines against viruses and cancer, we hypothesized
that pre-emptive therapy with GM-CSF would enhance EBV-
CTL immunity and decrease the incidence of EBV associated
post-transplant lymphoproliferative disease (PTLD). Five pedi-
atric patients, all T-cell depleted, matched unrelated donor mar-
row recipients, received GM-CSF (250µg/m2 IV 3 times/week) at
a median of 54 days post-transplant (range of 48-98 days) when
they became EBV PCR positive and developed symptoms, i.e.
fever, fatigue, nausea/vomiting, with no other identiﬁable etiolo-
gy. Median EBV DNA levels by semi-quantitative PCR at time of
symptoms were 350 copies/µg DNA (10-12200 copies). Median
time following GM-CSF to resolution of all symptoms was 15
days (7-20 days) and EBV PCR negativity was 20 days (7-32 days).
Four patients remained free of recurrence of symptoms or PTLD.
One patient, after GM-CSF was discontinued, developed grade IV
GVHD requiring increased immunosuppression, including ATG,
and subsequently developed PTLD. One patient (Table below)
had EBV-CTL quantitated using ﬂow cytometry to detect CD69+,
CD8+, and intracellular γ-IFN+ cells following stimulation with an
EBV transformed donor B-cell lymphoblastoid cell line (normal
controls = 1-2% EBV-CTL). This patient developed symptoms
on day +96 and started GM-CSF on day +98. In conclusion, these
preliminary results suggest that GM-CSF may enhance EBV-
CTL immunity post-BMT and may be an effective pre-emptive
therapy for post-BMT EBV disease.
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MEASUREMENT OF AUTOLOGOUS IMMUNITY TO PRESENTATION
LEUKAEMIC BLASTS IN PATIENTS IN FIRST COMPLETE REMISSION
CAN PREDICT THOSE WHO WOULD BENEFIT FROM IMMEDIATE
ALLOGENEIC STEM CELL TRANSPLANTATION
Lowdell, M.W.1; Samuel, D.2; Wood, M.E.3; O’Neil, E.1; Saha, V.2;
Prentice, H.G.1 1. Royal Free Hospital, London, United Kingdom; 2.
ICRF Childrens’ Cancer Group, London, United Kingdom; 3. Colch-
ester General Hospital, Colchester, United Kingdom
Graft-versus-leukaemia after allogeneic BMT is known to be
mediated by immune mechanisms. We have shown that
immune-mediated anti-leukaemia activity is the mechanism of
cure after autologous BMT. To further explore this phenome-
non, we have studied 19 patients after chemotherapy alone. All
patients were undergoing treatment for acute leukaemia (AML
- 10; ALL -9) and the group consisted of 11 adults and 8 chil-
dren (all cALL). Lymphocytes from each patient were collect-
ed in remission at completion of therapy and tested for in
vitro cytolytic activity against their own presentation
leukaemic blasts. Patients who subsequently relapsed were
found to have significantly lower leukaemia-cytolytic activity
(LCA) than those who remain in remission beyond two years
(p<0.001). The subset of lymphocytes mediating this activity in
vitro were CD56+/CD8wk+/CD3- natural killer cells (NK)
and the cytolytic signal was mediated through CD8-alpha and
CD69 molecules. The absence of LCA activity was able to
predict relapse with a sensitivity of 100% and specificity of
91%. 7/11 (63.6%) of patients with LCA <12.2% relapsed
within 2 years of attaining CR. The median time to relapse in
this group was 11 months. Patients with LCA >12.2% all
(13/13) remain in CR with median follow-up of 38 months
(range 13-86). Patients who achieve remission after
chemotherapy but fail to develop protective levels of NK-
mediated LCA within 3-6 months of completion of
chemotherapy should be considered as candidates for allogene-
ic transplantation or immunotherapy.
ASBMT Poster Presentations
81B B & M T
63
RECIPIENT PRIMING AGAINST DONOR MHC ANTIGENS EFFECTIVELY
AUGMENTS RESISTANCE TO ALLOGENEIC PROGENITOR CELL
ENGRAFTMENT IN THE ABSENCE OF PERFORIN, FASL AND TNFR1
SIGNALING.
Mammolenti, M.; Komatsu, M.; Jiang, Z.; Jones, M.; Levy, R. Uni-
versity of Miami, Miami, FL
Resistance against donor progenitor cell engraftment occurs fol-
lowing TCD of donor inoculum for GVH prophylaxis and in
patients unintentionally primed against donor antigens. We are
investigating radioresistant effector pathways in the barrier
response against MHC mismatched allografts. B6-wild type recip-
ients can resist up to 5 -10 x106 BALB/c TCD marrow allografts
as evidenced by the absence of donor progenitor cells in recipient
spleens 5 days post-BMT. Cytotoxically double deﬁcient (cdd) B6
mice lacking perforin and FasL dependent function also demon-
strated resistance, however, it was more easily overridden in these
recipients as evidenced by increased CFU numbers following
transplant of >5x106 donor marrow. Notably, the resistance in B6-
cdd as well as B6-wt recipients against TNFR1-/- deﬁcient donor
progenitors was not different vs progenitors from TNFR1+/+ nor-
mal donors. Therefore, a resistance pathway independent of per-
forin, FasL and TNFR1 signaling is present in recipients against
MHC mismatched marrow allografts. B6-cdd, as well as B6-wt
recipients, were then primed against donor antigens prior to
BMT. Both groups of recipients exhibited markedly increased
resistance as assessed by their rejection of greater than 3x107 allo-
geneic BM. B6-cdd primed recipients rejected TNFR1-/- donor
marrow equally efficiently compared to TNFR1+/+ marrow. We
conclude that priming of recipients efﬁciently augments the non-
perforin, FasL, TNFR1 pathway of resistance present in naive
recipients. In total, these results support the notion that more
than one effector pathway can contribute to resistance post- pro-
genitor cell transplant. Resistance in the absence of three cytotox-
ic pathways is consistent with the notion that non-lytic mecha-
nisms of inhibition (?reversible) may interfere with allogeneic
progenitor cell engraftment
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T CELLS LACKING FASL AND PERFORIN ARE CAPABLE OF INITIAT-
ING SEVERE GVHD IN A MINOR HISTOCOMPATIBILITY MISMATCHED
BMT MODEL.
Marks, L.; Levy, R. University of Miami School of Medicine, Miami, FL
The mechanisms T cells employ to initiate and effect GVHD
responses remain to be precisely deﬁned. In vitro donor anti-host
cytotoxicity assays do not always correlate with in vivo severity of
GVHD, however cytotoxic molecules have been considered
potential candidates for promoting host tissue damage following
allogeneic BMT. We have examined the relevance of two effector
mechanisms by utilizing cytotoxically double deficient (cdd) T
cells in a minor antigen-mismatched BMT model system. Donor
T cells from B6 mice expressing mutated fas ligand (B6-FasLgld )
and lacking perforin (B6-pfp-/-) were compared to wild-type (B6-
wt) T cells following injection into MHC-matched (H-2b)
C3H.SW hosts. Recipient mice received 9.0 Gy TBI on day −1
and either 5 x 106 B6-wt BM only, or B6-wt BM and 1.5 x 107
B6-wt T cells, or B6-wt BM and 1.5 x 107 B6-cdd T cells on day 0.
All control BMT recipients survived (100%) however greater
lethality was observed in recipients of B6-cdd (80%) compared to
B6-wt (20%) T cells. Histopathological findings revealed more
extensive mononuclear inﬁltrates and moderate to severe cellular
atrophy in the GVHD target tissues examined (liver, stomach) in
recipients of B6-cdd T cells vs. mild infiltrate and atrophy in
recipients of B6-wt T cells. These data suggest that T cells lack-
ing FasL and perforin function are capable of initiating GVHD
to an equal or greater degree than B6-wt T cells in a minor anti-
gen-mismatched BMT model. Interestingly, although BMT
recipients of both B6-wt and B6-cdd T cells contained elevated
ratios of CD8:CD4 T cells, the latter recipients exhibited
increased donor cell proliferation and increased host cell survival.
These two factors may have contributed to the large increase in
spleen cell numbers and the increased severity of GVHD follow-
ing BMT containing B6-cdd T cells.
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ELEVATED PLASMA IL-6 CONCENTRATIONS ARE AN EARLY MARK-
ER OF ORGAN DYSFUNCTION AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION.
McGuire, T.R.; Hock, L.; Schneider, J.; Bociek, G.R.; Pavletic, S.Z.;
Tarantolo, S.; Haire, W.D. University of Nebraska Medical Center,
Omaha, NE
Introduction: Organ dysfunction (OD) after allogeneic trans-
plantation is associated with morbidity and death. Clinically, OD
is preceded by weight gain and an increased respiratory rate which
may be cytokine related. Consequently, we measured plasma
cytokine concentrations at the time of admission, at the end of
preparation, 5 days before OD, on the day of OD, and 5 days after
the onset of OD and compared them to controls who never devel-
oped OD.
Methods: Plasma was collected daily in patients undergoing
stem cell transplantation. Patients were evaluated daily for pul-
monary dysfunction (O2 saturation <90), CNS dysfunction (drop
of 4 points on Folstein MMSE) and hepatic dysfunction (VOD by
the Jones Criteria). Plasma concentrations of TNF-alpha, IL-6,
and IL-10 were measured using an ELISA (R&D Systems, Minn
MN). The lower limit of sensitivity was 5pcg/ml or less for all
assays and intra-assay precision between 5-10%. Cytokine con-
centrations were compared between OD and control patients
using the Wilcoxon Rank Sum and Fisher’s Exact Test.
Results: The number of patients with measurable IL-6 levels
prior to preparation and median values 5 days prior to the onset of
OD were significantly greater in the OD group (p=0.022 and
p=0.0033, respectively). This signiﬁcant elevation continued at the
time of OD (p=0.0036) and 5 days later (p=0.0002). There were
few measurable TNF-alpha and IL-10 levels prior to preparation
or 5 days prior to onset of OD. There were significantly more
patients with detectable IL-10 and TNF-alpha levels at the time
of OD and 5 days later compared to controls.
Conclusions: IL-6 is an earlier predictor of OD than either
TNF-alpha or IL-10. IL-6 levels were signiﬁcantly elevated prior
to transplant and 5 days prior to onset of OD which may allow the
development of aggressive preventive strategies in these high risk
patients.
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EX VIVO T-CELL DEPLETION FOR GRAFT VERSUS HOST DISEASE
PROPHYLAXIS IN RELATED HAPLO-IDENTICAL ALLOGENEIC STEM
CELL TRANSPLANT RECIPIENTS.
McGuirk, J.P.1,2; Dix, S.P.1,2; Abhyankar, S.1,2; Greenﬁeld, D.4; Belt,
R.J.1,2; Picken, S.1,2; Barnhart, C.S.1,2; Meagher, R.3; Jensen, K.3;
Gilman, A.4 1. Oncology and Hematology Associates, Kansas City, MO;
2. Saint Luke’s Hospital, Kansas City, MO; 3. Community Blood Cen-
ter, Kansas City, MO; 4. Children’s Mercy Hospital, Kansas City, MO
Haploidentical stem cell transplantation is complicated by graft
rejection, GVHD, relapse, and prolonged immunodeficiency.
Aversa et al (NEJM 1998; 339: 1186-93.) report high stem cell
doses and T-cell depletion via CD34+ cell selection reduce graft
rejection and GVHD. Since Dec 1999, we performed haploidenti-
cal transplants in 9 patients (pts), median age=24yo, with high-risk
hematologic malignancies (AML=4, NHL=3, ALL=2). Pts
received TBI 800cGy with lung shielding to 400cGy (n=7) or mel-
phalan 140mg/m2 /d (n=2) (day −7), thiotepa 10mg/kg/d (day −6),
fludarabine 40mg/m2 /d (day −5 to −1), and rabbit ATG (Thy-
moglobulinTM) 2.5 mg/kg/d (day −5 to −2). Eight pts received
tacrolimus 0.03mg/kg/d from day −7 to −1. No GVHD prophy-
laxis or growth factor support was adminstered. Cell dose targets
were 10x106 CD34+ cells/kg and a maximum of 5x104 CD3+
cells/kg following T cell depletion via CD34+ cell selection (Clin-
iMACS, Milytenyi). Patients received a mean of 10.7x106 CD34+
cells/kg (median CD34+ cell recovery =55%) and 3.3x103 CD3+
cells/kg (median 5 log reduction). One pt died prior to engraft-
ment. Of 8 evaluable pts, the median time to ANC>500 was d12
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post PBSCT. Five of 8 evaluable pts achieved plt>20K by a medi-
an of d21 post PBSCT. Three pts had delayed platelet recovery.
No pt has developed GVHD. Signiﬁcant infectious toxicity occur-
ring by d100 included aspergillosis = 5 pts, CMV pneumonia = 3
pts, non-CMV viral pneumonia = 2 pts, bacterial infections = 2
pts, candidemia = 1 pt, and acyclovir-resistant HSV in 1 pt. Two
of nine pts are alive 101d and 197d post PBSCT. Seven pts have
expired due to relapse (1), multi-organ failure (1), PCP (1),
IP/HUS (1), IP (1), CMV pneumonia (1), or EBV lymphoma (1).
With this approach, pts experienced prompt neutrophil engraft-
ment and experienced no GVHD. However, delayed immune
reconstitution and infectious complications remain formidable
challenges.
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OSTEOPOROSIS IN THE STEM CELL TRANSPLANT PATIENT: A PRO-
TOCOL FOR EVALUATION, PREVENTION AND MANAGEMENT
Mitchell, S.A. University of Maryland, Greenebaum Cancer Center,
Baltimore, MD
Osteoporosis is a skeletal condition characterized by decreased
density of normally mineralized bone. The reduced bone density
leads to decreased mechanical strength, thus making the skeleton
more likely to fracture. Osteoporosis can be a signiﬁcant clinical
problem in the long-term follow-up of both men and women who
have undergone a stem cell transplant. It is associated with signiﬁ-
cant medical costs, and can have a detrimental effect on long-term
quality of life. Patients undergoing allogeneic transplantation have
multiple risk factors for osteoporosis, including systemic corticos-
teroid therapy for the treatment of graft versus host disease. Sig-
niﬁcant advances have been made in our ability to detect, prevent
and treat osteoporosis. However, to be most effective, therapy
should be started early, before serious bone loss has occurred.
Since there can be a latent period before the appearance of patho-
logic fracture, and since many different post-transplant issues
compete for our attention in these complex patients, insufﬁcient
attention may be given to osteoporosis prevention and treatment
until symptoms occur. This paper provides an overview of the
pathophysiology of osteoporosis, and presents an algorithm for its
evaluation, prevention and management in the stem cell transplant
patient. The algorithm incorporates (1) risk assessment and
screening, (2) diagnostic strategies, (3) preventive measures such
as exercise and fracture prevention counseling, and (4) the use of
pharmacologic agents, including hormone replacement, calcium
supplementation, bisphosphonates, calcitonin, vitamin D analogs,
and selective estrogen receptor modulators. The importance of
patient education, endocrinology consultation, and follow-up is
emphasized. With greater knowledge of the factors that affect
bone health and the options for screening and therapy in patients
at risk for or experiencing osteoporosis, the severity and conse-
quences of this problem can be minimized.
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ADHERENCE ISSUES IN STEM CELL TRANSPLANTATION: THEORETI-
CAL PERSPECTIVES AND CLINICAL INTERVENTIONS
Mitchell, S.A. University of Maryland, Greenebaum Cancer Center,
College Park, MD
Stem cell transplantation (SCT) provides long-term disease-free
survival for individuals with a variety of hematologic and non-
hematologic conditions. However, despite advances in technology
and clinical care over the past twenty years, the psychological
stresses of transplant remain. The procedure of stem cell trans-
plantation entails a prolonged, aversive treatment process; a long
and frequently complicated physical and psychological recovery
post-discharge; prolonged reliance on the healthcare system; and
unpredictability of the transplant course and eventual outcome.
Clinical experience, as well as the literature suggests that this is a
situation in which adherence problems often develop. The daily
struggles that can ensue between patient and staff are a major
focus for the caregiving team and may have life-threatening
implications.
This paper presents an overview of the adherence issues
involved in SCT. After a review of the demands for adherence
imposed by the SCT regimen, the cognitive, socio-behavioral,
environmental and illness-related factors that may influence
adherence in the SCT patient population are discussed. The paper
then summarizes the five major theoretical orientations within
which the problem of non-adherence can be conceptualized. The
paper concludes by describing an interaction model designed to
facilitate a therapeutic alliance, as well as presenting some partner-
ship and problem-solving strategies that health care providers can
use to create a supportive climate conducive to adherence, as well
as perceived control. Case summaries are used to highlight signiﬁ-
cant clinical concepts, relevant ethical issues, and multi-discipli-
nary intervention strategies.
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REAL-TIME PCR-GUIDED PREEMPTIVE THERAPY FOR
CYTOMEGALOVIRUS FOLLOWING ALLOGENEIC STEM CELL
TRANSPLANT
Mori, T.1,2; Okamoto, S.1; Watanabe, R.1; Takada, R.1; Hamano, Y.1;
Takayama, N.1; Ikeda, Y.1 1. Division of Hematology, Keio University
School of Medicine, Tokyo, Japan; 2. Dept. of Internal Medicine, Saita-
ma Medical School, Saitama Medical Center, Saitama, Japan
We previously reported that cytomegalovirus (CMV) antigene-
mia infrequently precedes the onset of CMV gastroenteritis, and
that real-time PCR detects viral reactivation earlier than antigene-
mia. We report here the results of prospective preemptive therapy
(PT) for CMV diseases based upon real-time PCR. Twenty-nine
patients who underwent allogeneic stem cell transplantation
(related; 11, unrelated; 18) were evaluable. After engraftment,
real-time PCR using DNA extracted from plasma was monitored
weekly, and once it revealed positive, monitored twice a week.
The sensitivity of PCR method used in this assay was 200
copies/ml. CMV antigenemia was simultaneously monitored.
Only patients who developed grade II-IV acute GvHD were con-
sidered at high-risk of developing CMV diseases, and were
designed to receive PT based upon real-time PCR. If real-time
PCR revealed positive, ganciclovir (GCV) was initiated at a dose
of 5mg/kg/day for 14 days. If viral copies continued to increase
after initiation of GCV, the dose of GCV was increased up to
10mg/kg/day. Of the 29 patients, 22 developed grade II-IV acute
GvHD (group A), and 7 developed grade O-I (group B). In group
A, 19 (83%) developed positive PCR, and received PT. One
patient in group A developed CMV disease (gastroenteritis), in
whom real-time PCR did not precede the onset of gastroenteritis.
Except in 2 cases, antigenemia did not precede the real-time PCR,
and it did not correlate with viral copies assessed by real-time
PCR after initiation of GCV. In group B, only 1 patient devel-
oped positive PCR without developing positive antigenemia,
which became negative without treatment. In conclusion, these
results suggest that real-time PCR-guided PT was effective in the
prevention of CMV diseases including gastroenteritis. However, it
should be applied only to high-risk patients to reduce the
overtreatment.
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INDUCTION CHEMOTHERAPY FOLLOWED BY MINI-ALLOGENEIC
STEM CELL TRANSPLANTATION (ALLO-SCT) - A SUCCESSFUL TREAT-
MENT STRATEGY FOR OLDER AND HIGH RISK ADULTS WITH DIAG-
NOSIS (DX) OF MYELOID MALIGNANCIES
Nath, R.; Janakiraman, N.; Shurafa, M.; Wong, W.; Al-Janadi, A.;
Vial, I.; Burt, S.; Green, J.; Ford-Cattaneo, C.; Chapman, R. Henry
Ford Health System, Detroit, MI
Allo-SCT is a curative option for patients with poor prognostic
myeloid malignancies. However, older patients and patients with
comorbid conditions are not offered potentially curative treatment
options.
We report on four high-risk patients. Two were older than 65
years: UPN1 (70 yrs; dx secondary AML), UPN2 (66 yrs; dx blast-
phase CMML). Two had prior solid organ transplantation and
comorbid conditions: UPN3 (kidney transplant, h/o lupus, stroke,
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DLCO of 35%; dx MDS) and UPN4 (liver transplant, h/o hepati-
tis C; dx AML with 11q23 abnormality). All received remission-
inducing chemotherapy Ara-C/mitoxantrone (UPN1, UPN2), ﬂu-
darabine/Ara-C/mitoxantrone with allo-SCT (UPN3), and
mitoxantrone/etoposide/topotecan (UPN4). Mini-allo SCT was
performed using Fludarabine 25mg/m2 for 5 days, Melphalan
(140-180mg/m2) and peritransplant horse ATG (30-60mg/kg).
Patients were infused a median of 8.42 (range 6.52 to 12.88) x 106
CD34 cells/kg. Graft versus host disease (GVHD) prophylaxis
consisted of mycophenolate mofetil from day -1 to 30 and
cyclosporine. 3/4 patients were in CR and one patient (UPN3) in
cytogenetic relapse (after an initial CR) at the time of transplant.
Neutrophil engraftment (>1,000/µL) occurred at a median of 10
days (range 9 to 11) and platelet engraftment (>50,000/µL) at a
median of 20 days (range 16 to 21). 2/3 evaluable patients devel-
oped overall grade II GVHD which responded to steroids. Two
patients developed chronic GVHD (UPN1, limited; UPN3,
extensive). UPN1 had a complete response to therapy with
steroids. UPN3 was taken off immunosuppression on day 92 and
developed chronic GVHD around day 130, which responded to
cyclosporine and prednisone. Three patients with follow-up >100
days (UPN3, 283; UPN1, 282; UPN2, 144) are alive and disease-
free with 100% donor chimerism documented on days 170, 169
and 134, respectively. Conclusion: Induction chemotherapy fol-
lowed by mini-allo SCT can be performed safely and may be cura-
tive in older and high risk patients with myeloid malignancies.
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PERIPHERAL CD 34 CELL CONCENTRATIONS CORRELATE CONSIS-
TENTLY WITH CD34 YIELD IN APHERESIS PRODUCT INDEPENDENT
OF MOBILIZING REGIMEN
Nayak, S.; Dorr, S.; Akhtar, A.; Garner, P.; Momin, F. Oakwood
Hospital BMT Program, Dearborn,, MI
Peripheral blood (PB) CD34 concentrations were measured by ﬂow
cytometry and compared with CD34 yield in the apheresis product
(AP) in 156 stem cell collection procedures. Twenty-nine of these
were done on allogeneic sibling donors who received 10 mg/kg G-
CSF for 5 days as mobilizing regimen (Allo G). Of the 127 autolo-
gous stem cell collections, 60 were mobilized with the same dose of
G-CSF as the sibling donors (Auto G), 29 received cytoxan 2 gms/m2
+ Taxol 175 mgs/m2 followed by 10 mg/kg G-CSF (CTG), and 38
were mobilized with cytoxan 2 gms/m2 + 10 mg/kg of G-CSF (CG).
Target cell dose was 5 x 106 CD34 cells for allos and 2 x 106 CD34 for
autologous donors. Number of aphereses required to achieve target
dose were compared between groups. Results are shown in the table.
PB concentration of CD34 was found to have linear correlation with
CD34 concentration in the AP in all 4 groups. Coefﬁcient of correla-
tion (r2) was equal to or greater than 0.90. Auto G yielded the lowest
CD34 cells and required the most apheresis to achieve target dose.
CD34 yield from allogeneic donors was signiﬁcantly higher than
Auto G donors. The highest CD34 yield was in CG group. Our data
shows that the best predictor of CD34 yield in AP is the PB CD34
concentration. PB CD34 concentration can be used to time the stem
cell collections in donors mobilized with chemotherapy and G-CSF.
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SUCCESSFUL ENGRAFTMENT AND FEW DONOR COMPLICATIONS
ASSOCIATED WITH AUTOLOGOUS AND ALLOGENEIC STEM CELL
TRANSPLANTS USING VERY YOUNG DONORS
Nieder, M.L.; Fisher, V.L. Rainbow Babies and Children’s Hospital,
Cleveland, OH
Very young children are being utilized as peripheral blood stem
cell (PBSC) donors for autologous or allogeneic transplantation.
We report on 15 patients, ages 7 months to 8 1/2 years, who have
undergone successful leukapharesis. They ranged in size from 6.4
- 22kg. Thirteen of 15 patients had the PBSC’s infused after abla-
tive therapy and all were successfully engrafted. Six patients were
mobilized using their chemotherapy protocols {VCR/CYT/
CPDD/VP (2); CPDD/VP (3); VCR/CYT/ADR(1) and 6
received priming with CYT alone. The 3 normal donors were
mobilized with GCSF. Thirteen of 15 children required place-
ment of an apheresis catheter. There were no complications asso-
ciated with placement or use of these catheters. The large volume
apheresis procedures were associated with minimal complications
such as hypocalcemia (2), agitation requiring conscious sedation
(2), mild dehydration (1). Three children underwent collection on
a single day, 9 had two collections and 3 had three days of collec-
tion. No long term complications have been noted. Cell doses
ranged from 1.4 - 49 x 106 CD34+ cells/kg of recipient weight. In
our experience, PBSC collection can be performed safely on very
small children and with only minor complications.
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SIGNIFICANT IMPROVEMENT IN PULMONARY FUNCTION AFTER
ACITRETIN THERAPY IN A CHILD WITH BRONCHIOLITIS OBLITER-
ANS SYNDROME (BOS)
Nieder, M.L.; Fisher, V.L.; Carl, J.C. Rainbow Babies and Children’s
Hospital, Cleveland, OH
We report a 14 year old boy who developed severe mixed obstruc-
tive/restrictive pulmonary defect 14 months after 6/6 MRD sibling
transplant for ALL in second remission. He presented with wheez-
ing, cough, low grade fevers, pneumomediastinal and apical pneu-
mothoraces. FEV1 decreased from 118% (pre-BMT) to 56% at the
time of presentation. Bronchoalveolar lavage revealed no evidence of
infection and a high resolution CT showed a mosaic pattern consis-
tent with BOS. The patient’s immunosuppressive regimen was
broaded to include ATG (4 day course), methylprednisolone and
tacrolimus. His Lansky score declined from 100% (12 months post-
BMT) to 50% with marked activity intolerance and he developed a
requirement for supplemental oxygen. Acitretin was started at
0.6mg/kg/day; prednisone and tacrolimus were continued. Inhaled
corticosteroid and β agonist therapy was also initiated. FEV1 and
FVC nadirs of 0.51L and 1.01L improved to 0.76L and 1.82L within
6 months. Measures of restrictive pulmonary disease also improved
over the 6 month period: SVC (46%→77%); IC (47%→75%); ERV
(45%→83%); RV (280%→179%); RV/TLC ratio (63%→40%).
The TLC remained stable at 2.9L. During this same period, his per-
formance scale increased to 70% and oxygen was discontinued. The
clinical course of BOS post-BMT ranges from slow progression to
diffuse necrotizing fatal bronchiolitis. We hypothesize that the addi-
tion of acitretin, a retinoid, who known functions include normaliza-
tion of epidermal differentiation and decreased epidermal inﬂamma-
tion, contributed to the improvement in this patient’s pulmonary
function. Acitretin may be of beneﬁt in patients experiencing severe
decrement in pulmonary function in post-BMT BOS.
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GRANISETRON PLUS DEXAMETHASONE VS. GRANISETRON ALONE IN
THE PREVENTION OF VOMITING INDUCED BY CONDITIONING FOR
STEM CELL TRANSPLANTATION: A PROSPECTIVE RANDOMIZED STUDY
Okamoto, S.; Matsuoka, S.; Watanabe, R.; Mori, T.; Hamano, Y.;
Ikeda, Y. Keio BMT Program, Keio University School of Medicine,
Shinjuku-ku, Tokyo, Japan
Nausea and vomiting are acute symptomatic problems for
patients receiving high-dose chemotherapy or chemoradiotherapy
prior to stem cell transplantation. We have previously demon-
strated that granisetron is superior to standard antiemetics con-
sisting mainly of methoclopramide against the vomiting induced
by conditioning for stem cell transplantation. This prospective
randomized study compared the efficacy and toxicity of
granisetron and dexamethasone with granisetron alone for
antiemetic control in patient receiving high-dose chemotherapy
with or without total body irradiation for stem cell transplanta-
tion. Patients were randomized to receive granisetron at a dose of
40mg/kg with or without dexamethasone (8 mg) orally (GS vs G
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group) starting 30 min prior to each dose of chemotherapeutic
agent or TBI. Fifty patients were evaluated for analysis. During
the ﬁrst 24 hours of conditioning, 23 of 25 patients (92%) in the
GS group achieved a complete control of emesis (no emetic
episodes a day) compared with 72% in the G group (p=0.06). For
patients receiving TBI on the ﬁrst day of conditioning, a complete
emetic control was achieved in all patients (100%) in the GS
group compared with 63% in the G group (p=0.02). The same
degree of emetic control was maintained throughout conditioning
period in 65% of the GS group compared with 45% of the G
group (p=0.10). Adverse reactions were observed more frequently
in the GS group (60% vs 5%), which included insomnia,
headache, ﬂushing, and hyperglycemia. None of the events were
serious. We conclude that granisetron and dexamethasone seems
superior to granisetron alone for the prevention of emesis result-
ing from conditioning, however, the side effects were more fre-
quent which may limit the wide use of this combination.
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IMMUNOLOGICAL MECHANISM OF MS FLARES ASSOCIATED WITH G-
CSF IN STEM CELL TRANSPLANT PATIENTS
Openshaw, H.1; Lund, B.2; Atkinson, R.2; Kashyap, A.1 1. City of Hope
National Medical Center, Duarte, CA; 2. Keck School of Medicine,
University of Southern California, Los Angeles, CA
High dose immunosuppression with peripheral blood stem cell
transplantation (SCT) has been given as investigational therapy to
over 100 multiple sclerosis (MS) patients worldwide. In most of these
patients, cyclophosphamide or Prednisone has been used along with
granulocyte colony stimulating factor (G-CSF) for stem cell mobi-
lization. Four of 10 patients who received G-CSF alone developed
transient ﬂares of MS disease activity (Neurology 2000; 54: 2147-
2150). We present results here to suggest a possible mechanism.
Methods: Peripheral blood mononuclear cells (PBMC) were
obtained before the first G-CSF dose and 4 days later before
apheresis in 6 subjects (2 with MS and 4 normal controls). These
paired samples were assayed for lymphoproliferative responses to
myelin antigens and cytokine production by ELISPOT.
Results: Four days of G-CSF increased counts of total leukoc-
tytes 5-fold, neutrophils 7-fold, monocytes 4-fold, and lympho-
cytes 1.5-fold. With G-CSF, there was suppression of PBMC pro-
liferative reponses to epitopes spanning myelin basic protein as
well as immunodominant peptides of proteolipid protein and
myelin oligodendrocyte glycoprotein. ELISPOT assays consis-
tently showed a marked increase in cytokine secreting cells after
G-CSF, including the Th1 cytokines IL-2 and interferon-gamma
and the Th2 cytokines IL-4 and IL-10.
Discussion: Increases in inhibitory monocytes may account for the
suppression of PBMC proliferative responses during G-CSF admin-
istration. In contrast, PBMC cytokine production was upregulated
after G-CSF, including Th1 cytokines that have been associated
with MS exacerbations. Our hypothesis is that shifts in PBMC pop-
ulation brought about by G-CSF inﬂuence the monocyte-lympho-
cyte inﬁltrate of the MS plaque. After SCT, we have found lympho-
cytes to be absent and macrophage-monocytes sparse in MS plaques.
However, at the time of stem cell mobilization, most patients eligi-
ble for protocol treatment would be expected to have active inﬂam-
matory plaques. Changes in the cytokine microenvironment of these
plaques may explain the disease ﬂares seen with G-CSF.
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REPIFERMIN (KERATINOCYTE GROWTH FACTOR-2) PROMOTES
MUCOSAL HYPERPLASIA THROUGHOUT THE ALIMENTARY TRACT IN
NORMAL MONKEYS
Parry, T.J.; Fikes, J.D. Human Genome Sciences, Rockville, MD
Complications arising from chemotherapy or radiation-induced
mucositis often limit cancer treatment. The development of a sin-
gle agent that promotes mucosal healing following chemo- or
radiation therapy is desirable. Repifermin is an FGF-like epithelial
mitogen that has been shown to reestablish intestinal mucosa in a
rodent ulcerative colitis model. The goal of this study was to
determine whether daily administration of repifermin promotes
epithelial hyperplasia within the alimentary tract of normal
cynomolgus monkeys. Vehicle (IV only) or repifermin was admin-
istered intravenously (20, 75 or 200 µg/kg/d) or subcutaneously
(750 µg/kg/d) once daily to normal cynomolgus monkeys over 29
days. A 28 day recovery subgroup was also included for the vehicle
as well as SC and 200 µg/kg/d IV groups. Repifermin-induced
changes were noted throughout the alimentary tract. Epithelial
hyperplasia in the buccal mucosa and dorsal aspect of the tongue
was noted in all animals receiving repifermin. Esophageal mucosal
thickening was observed at necropsy in the high dose IV group.
This correlated histologically with minimal to mild esophageal
epithelial hyperplasia that was noted in all treatment groups
(including SC). The incidence and degree of this hyperplastic
response were dose-dependent in the IV-treated animals. No
mucosal changes were seen in the stomach. Additionally, repifer-
min induced mucosal and goblet cell hyperplasia throughout the
intestine. Following the recovery period, the incidence and degree
of the hyperplastic changes were substantially reduced or com-
pletely resolved. These results indicate that repifermin stimulates
reversible mucosal hyperplasia throughout most segments of the
alimentary tract of normal monkeys. Thus, repifermin may be use-
ful in treating chemo- and radiation therapy-induced mucositis.
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IMPLICATIONS OF GLOBAL PRICING IN PEDIATRIC STEM CELL
TRANSPLANTATION: RISK MINIMIZATION STRATEGIES
Parsons, S.K.; Weidner, R.; Guinan, E.C. Dana-Farber Cancer Insti-
tute, Boston, MA
Introduction: Over the past 20 years, healthcare reimbursement
has shifted from fee-for-service to prospective payment with
increased risk sharing between payors and providers. Global pricing
(GP) is a strategy in which a price (base and outlier rate) is negotiat-
ed for all contracted services within a designated time frame; the
provider assumes the ﬁnancial risk. We developed GP for pediatric
stem cell transplant (SCT) services, emphasizing risk minimization.
Methods: Charge and cost data were compiled for 237 SCTs (209
patients) from FY 96-99 from the date of admission through day
100.The primary focus of pricing alternatives was the peri-SCT
hospitalization since it contributed >90% of total costs. A Monte
Carlo simulation of different pricing assumptions was undertaken.
For each value selected, the model calculated a proﬁt or loss: (Base
rate + outlier rate)-total cost =proﬁt or loss. Hypothetical simula-
tions for unrelated donor SCT (N=66) demonstrate the impact of
parameter changes on the probability of running a loss (PLOSS).
Results: Using the median length of stay (LOS) of 40 days and
median charges of $160,000, a change in the outlier rate from
$2500 to $3500 would decrease the PLOSS from 10% to 5%. If
LOS and the outlier rate were held constant (40 days; $2500), the
PLOSS could be maintained at 5% with a base rate increase from
$160,000 to $200,000. An increase in the period covered by the
base rate to 60 days (75th percentile) would necessitate an adjust-
ment in base rate to $250,000 with a $2500 outlier or $225,000
with a $3500 outlier to minimize the PLOSS to 5%.
Conclusions: To successfully negotiate contracts for SCT under
a GP mechanism, it is essential to understand the risks associated
with certain negotiation requests. This model allows us to vary
assumptions to develop competitive, but ﬁscally responsible prices.
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OUTPATIENT AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION IN A COMMUNITY SETTING
Easler, C.D.; Morrow, L.A.; Corso, S.W.; Bearden, J.D.; Bradof, J.E.;
Nelson, E.C.; Pati, A.R. Palmetto Hematology Oncology PC & Spar-
tanburg Regional Healthcare System, Spartanburg, SC
In order to be cost-effective, high dose chemotherapy and autol-
ogous blood stem cell transplants (ASCT) are frequently being
performed on an outpatient basis. We report our experience of
outpatient ASCT in a private practice-community hospital setting.
From September 1997 to September 2000, 42 individuals received
high-dose chemotherapy with autologous blood stem cell trans-
plant. Of these patients, 9 were diagnosed with relapsed non-
Hodgkin’s lymphoma (NHL), 2 with relapsed Hodgkin’s disease
(HD), 6 with multiple myeloma (MM), and 25 with breast cancer
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(BC). The median age was 48 years (range 17-67 years) with 29
females and 13 males. The transplant conditioning regimens con-
sisted of BEAM (BCNU, Etoposide, Ara-C, Melphalan) for NHL
and HD; Etoposide and Melphalan for MM; TTCM (Taxol,
Thiotepa, Carboplatin, Melphalan) for BC (8 patients)and Stamp
V (Carboplatin, Cyclophosphamide, Thiotepa) for BC (17
patients). The median day to white blood cell engraftment
(ANC>1000/µL) was 11 with a range of 7-21 days. The median
day to platelet engraftment (PLT>20K/µL) was 22 with a range of
8-210 days. One patient died within 100 days of transplant due to
sepsis and progressive disease. During the first 100 days post-
transplant, 14 of the 41 patients treated as outpatients (34%)
remained outpatients. Sixty-six percent, or 27 patients, required
hospitalization with an average length of stay of 8 days. The most
frequent admitting diagnoses were culture negative sepsis (48%),
culture positive sepsis (18%), bleeding (15%), and mucositis
(11%). Overall survival for this small number of patients with lim-
ited follow-up is as follows: NHL 67%, HD 50%, MM 100%, BC
88%. We conclude that high dose chemotherapy and autologous
blood stem cell transplantation is feasible and appears safe to be
performed as an outpatient in a community hospital setting.
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THE IMPACT OF HISTOLOGY ON HIGH-DOSE THERAPY AND AUTO-
LOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH
RELAPSED NON-HODGKIN’S LYMPHOMA: EXPERIENCE OF A SINGLE
TRANSPLANT CENTER
Qazilbash, M.H.; Lynch, J.P.; Beall, C.L.; Auber, M.; Werisenborn, R.;
Bunner, P.; Ericson, S.G. West Virginia University, Morgantown, WV
Purpose: To evaluate the relapse-free survival (RFS), overall sur-
vival (OS) and transplant-related mortality (TRM) after high-dose
therapy and autologous stem cell transplant (SCT) in patients
with Non-Hodgkin’s lymphoma (NHL).
Methods: A total of 48 patients with relapsed NHL (28 with inter-
mediate/high-grade lymphoma [I-HGL] and 20 with low-grade lym-
phoma [LGL], according to International Working Formulation)
were treated between 1993 and 2000. The median age at transplant
was 49 years (range 17-65). There were 23 females and 25 males.
Fourty-two patients were in ﬁrst relapse, chemosensitive or untreat-
ed, and 6 were in second or higher chemosensitive relapse. The medi-
an interval between initial diagnosis and transplant was 31 months
(range 4-185). The conditioning regimens used were VP/Cy/TBI in
29 patients, TT/TBI in 8 patients and VP/Cy/TT in 11 patients.
Five patients received unmanipulated stem cells from bone marrow
(BM) only, 20 from peripheral blood (PB) only, 22 patients from both
BM and PB, and one patient died prior to HSC infusion. The median
duration of follow up was 20 months (range 1-92).
Results: The median time to engraftment (ANC >500) was 12
days. Using Kaplan-Meier analysis, for all patients who underwent
high-dose therapy, the 5-year RFS was 45% +/-5%, and 5-year OS
was 58% +/- 5%. The 5-year RFS for patients with I-HGL was
35% +/-4% and for LGL was 55% +/- 7%, P>0.05. The 5-year
OS for patients with I-HGL was 42% +/-7%, and for LGL was
78% +/-7%, P<0.05. Five patients (10%) died of transplant-related
causes. Using multivariate analysis, there was no impact of age, sex,
stem cell source or conditioning regimen on RFS, OS or TRM.
Conclusions: HDT with ASCT is highly effective in patients
with relapsed low or intermediate/high-grade NHL, with accept-
able transplant-related toxicity. The RFS and OS were superior in
patients with low-grade NHL.
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SUCCESSFUL REPRIORITIZATION OF ALTERNATE DONOR SELECTION
TO UNRELATED CORD BLOOD FOR HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) IN CHILDREN AND ADOLESCENTS WITH
LEUKEMIA
Quinones, R.R.; Shpall, E.; Prothe, K.; Pelz, A.; Schissel, D.; Hild, E.;
Malcom, J.; Rottman, S.; Pasut, B.; Giller, R. University of
Colorado/The Children’s Hospital, Denver, CO
Allogeneic HSCT can cure refractory leukemia. The optimal
alternate HSC source for patients without a matched sibling (MS)
is uncertain. Unrelated cord blood (UCB) is increasingly available
and may have a lower GVHD risk with decreased toxicity. We
explored reprioritizing UCB as the alternative donor HSC source
over MUD or T cell depleted HLA disparate relatives (Fam). We
report results of 61 consecutive HSCT for leukemia. Condition-
ing was with TBI, Cytarabine, Cyclophosphamide, ATG (6/26
MS Bu/Cy). UCB patients received 2.45 (0.7−12.5) x107
TNC*/kg, with 13/23 UCB ex vivo expanded. (*median range)
We conclude that in patients receiving consistent cytoreduction
and supportive cares, UCB produces results similar to MS HSCT.
Despite a wide range of TNC/kg, engraftment occurred with all
UCB, although it may be delayed. The low relapse rate with UCB
is encouraging, particularly with the reduced GVHD risk. We
continue efforts to accelerate engraftment through ex vivo expan-
sion and to minimize non-relapse mortality.
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THE STEM CELL CRYOPROTECTANT DMSO (DIMETHYLSULFOXIDE)
ACTIVATES MORPHOLOGIC GRANULOCYTIC DIFFERENTIATION
THROUGH THE RETINOIC ACID RECEPTOR ALPHA
Robertson, K.A.; Perry, J.; Bullock, H.; McDaniels, A.; Zimmerman,
E. Indiana University, Indianapolis, IN
DMSO is a low molecular weight organic compound, which is
used widely as a cryopreservative for hemaotpoietic stem cells and
other cells. It has antioxidant properties and is capable of inducing
granulocytic differentiation, growth inhibition, and apoptosis of
HL-60 myeloid leukemia cells. We have previously characterized a
subclone of HL-60 cells, HL-60R, that is resistant to retinoic acid
(RA)-induced myeloid differentiation. The basis of the resistance to
RA involved a point mutation in the ligand-binding domain of RAR-
α to create a dominant negative RAR-α (RAR-α411). To determine
whether DMSO-induced myeloid differentiation might also involve
RAR-α, we treated HL-60R cells with DMSO and found them to be
relatively resistant to DMSO-induced morphologic differentiation.
Moreover, the DMSO response could be rescued by transducing
HL-60R cells with the retroviral vector LRARαSN. To determine
whether this was a speciﬁc effect of DMSO with RAR-α, we trans-
duced HL-60 cells with a retroviral construct containing the domi-
nant negative RAR-α411 which conferred resistance to DMSO-
induced morphologic granulocytic differentiation, but resulted in
profound growth inhibition upon treatment with DMSO. To deter-
mine whether DMSO would activate transcription through RAR-α,
we co-transfected RAR-α and an SV40 promoter driven luciferase
gene containing an upstream RA response element. DMSO activat-
ed luciferase gene expression as measured by luminescence com-
pared to untreated, ethanol treated, and RA-treated controls. We
conclude that DMSO induced morphologic myeloid leukemia cell
differentiation is mediated in part through RAR-α, which may have
implications for use of DMSO as a cryopreservative.
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TOLERANCE INDUCTION BY HUMAN CD34+ CELLS AND ANTI-CD40L
ANTIBODY PLUS CTLA-4 IG: PRECLINICAL STUDIES
Rondelli, D.; Arpinati, M.; Chirumbolo, G.; Bandini, G.; Tura, S. Inst.
of Hematology/Oncology “Seragnoli”-Univ. of Bologna, Bologna, Italy
We previously demonstrated that human CD34+ cells induce
allogeneic T cell proliferation in vitro. In this study we addressed
ASBMT Poster Presentations
86
the hypothesis of inhibiting allogeneic T cell reactivity to CD34+
cells and inducing T cell tolerance by blocking CD40:CD40L
and/or B7:CD28 pathways. In vitro primary mixed lymphocyte
cultures (MLC)(n=4 exp.) were performed with irradiated normal
G-CSF-mobilized-CD34+ blood cells, or mononuclear cells
(MNC) from the same donor, and HLA mismatched allogeneic
CD4+ T cells or MNC as responders. Anti-CD40L (CD154)
monoclonal antibody (BIOGEN Inc., Cambridge, MA) induced
on average 55±20% and 64±20% inhibition of T cell response to
CD34+ cells and to MNC, respectively, but a higher dose of the
antibody was required with CD34+ cells (50 µg/mL) than with
MNC (2 µg/mL). T cell alloreactivity was similarly reduced also
by CTLA-4 Ig (2 µg/ml)alone, whereas combination of CD154
and CTLA-4 Ig potently blocked T cells after stimulation with
either CD34+ cells (86±9% inhibition) or with MNC (84±10%)
in primary MLC. Then, responder cells were rechallenged with
irradiated stimulators from the same donor in secondary MLC.
Only responders obtained from cultures with CD34+ cells or
MNC plus CD154 and CTLA-4 Ig were unresponsive(n=4 exp.),
whereas comparable responses to third party stimulators were
obtained by anergic or control T cells (n=2 exp.). Interestingly,
addition of IL-2 (50 UI/mL) did not seem to reverse T cell unre-
sponsiveness. Finally, we demonstrated that irradiated CD34+
cells induce potent allogeneic cytotoxic responses in a standard
51Cr release assay (n=4 exp). In these experiments, cytotoxicity
could be prevented by the presence of CTLA-4 Ig alone. In con-
clusion, since CD154 and CTLA-4 Ig have a synergistic effect in
inducing T cell anergy after stimulation with human CD34+ cells
in vitro, new strategies for inducing tolerance across HLA barriers
may be investigated in allogeneic hematopoietic CD34+ cell
transplantation.
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PULMONARY INFILTRATES (PI) IN HEMATOPOIETIC CELL TRASPLAN-
TATION (HCT) RECIPIENTS: CLINICAL IMPACT OF A PROSPECTIVE,
SEQUENTIAL DIAGNOSTIC APPROACH.
Rovira, M.; Raño, A.; Carreras, E.; Danés, C.; González, J.; Fer-
nández-Avilés, F.; Torres, A.; Montserrat, E. Hospital Clínic,
Barcelona, Spain
Over a 30-month period, we prospectively evaluated all consecu-
tive HCT patients with PI with the same diagnostic approach that
included non-invasive and bronchoscopic techniques. Non-inva-
sive methods were: serologic tests; blood antigen detection; blood,
sputum, nasopharyngeal wash (NPW) and tracheobronchial aspi-
rates (TBAS) cultures. Bronchoscopic techniques included pro-
tected specimen brush (PSB) and bronchoalveolar lavage (BAL).
Overall, 61 patients with PI were evaluated: 52 had received an
allogeneic HCT and 9 an autologous HCT. An etiological diag-
nosis was obtained in 47 (77 %) patients. Etiology was infectious
in 33 (70 %) and non-infectious in 14 (30%) . Fourteen episodes
(23%) remained undiagnosed. Main infectious etiologies were
viral (36%), fungal (24%), bacterial (21%), and polymicrobial
(15%). Most frequent pathogen were Aspergillus fumigatus (n= 6),
cytomegalovirus (n=6) and Candida spp (n=3). Most common
non-infectious etiologies were pulmonary edema (23%) and dif-
fuse alveolar hemorrhage (38%). Non-invasive techniques led to
the diagnosis in 38% of the episodes. The diagnostic yield of
blood culture was 16%, of sputum cultures 24%, of NPW 15%,
and of TBAS 29%. Bronchoscopic techniques were diagnostic in
53% of the episodes in which they were employed (BAL 44% and
PSB 16%). Antibiotic treatment was changed according to the
results obtained with the different techniques in 48% episodes.
Overall mortality was 52.5%, this being higher in those patients
with an infectious etiology (64%) as compared to those with a
non-infectious etiology (28%) (p: 0.05) and also in those patients
requiring mechanical ventilation (97%) in comparison to those
not requiring it (10%) (p <0.0001). In the univariate analysis the
following variables were related to a poor prognosis: APACHE II
score >20, PaO2/FiO2 <250, bilateral radiographic involvement
and mechanical ventilation. Although the diagnostic yield of PI
has improved with this approach, allowing an etiology-adjusted
treatment, the mortality in this population is still too high.
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ELIMINATION OF NON-HODGKIN’S LYMPHOMA (NHL) AND CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL) WITH A RHODAMINE-DERIVED
PHOTODYNAMIC THERAPY
Roy, D.1; Dallaire, N.1,2; Moreau, B.1,2; Paquette, Y.1,2; Balassy, A.1,2;
Giorgi, O.1,2; Gladu, I.1,2; Freeman, G.J.3; Hamel, R.2 1. Maisonneuve-
Rosemont Hospital, Montreal, PQ, Canada; 2. Theratechnologies Inc.,
Montreal, PQ, Canada; 3. Dana-Farber Cancer Institute, Boston, MA
TH9402 is a dibromorhodamine derivative with potent photo-
sensitizing capacity that targets malignant cells through specific
intracellular handling and mitochondrial localization, leading to
the demise of targeted cells via oxydative damage. The importance
of mitochondrial involvement in anti-apoptotic regulatory path-
ways of several NHLs prompted us to evaluate TH9402 photody-
namic therapy for the elimination of B-lineage lymphoma and
leukemia. The influx/efflux kinetics and cytotoxicity profile of
TH9402 were evaluated against B-lineage cell lines (Raji,
Namalwa, DHL16 and RL), normal B lymphocytes, bcl-2/IgH
rearranged patient NHL cells, and primary B-CLL cells. Reten-
tion of TH9402, as measured at rest by HPLC, and upon light
excitation by flow-cytometry, was maximum after 40 minutes.
Cytotoxicity towards cell lines, as measured in a limiting dilution
assay, was directly proportional to the concentration of TH9402,
cellular concentration and light energy applied; and inversely pro-
portional to the time of dye efﬂux from cells, achieving more than
5 logs of eradication of Raji, Namalwa, DHL16 and RL cells.
Elimination of normal B lymphocytes, as well as patient NHL and
CLL cells were evaluated after culture on a CD40 ligand express-
ing feeder layer. Normal (n=6) and malignant B-NHL (n=5) and
CLL (n=4) cells were eradicated according to dose-intensity
parameters, TH9402 achieving 2.5 or more logs of cytotoxic
activity (the detection threshold of the assay). Moreover, in all
NHL samples, bcl-2/IgH rearranged cells were not detectable,
using a highly sensitive nested PCR assay, after PDT with
TH9402. Importantly, treatment of normal hematopoietic pro-
genitors, in the same conditions, preserved greater than 40% of
CFU-GM, BFU-E and CFU-Mix colonies, and >75% of LTC-
IC. In conclusion, photodynamic therapy with TH9402 can elimi-
nate several logs of B-lineage NHL and CLL cells while preserv-
ing normal progenitors for hematopoietic engraftment. A clinical
trial will evaluate this phototherapeutic approach for the elimina-
tion of B-lineage cells prior to autologous transplantation.
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DEFINITIVE TREATMENT OF ADVANCED MALIGNANT DISEASE BY
ADOPTIVE IMMUNITY
Rubin, A.D.; Ojha, R.; Stives, S. St. Joseph’s Hospital and Medical
Center, Paterson, NJ
Twenty-one patients with advanced or chemotherapy resistant
malignancies (including 6 AML, 3 ALL, 2 MDS, 6 NHL, 2 Acute
Phase CML, 1 Myeloma, 1 Renal Cell) were subjected to allo-
geneic stem cell transplantation from an HLA compatible sibling
(19) or unrelated donor (2) under subablative conditioning. All of
these patients were relapsed and failures on chemotherapy They
were also not candidates for ablative bone marrow transplantation
because of age > 60 years (11), inﬁrmity (6) or failure of previous
allogeneic BMT (4). Patients were conditioned by Fludarabine,
anti-thymocyte globulin and subablative doses of Cyclophos-
phamide (for lymphoproliferative) or Busulfan and VP-16 (for
myeloproliferative disease). After infusion of > 5 x 106 CD34+ and
> 108 CD3+ cells/kg, patients were started on cyclosporine (CSP)
to prevent GVHD. In the absence of GVHD at +30 days, CSP
was discontinued and 108 CD3+ cells/kg were infused as a boost.
Regimen related toxicity was mild and well tolerated particularly
in older patients. Graft versus host disease was the main cause of
therapeutic failure and death. Persistent and fatal malignant dis-
ease was seen in only 2 AML and 1 ALL patients. Nine patients
are alive and free of disease from 1-53 months with a projected
survival of 25%. The survivors include 5 patients with leukemia,
one patient with lymphoma and one with renal cell carcinoma. In
all of the survivors the complete engraftment was associated with
disappearance of bulk disease. One 12-year-old girl with AML,
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having relapsed post-allogeneic BMT, was transplanted 9 times
over 4 years to maintain her in CR and full donor engraftment.
She was conditioned by mitoxantrone, HIDAC and VP-16 with
no GVHD prophylaxis. Therefore it appears that these allografts
were therapeutically competent and could achieve remissions
when chemotherapy failed and that these remissions could be
durable.
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ONCE DAILY INTRAVENOUS BUSULFAN (IVBU): PHARMACOKINETIC
STUDY AND COMPARISON WITH ORAL BUSULFAN (POBU) IN COM-
BINATION WITH FLUDARABINE (FLU) AS CONDITIONING FOR ALLO-
GENEIC STEM CELL TRANSPLANT
Russell, J.A.1; Tran, H.T.2; Chaudhry, A.M.1; Duggan, P.1; Stewart,
D.1; Ruether, D.1; Gluck, S.1; Morris, D.1; Brown, C.B.1 1. Tom Baker
Cancer Centre and Foothills Hospital, Calgary, AB, Canada; 2. MD
Anderson Cancer Center, Houston, TX
Myeloablative conditioning comprising FLU 50mg/m2 on days
-6 to -2 plus BU( Busulfex®) on days -5 to -2 inclusive was
given to 75 adults. Twenty-five received POBU l mg/kg QID x
16 doses and 50 received IVBU 3.2 mg/kg over 3 hours daily x
4. Blood specimens were collected on the 1st and 4th doses to
determine the disposition of IVBU when given once-daily. The
IVBU and POBU groups respectively included similar propor-
tions of patients with high-risk malignancy (66% vs. 67%),
unrelated or genotypically mismatched-related donors (34% vs
26%) and recipients of bone marrow rather than blood (46% vs
44%). All patients received acute GVHD prophylaxis with CsA
plus methotrexate and folinic acid. 98% IVBU and 60% POBU
also received ATG (Thymoglobulin, Sangstat) 4.5mg/kg over 3
days pretransplant (p < 0.0001). IVBU patients developed signif-
icantly less grade 2 stomatitis (60% vs 96%, p = 0.0008). Hem-
orrhagic cystitis occurred in 10% IVBU and 8% POBU. Eleva-
tions of ALT and bilirubin were similar in the month
post-transplant. One case of reversible VOD occurred, after
POBU. There were two graft failures (one in each group) in
recipients of unrelated donor marrow. There were 2 transplant-
related deaths (4%) by 100 days in the IVBU group (from
myocardial infarction and PTLD) and one (from acute GVHD)
in the POBU group (4%). Preliminary PK mean parameters
from 6 patients are summarized in the table. IVBU continues to
display linear PK with expected exposure (AUC) four times that
observed with the standard Q6H regimen, with no accumula-
tion. Daily IVBU seems as well tolerated as POBU, has present-
ed no unexpected toxicities, and is more convenient than QID
dosing.
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GRAFT RELATED SURVIVAL FOLLOWING ALLOGENEIC PERIPHERAL
BLOOD HEMATOPOIETIC CELL TRANSPLANTATION WITH TACROLI-
MUS AND METHOTREXATE GVHD PROPHYLAXIS
Rybka, W.B.; Ehmann, W. Penn State Milton S. Hershey Medical
Center, Hershey, PA
We assessed the benefit of tacrolimus GVHD prophylaxis in
allogeneic peripheral blood hematopoietic cell transplantation.
Forty-nine patients with hematologic malignancies were entered
on study. Donors were mobilized with G-CSF 16 µg/kg/day x 5
with apheresis starting on the ﬁfth day processing 20 l to collect a
minimum of 2x106 CD34+ cells/kg recipient weight. All 49 have
engrafted without graft failure. The first 14 patients received
tacrolimus alone for GVHD prophylaxis. Four patients remain
alive and in remission 1207 to 1439 days following transplantation.
Two patients died of relapsed disease. Eight died of transplant
related causes. The protocol was amended to alter GVHD pro-
phylaxis by adding methotrexate 5 mg/m2 days +1, +3, +6 and +11.
35 additional patients have been treated. Fifteen remain alive and
in remission while an additional 4 patients remain alive with
relapsed disease. Seven patients have died of relapsed disease. Nine
patients have died of transplant related causes. Median follow-up
to date is 448 days, ranging from 22 to 1439 days. Graft related
toxicity was assessed by determining survival, censoring for deaths
from relapsed disease. The 100 day, 1 year and 2 year graft related
survival for patients treated without methotrexate is 71%, 57%
and 46% and with methotrexate 80%, 74% and 74% respectively
(p=0.04). There has been a marked improvement in outcome since
the addition of methotrexate to the regimen with a decrease in
severity of both acute and chronic graft versus host. The addition
of short course methotrexate appears to impact intermediate and
long term survival related to tacrolimus prophylaxis in allogeneic
peripheral blood hematopoietic cell transplantation.
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COMPARISON OF HARVEST YIELDS OF PERIPHERAL BLOOD
HEMATOPOIETIC CELLS FROM ALLOGENEIC AND AUTOLOGOUS
TRANSPLANT DONORS
Rybka, W.B.; Ehmann, W.; Mierski, J.; Bongiovanni, M. Penn State
Milton S. Hershey Medical Center, Hershey, PA
We compared yields for hematopoietic cells from allogeneic
(ALLO) and autologous (AUTO) donors. 60 ALLO collections
were mobilized with G-CSF 16 µg/kg/day x 5 with apheresis on
the ﬁfth day, processing 20 l. 425 AUTO collections were mobi-
lized with myelosuppressive chemotherapy and G-CSF 5 µg/kg/
day continued until recovery from myelosuppression and comple-
tion of harvesting, processing 15 l. The target for collection was
2x106 CD34+ cells/kg to 107 CD34+ cells/kg. Circulating CD34+
cells were comparable despite different mobilization approaches.
Hematopoietic progenitor distribution was identical for the two
groups. Difference in yield may reflect the different volumes
processed. The level and distribution of hematopoietic progenitor
cells achieved in allogeneic and autologous donors appear to be
independent of the method of mobilization employed.
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LOW RISK FOR INFECTIOUS COMPLICATIONS AFTER BLOOD STEM
CELL AUTOGRAFTING FOR MULTIPLE MYELOMA
Sandherr, M.; von Schilling, C.; Peter, R.; Peschel, C. Klinikum Rechts
der Isar, III. Medizinische Klinik, München, Germany
In multiple myeloma (MM), treatment with repeated high-dose
Melphalan followed by blood stem cell autografting results in pro-
longed overall survival when compared to conventional
chemotherapy. Neutropenic febrile complications are the main
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transplant-related toxicity. To evaluate the impact of post-trans-
plant infections in MM patients we compared data of 55 trans-
plants for MM with data of 105 transplants for other diseases
(NHL/HD 59, acute leukemia 10, GCC/BC 26, STS 10). All
patients received prophylaxis with Ciproﬂoxacin/Fluconazole and
G-CSF. Overall incidence of neutropenic fever (NF) was 65%.
While the incidence of NF in MM was 42% without serious
sequelae, the incidence of NF after transplant for other diseases
was as follows: NHL/HD 75%, acute leukemia 80%, GCC/BC
77%, STS 100%. Duration of fever, days with antibiotic treat-
ment and duration of hospitalization was shorter in MM patients.
There was one sepsis-related death in a patient with NHL. The
lower incidence of NF in MM correlates with a higher stem cell
mobilization capacity, reinfusion of higher CD34 numbers, less
mucositis and the use of non-TBI containing regimens. In conclu-
sion, the risk of post-transplant infections in MM patients is con-
siderably low. Therefore, first, blood stem cell autografting in
multiple myeloma may be performed in an out-patient setting and
second, should be considered as standard treatment also in elderly
MM patients.
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DONOR T-CELL−DERIVED TNF IS REQUIRED FOR GVHD, GVL AND
COMPLETE T-CELL CHIMERISM
Schmaltz, C.; Alpdogan, O.; Muriglan, S.J.; Kappel, B.J.; Rotolo, J.;
Richetti, E.T.; Marino, M.W.; van den Brink, M.R. Memorial Sloan-
Kettering Cancer Center, New York, NY
Previous studies in murine bone marrow transplant (BMT)
models using neutralizing anti-tumor-necrosis-factor (TNF) anti-
bodies or TNF receptor-deficient recipients have demonstrated
that TNF can be involved in both graft-versus-host disease
(GvHD) and graft-versus-leukemia (GvL). TNF in these GvHD
and GvL models was thought to be produced by activated mono-
cytes and macrophages. We used TNF-/- mice to study the spe-
ciﬁc role of TNF produced by donor T cells in a well established
parent-into-F1 hybrid model (C57BL/6 → B6C3F1). Recipients
of donor bone marrow + TNF-/- T cells developed signiﬁcantly
less morbidity and mortality from GvHD than recipients of wild
type (wt) T cells. Thymic cellularity was signiﬁcantly increased in
recipients of TNF -/- cells, indicating a role for donor T cell-
derived TNF in thymic GvHD. Other GVHD target organs
(liver, intestines and skin) are currently being analyzed. In vitro
proliferation to alloantigen as well as in vivo expansion of TNF -/-
T cells was intact. Recipients of TNF -/- T cells that were also
inoculated with 32Dp210 leukemia cells at the time of BMT
showed increased mortality from leukemia when compared with
recipients of TNF wt cells. Interestingly, we found that animals
transplanted with TNF -/- T cells exhibited mixed chimerism
with significant numbers of remaining host T cells on days 14
and 28 post-transplant, while recipients of wt T cells (as well as
FasL deﬁcient and perforin -/- cells) had virtually 100% donor T
cell engraftment. This ﬁnding suggests a speciﬁc role for donor T
cell-derived TNF in T cell chimerism and the elimination of host
T cells, that has not been described previously. Further experi-
ments in different murine models previously established to study
graft rejection and engraftment are currently underway.
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ACCEPTABLE OUTCOME AFTER MAJOR ONE ANTIGEN MISMATCHED
RELATED OR UNRELATED DONOR STEM CELL TRANSPLANTATION
FOR ADVANCED LEUKEMIA
Schwarer, A.P.; Spencer, A.; Muirhead, J. Alfred Hospital, Melbourne,
Australia
Some patients with advanced leukemia do not have HLA-
matched donors, therefore we offered selected patients allogeneic
SCT from donors with single HLA-A, -B or -DR mismatches.
Many donor/recipient pairs were also mismatched for HLA-Cw
(n=6) or -DQ (n=4). We transplanted 17 patients using HLA-A
(n=5), -B (n=3), -DR (n=9) mismatch-related (n=9) or unrelated
(n=8) donors: 12 males; 5 females. Median age: 35 (19-54) yrs. All
had advanced leukemia: AML>CR1 (n=6); untreated 2oAML
(n=1); ALL>CR1 (n=5); CML>CP1 (n=5). Either bone marrow
(n=9), PBSCs (n=7) or both (n=1) were used. TBI (n=14) or
chemotherapy alone (n=3) were used as conditioning regimens. All
patients received CSA/MTX plus 5 (related) or 10 days (unrelat-
ed) of ATGAM. Two patients died before engraftment. All others
engrafted without early or late rejection. Fifteen patients were
assessable for acute GVHD: grade 0 (n=2; 13%); grade I (n=3;
20%); grade II (n=7; 47%); grade III (n=1; 7%); grade IV (n=2;
13%). Nine (53%) patients died before day +100: multiorgan fail-
ure (n=2); acute GVHD (n=2); interstitial pneumonitis (n=2);
infection (n=1); relapse (n=2). Eight patients were assessable for
chronic GVHD: none (n=4; 50%); limited (n=2; 25%); extensive
(n=2; 25%). TRM was 7 (41%) of 17 patients, and relapse
occurred in 4 (40%) of the remaining 10 patients. There were 2
deaths >day +100, both due to relapse leaving 6 (35%) patients
surviving at a median of 391 (112-919) days. Of survivors, 2 had
HLA-A, 1 -B, 3 -DR mismatches. Three remain on tapering doses
of immunosuppression at +112, +125 and +433 days with Karnof-
sky scores of 80-90%; and 3 are on no medications at +349, +581
and +919 days with Karnofsky scores of 100%. Our results show
that selected patients with advanced leukemia can be successfully
treated with SCT using related or unrelated donors with a major
HLA mismatch.
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AN AUDIT OF A PCR-BASED CMV SURVEILLANCE STRATEGY FOR
PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTS
Scriven, J.1; Nicoll, S.2; Burns, S.2; Johnson, P.1 1. Western General
Hospital, Edinburgh, United Kingdom; 2. City Hospital, Edinburgh,
United Kingdom
CMV reactivation is a major complication in at-risk patients
undergoing allograft. Prophylactic strategies utilising Ganciclovir
in all at-risk patients have been shown to reduce the incidence of
CMV reactivation, but result in many patients being treated unnec-
essarily. With the development of sensitive PCR and antigenaemia
assays designed to detect CMV reactivation before the develop-
ment of clinical disease, strategies of intensive surveillance, with
preemptive therapy at the ﬁrst sign of reactivation have been imple-
mented. We sought to audit our CMV surveillance strategy - to
identify organisational problems, assess the CMV reactivation rate,
and monitor the outcome of preemptive therapy. All allografts per-
formed at our centre over a 14-month period were included. At-
risk patients received high-dose aciclovir prophylaxis. CMV sur-
veillance was performed weekly on plasma samples using 2 PCR
detections; testing was continued at least to day +105. Patients with
positive results were treated with GCV twice daily for 2 weeks and
then once daily, 5x weekly, with treatment monitored by PCR
assays. Nineteen sibling allografts were performed during the study
period of which 14 were CMV at-risk. Audit of testing frequency
showed that a PCR result was obtained in 108/132 (82%) possible
weeks. Reasons results were not obtained included wrong sample
type, transportation delays, and laboratory failure. PCR result
became positive in 4/14 patients. In 3 cases, CMV was cultured on
shell-vial assay from the urine 0, 7 and 20 days from the time of
PCR positivity. Treatment with ganciclovir was effective in all
cases. We conclude that audit is essential to identify organisational
problems with a CMV surveillance policy. We report a low inci-
dence of CMV reactivation in our patients. We show that the
“lead-time” from positive PCR result to CMV disease may be
short, emphasising the need to optimise organisational issues, and
start treatment at ﬁrst PCR positivity.
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RISK FACTORS AND CLINICAL CHARACTERISTICS OF HEPATITIS B
VIRUS (HBV) REACTIVATION POST ALLOGENEIC STEM CELL TRANS-
PLANTATION (ASCT) IN PATIENTS PREVIOUSLY INFECTED AND
IMMUNE TO HBV
Seth, P.; Stuart, R.K.; Sahovic, E.; Chaudhary, M.A.; Aljurf, M.; Col-
col, E.; Aslam, M.; Chaudhri, N.; Mohareb, F.; Gyger, M. King Faisal
Specialist Hospital and Research Center, Riyadh, Saudi Arabia
The immune deﬁciency associated with aSCT can compromise
the effector function of HBV speciﬁc CD8+ cells and contribute
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to HBV replication posttransplant. Moreover, corticosteroids used
for GVHD prophylaxis/treatment may contribute to further accu-
mulation of HBV peptides on the hepatocyte surface through
direct genomic transcriptional regulation. Immune reconstitution
and immunosuppressive therapy withdrawal can then lead to clini-
cal flare-up. To identify risk factors and clinical characteristics
associated with HBV reactivation post aSCT in patients immune
to HBV, KFSH&RC IBMTR database from January 98 to June
2000 was reviewed. Of 131 patients treated with aSCT, 127 had
complete screening for HBV. Fifty-three (42%) had prior infec-
tion to HBV and were immune (HBsAg-, HBeAg-, HBcAb+,
HBsAb +/-). Treatment related deaths before day 120 occured in
eleven patients,and eight were on full immunosuppressive therapy
at the time of analysis. Thirty-four were evaluable. Five (15%)
reactivated, and developed hepatitis with seroconversion
(HBsAg+, HBeAg+) and/or +HBV DNA by PCR. Three groups
were identified. I: 22 patients with no GVHD. One/22 (4.5%)
reactivated at 5.5 months post aSCT. II: 5 patients with aGVHD
responsive to therapy. No reactivation. III: 7 patients with
cGVHD, where 4 (57%) reactivated at 18, 18, 19, and 21 months
post aSCT. Three patients had clinical evidence of cGVHD at the
time of reactivation. Only 1/27 patients without cGVHD had
HBV reactivation, in comparison to 4/7 with cGVHD, p=0.0035,
relative risk 15.4 (CI 95% 2.0-117). Reactivation occurred during
immunosuppressive therapy tapering in two patients and at 20, 25,
and 40 days after its withdrawal in three. Flare up resolved in four
patients within a period of 10 weeks after initiation of anti-viral
therapy, while one died of pulmonary infection during flare up.
Prospective molecular monitoring of patients at risk could lead to
early diagnosis of HBV reactivation and timely institution of anti-
viral therapy.
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IMMUNOTHERAPY WITH DONOR LEUKOCYTE INFUSIONS FOR
TREATING CHILDREN WITH POST-TRANSPLANT RELAPSED ACUTE
LEUKEMIA: SINGLE CENTER PEDIATRIC EXPERIENCE
Sharathkumar, A.; Thornley, I.; Lau, W.; Saunders, E.; Freedman,
M.H.; Calderwood, S.; Doyle, J. Hospital for Sick Kids, Toronto,
ON, Canada
Donor Leukocyte Infusions (DLIs) offer a therapeutic option
for patients with post allo-BMT relapse,though its efficacy in
acute leukemia is questioned. We reviewed our Institutional DLI
experience for children with post-transplant relapsed leukemia.
Between 1997 and 2000, 9 children (5 ALL,4 ANNL) received
DLI from HLA-matched family donors. Median interval between
relapse and BMT is 7 months (Range: 2 to 22 months). We used
filgrastim (10 mcg/kg/day x 5 days) mobilised peripheral blood
stem cells as a source of donor leukocytes. All received cytoreduc-
tive chemotherapy prior to DLI:7 received 2-chlorodeoxyac-
etate(10 mg/m2 on Day 1-3)and Idarubicin (8 mg/m2 on day 1-5),
2 ALL children re-induced with salvage protocols. First course of
DLI was given at a median of 25 days (12 to 67 days) from initial
relapse: 5 received 1 infusion,4 received 2 infusions. Median CD3
count for the ﬁrst infusion was 1.6x108 cells/kg (1 to 9); for the
second infusion 4.6x108 cells/kg (1.3 to 8.9). Corresponding
CD34+ counts: 1.8x106/kg (0.9 to 9.6) and 5.7x106/kg (1.3 to 5.7)
respectively. Among 5 ALL children: 1 died with extensive
cGVHD (15 months), 1 died with postDLI pancytopenia related
complications(4 months), 2 relapsed at extramedullary sites (1
testis, 1 breast at 4 and 25 months respectively): both alive with
disease. Among 4 ANLL:1 relapsed (limited cGVHD)and died, 1
with isolated testicular relapsed at 24 months is alive 2 years after
second allo-BMT,2 alive in CR with extensive cGVHD at 26 and
43 months (Lansky scores 60 and 80%). In summary, 7 children
responded to DLI:4/7 transient response(2 ALL,2 ANLL),3/7
durable response(1 ALL,2 ANLL);all developed GVHD. Median
follow up 1.8 years(Range 4 to 43 mths). Overall actuarial survival
:56± 17%. EFS at 2 years 22± 14%. This limited sample shows
cGVHD significantly affects EFS (p=0.02). The likelihood of
inducing remisson appears better for ANLL. More insight is
required to offer the benifit of GVL effect without inducing
GVHD morbidity.
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PHASE I DOSE ESCALATION STUDY OF MELPHALAN WITH IFOS-
FAMIDE, CARBOPLATINUM, AND ETOPOSIDE (MICE) WITH AUTOLO-
GOUS STEM CELL SUPPORT
Shaughnessy, P.; Ririe, D.; Ornstein, D. Wilford Hall Medical Center,
Lackland AFB, TX
High dose ifosfamide, carboplatinum, and etoposide have been
studied extensively and shown to be effective in a wide range of
malignancies. The addition of another alkylator in high doses may
potentiate the activity of this regimen. We devised a phase I dose
escalation study of melphalan in combination with ﬁxed doses of
ifosfamide, carboplatinum, and etoposide (MICE) followed by
autologous stem cell rescue. Six patients were entered on study, 4
males, with a median age of 26 (21-48) years. All patients had
failed standard therapy and had measurable disease. The median
number of infused CD34+ cells was 2.6 x 106/kg (0.8 -5.9x
106/kg). The preparative regimen consisted of Ifosfamide
14gm/m2 divided into 8 doses given IV bolus q 12 hours with
MESNA in equivalent doses given by CIV D-6 through D-3, car-
boplatinum AUC 6 IV bolus q day for 4 doses D-6 to D-3, and
etoposide 1600mg/m2 divided into 8 doses IV q 12 hours D-6 to
D-3. The ﬁrst dose level of melphalan was 60mg/m2 divided into
two equal doses on D-8 and D-7. All patients received only the
ﬁrst dose level of melphalan. One patient developed grade V lung
toxicity, although it was unclear if this was interstitial pnemonitis
or tumor progression, and another developed grade III renal fail-
ure with grade IV elevation of creatinine. Three patients have
died, all with tumor progression: 2 germ cell cancers and 1 soft
tissue sarcoma. Three patients survive: one with Ewings sarcoma
in CR, one with phyloides sarcoma and disease progression, and
one with small cell lung cancer that is too early to assess. In con-
clusion, we believe this regimen has excessive toxicity and do not
recommend its use at these dose levels. We plan to study a similar
combination of drugs with less ifosfamide and further dose escala-
tions of melphalan.
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INFECTIONS IN PATIENTS WITH HIGH RISK MALIGNANCIES UNDER-
GOING THERAPY WITH A NONMYELOABLATIVE REGIMEN FOL-
LOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION
Magalhaes-Silverman, M.; Hohl, R.; Lee, C.; Gingrich, R.D. Univer-
sity of Iowa, Iowa City, IA
Less intensive regimens followed by allogeneic stem cell trans-
plantation have been increasingly used. Few data are available
about infectious complications after these regimens. Here we
report our data on 12 patients (pts) with high risk malignancies
treated with fludarabine (25 mg/m2x3) doses and cyclophos-
phamide (750mg/m2x3 doses) followed by allogeneic peripheral
blood stem cell transplantation from HLA identical siblings. In
addition 4 pts received antithymocyte globulin at 30mg/kg x 3
doses. As GVHD prophylaxis 9 pts received cyclosporin (CSA)
and minidose methotrexate, 2 pts CSA and mycophenolate mofetil
and 1pt CSA and prednisone. CSA was given until day 60 then
tapered if no GVHD occured. All pts received low dose ampho-
tericin as antifungal prophylaxis, CMV and PCP prophylaxis.
There were 5 females and 7 males with a median age of 57 years
(range 31 to 67). Five pts had previous transplants (2 auto, 3 allo).
All pts were CMV positive with 10 of 12 donors also positive. G-
CSF mobilized blood stem cells were infused with a median of
5x106/Kg CD34+ and 2x108/Kg CD3+. Eleven pts engrafted with
a median time to ANC ≥0.5x109 /L of 11 days (range 6 to 13)and a
median time to platelet ≥20x109/L of 14 days (range 6 to 18). No
bacterial infections were diagnosed during the neutropenic period.
CMV reactivation was diagnosed in 8 pts, presumed aspergillus
infection in 1 pt and proven aspergillus in 2. Two pts developed
adenovirus enteritis and 1 HSV enteritis. The two pts developing
adenovirus enteritis were treated with cidafovir with resolution.
Seven pts had grade III-IV acute GVHD. Aspergillus infection
contributed to the death of 2 pts. In Summary: Although the num-
ber of pts in this series is small, a less intensive conditioning regi-
men does not lower the incidence of fungal or viral infections in




METACHROMATIC LEUKODYSTROPHY (MLD) TREATED WITH VUD
BMT. A NEW THERAPY FOR A PREVIOUSLY LETHAL DISORDER
Singh, H.; Scigliano, E.; Isola, L.; Richards, S.; Sivak, M.; Fruchtman,
S. Mount Sinai Medical Center, New York, NY
MLD is a lethal autosomal recessive disease, caused by the
inherited deficiency of arylsulphatase A. Deficiency of this
enzyme causes intralysosomal storage of the sphingolipid cere-
broside sulphate. Patients suffer from a progressive demyelina-
tion in both central and peripheral nervous system. The disease
is invariably fatal. BMT provides a method for permanently
replacing deficient enzyme activity. Microglia and astraglia are
derived from the newly engrafted marrow and corrects the
recipient’s enzyme deficiency. There is only one published
report of allogeneic related transplantation in an adult patient
with MLD. The patient had disease stabilization for 4 years,
but no improvement. We report a 22-year-old man who under-
went BMT for MLD. He presented with numbness of lower
extremities and paraparesis. Within 4 years, he developed
dysarthria and became wheelchair-bound. EMG studies showed
severe demyelinative neuropathy. MRI of the brain showed
bilateral symmetric white matter disease. The diagnosis of
MLD was confirmed by a low arylsulphatase A level in leuko-
cytes. He had no siblings but an HLA-matched unrelated donor
was identified through the NMDP. His conditioning regimen
included cyclophosphamide and 1500 cGY of TBI. He engraft-
ed and had 99.7% gender mismatched donor mononuclear cells
by day 23 on FISH analysis. He had normal leukocyte arylsul-
phatase A level by 3 months and a MRI done at 5 months
showed resolution of earlier white matter disease. EMG studies
showed improvement. His dysarthria resolved and he is walk-
ing. This report highlights the potential cure of this lethal dis-
order by repopulation the glial cells of the nervous system.
Reports in other storage diseases suggest limited benefit of
BMT, in the presence of neurological compromise. Our results
may be superior due to the use of an unrelated instead of a sib-
ling donor.
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HIGHER DOSE TOTAL BODY IRRADIATION WITH ALLOGENEIC BMT
FOR CHRONIC PHASE CML RESULTS IN LOW RELAPSE RATE
Singh, H.; Isola, L.; Richards, S.; Scigliano, E.; Fruchtman, S.M.
Mount Sinai Medical Center, New York, NY
The most common conditioning regimens for allogeneic BMT
in CML are TBI/CY or Bu/CY. Ideal doses of TBI have not been
determined. We describe 44 patients with CP-CML undergoing
sibling HLA−matched BMT using TBI and CY. Median age was
37 years (range, 12-63 years) with 61% males and 39% females.
Preparative regimen was TBI 1500 cGy, 10 fractions of 150 cGy
d−8 to −4, CY 60 mg/kg QD d−3 and −2. BMT was unmanipulat-
ed. GVHD prophylaxis included CSA or Tacrolimus and MTX.
Supportive care included gut decontamination, sterile LAF, flu-
conazole, acyclovir and PCP prophylaxis. No growth factor sup-
port was used. Median follow-up for this cohort is 603 days post-
BMT (range, 19-3657 days). Twenty-one transplants were
sex-mismatched. Median time to an ANC of 500/µL was 23.5 days
(range, 10-47 days), and to an ANC of 1000/µL, 26.5 days (range,
11-53 days). Median time to PLT >20,000/µL was 20 days (range,
10-47 days). Six patients died from infections and 5 from non-
infectious causes. Acute GVHD occurred in 13 patients with 1
death. Four pts (9%) relapsed, 2 received DLI and one a second
allogeneic transplantation. Overall transplant related mortality at
day 100 was 27%. Twenty-eight patients remain alive on days
247-3788 post-BMT. Kaplan-Meier estimates for EFS at 3 years
is 62±7%. Reported relapse rates post-HLA identical sibling
transplant for CML-CP range from 19% with 1,200 cGY dose
(Cliff et al, Blood, 77(8) 1991) to 30% with 1,000cGY of TBI
(Devergie et al., Blood 85(8) 1995). This data suggest that a high-
er dose of TBI (1500cGY) results in a lower relapse rate although
it results in signiﬁcant TRM.
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SALVAGE OF A TUNNELED CENTRAL VENOUS ACCESS CATHETER
WITH LONG TERM INTRAVENOUS LINEZOLID DESPITE VANCOMYCIN
RESISTANT ENTEROCOCCAL (VRE) SEPSIS
Stolar, K.; Salzman, D.; Lopez, R.; Vaughan, W. UAB at Birming-
ham, Birmingham, AL
Vancomycin-resistant enterococcus is an increasing problem in
hospitalized patients. Linezolid, a recently approved oxazolidi-
none, has demonstrated efﬁcacy in the treatment of VRE. Recom-
mended therapy generally includes the removal of any existing
indwelling catheters. We are reporting a case in which a tunneled
long-term central venous catheter was salvaged in an immunosup-
pressed BMT patient by administration of intravenous linezolid.
The patient is a 49-year-old woman approximately 250 days status
post-allogeneic−matched related-donor transplant for non-
Hodgkin’s lymphoma. Her transplant course has been complicat-
ed by extensive chronic graft versus host disease requiring signiﬁ-
cant doses of immunosuppressive medications. More recently, she
developed pulmonary nocardiosis and an inferior vena cava tun-
neled catheter was placed for IV trimethoprim/sulfamethoxazole
therapy. The inferior vena cava approach was her only option for
long term access because multiple prior central venous devices
limited catheter options. Approximately 1 month after line place-
ment, she presented to clinic for routine evaluation with general
malaise and a low grade fever. Blood cultures were drawn and van-
comycin-resistant Enterococcus faecium was isolated from two of
four blood cultures drawn from the catheter. Linezolid, 600 mg
IVPB every twelve hours for 30 days was administered to the
patient. Blood cultures drawn through the catheter ﬁve days after
the initiation of therapy were negative. She was discharged and
self-administered her remaining therapy as an outpatient. Blood
cutures remain negative two months after discontinuation of ther-
apy. Rectal swabs performed at 2 weeks and again at 2 months of
therapy were negative for VRE colonization. The central access
catheter is still in place and in intermittent use. In summary, while
removal of potentially contaminated venous access in the setting
of VRE is ideal, indwelling catheters may be salvaged with extend-
ed linezolid therapy.
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CULTURED DENDRITIC CELLS CAN PRIME POTENT CTL RESPONSES
TO A HER-2+VE BREAST CANCER CELL LINE
Syme, R.M.; Stewart, D.; Gluck, S. Tom Baker Cancer Centre/Uni-
versity of Calgary, Calgary, AB, Canada
Dendritic cells (DC) are potent antigen-presenting cells, which
are integral to the initiation of T-cell immunity. The ability to
culture these cells in vitro has allowed DC immunotherapy to be
investigated as a mechanism to enhance immune responses for a
variety of malignancies. We want to establish an immunotherapy
program for patients after high dose chemotherapy. This is the
time when a patient is likely to have minimal residual disease, and
when speciﬁcally targeted immune cells may eradicate remaining
cancer cells. We undertook the following study to determine if we
could induce CTL responses to breast cancer cells. Since many
patients with metastatic breast cancer overexpress the HER-2
protein we have employed a HER-2 +ve breast cancer cell line as
our antigen source. A sample of apheresis product was obtained at
the time of apheresis from consenting patients, or from discarded
frozen product. Dendritic cells were cultured from adherent
PBMC in the presence of IL-4 and GM-CSF. After 7 days, den-
dritic cells were harvested and pulsed with tumor lysate. After a
further 7 days, the primed cells were harvested, counted, and used
in an LDH-based cytotoxicity assay. We could generate cytotoxic-
ity (62-100%) at a high (10:1) effector (primed cells) to target cell
(SKBR3) ratio. However, cytotoxicity dropped off when the E:T
ratio fell to 5:1 (<15% cytotoxicity). By utilizing whole protein
instead of lysate we were able to obtain up to 100% (23-100%)
cytotoxicity at this lower E:T ratio of 5:1. Using total RNA
resulted in 24% cytotoxicity at an E:T ratio of 0.5:1. Experiments
are now focused on further purifying the antigenic source to
reduce the E:T ratio, while ensuring a high level of specificity.
Together this demonstrates that we can generate potent cytotoxic
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responses to HER-2+ve breast cancer cells. Further experiments
are underway .
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PREDICTIVE VALUE OF EARLY STUDIES OF IMMUNE RECONSTITU-
TION IN CHILDREN POST-UNRELATED CORD BLOOD TRANSPLANTS
ON INFECTIOUS COMPLICATIONS AND ACUTE GVHD
Szabolcs, P.; Park, K.; Reese, M.; DeOliveira, D.; Niedzwiecki, D.;
Kurtzberg, J. Duke University Medical Center, Durham, NC
Objectives: Opportunistic infections are the major cause of
death after transplantation with HLA-mismatched banked umbili-
cal cord blood. Almost 80% of these infections occur during the
first 100 days. We hypothesized that early studies of immune
function will identify patients at increased risk for infections and
those at risk for acute GVHD. Peripheral blood from 20 children
at a mean of 51.4 days post-transplant was studied by 4 color sur-
face-intracellular FACS and proliferation assays.
Results. All patients engrafted, and 14 of the 20 patients are
alive, with a mean survival of 305 days. Seven of the 20 patients
developed de novo opportunistic infections (6 viral, 1 fungal) and
12 developed grade II-IV aGVHD. Employing Spearman correla-
tion analysis, a signiﬁcant inverse correlation was found between
age and recovery of T cells (p=0.006) and CD4+ T cells
(p=0.0001). Unlike following bone marrow allografts, recipients of
cord blood reconstituted T cells with a dominant CD4+ pheno-
type (mean: 62%). However, only 7% of T cells had the pheno-
type of recent thymic emmigrants (CD45RA+/CD62L+). Mean
PHA count was 25,832CPM. There was significant correlation
between PHA responses and T cell (p=0.001) and CD4+ (p=0.007)
cell recovery. Lymphoid DCs (1.4/µL) and myeloid DCs
(16.4/µL) were detected. We found significantly lower (t-test)
CD3+ (p=0.04) and CD4+ (p=0.001) counts in patients with
opportunistic infections compared to ones without. Patients with
infections demonstrated an increase of T cells expressing TCRγδ,
CD8, and HLA-DR (p=0.001). The proportion of T cells secret-
ing Th1-type cytokine was signiﬁcantly elevated in patients with
GVHD measuring mean % IL-2 at 3.7% vs 20.3%, TNFα: 1.5%
vs 20.6%, IFNγ 2.5% vs 10.9% in the absence (n=6) vs presence
(n=5) of grade 3-4 aGVHD respectively.
Conclusion: This analysis suggests that early monitoring of
immune reconstitution will aid identiﬁcation of patients at risk for
development of opportunistic infections and acute GVHD.
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FACTORS AFFECTING NEUTROPHIL AND PLATELET RECONSTITUTION
FOLLOWING T-CELL−DEPLETED BONE MARROW TRANSPLANTA-
TION: DIFFERENTIAL EFFECTS OF GROWTH FACTOR TYPE AND ROLE
OF CD34+ CELL DOSE
Keever-Taylor, C.A.; Klein, J.P.; Eastwood, D.; Bredeson, C.; Casper,
J.T.; Burns, W.H.; Vesole, D.H. Medical College of Wisconsin, Mil-
waukee, WI
Univariate and multivariate analyses were performed to identify
the factors that affect the kinetics of neutrophil and platelet recov-
ery in 546 recipients of T-cell−depleted marrow allografts. Mar-
row was depleted of CD3+ cells by complement-mediated lysis
using T10B9 -1A3 (N=489) or Muromonab-Orthoclone OKT3
(N=57) mAb. Neutrophil engraftment to 0.5 x 109/L and platelet
engraftment to 20 x 109/L were assessed as endpoints. Factors sig-
niﬁcantly affecting neutrophil or platelet engraftment in the uni-
variate analysis included: patient age, T-cell dose, ATG, gender,
diagnosis, CMV serostatus, HLA mismatch, CD34 cell dose
(N=249), and growth factor use and type. These variables were
included in the multivariate Cox proportional hazards regression
model. The results showed that faster neutrophil engraftment was
independently associated with CD34+ cell dose ≥ 5 x 106/kg and
most strongly with growth factor. Faster platelet engraftment was
associated with transplant for chronic leukemia, CD34+ cell dose
≥ 2 x 106/kg, an HLA matched related donor, and the absence of
growth factor use. G-CSF had a higher relative risk (RR) of
enhancing neutrophil engraftment and in delaying platelet
engraftment than GM-CSF, and the combined use of G-CSF +
GM-CSF was similar to G-CSF alone. The enhancing effect of
G-CSF for neutrophil recovery was most striking for patients who
engrafted to 0.5 x 109/L ≤ day 12 (RR=9.5, p=<0.0001) compared
to patients who received no growth factor. Conversely, the delay-
ing effect of G-CSF on platelet engraftment was strongest for
patients engrafting ≤ 25 (RR=0.4, p=0.0004). Of the independent
variables affecting engraftment kinetics only growth factor and to
a limited extent, CD34+ cell dose can be controlled by the clini-
cian. A higher CD34+ cell dose enhances the rate of both neu-
trophil and platelet engraftment whereas the beneﬁts of myeloid
growth factor in enhancing neutrophil recovery may be partly off-
set by a delay in platelet engraftment.
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STRATEGY TO FACILITATE PROSPECTIVE STUDY DESIGN AND
CONDUCT
Van Hoef, M.E. Transplant Creations, L.C., Falls Church, VA
Introduction: The quality of protocol design, selection of study
methods and data collection process may inﬂuence the interest in
and commitment to participation in prospective clinical studies.
Methods: Protocol design should start with identification of
established prognostic factors and treatment procedures. A data
analysis plan listing factors that define patient, treatment, graft,
donor and outcome parameters should subsequently be drafted.
Definition of primary and secondary outcome parameters is
mandatory. Study objectives should in ﬁrst instance reﬂect evalua-
tion of safety and efficacy of the treatment/product that will be
tested and should address outcome parameters. Selection of estab-
lished treatment procedures in the study design to support evalua-
tion of the therapy to be tested will facilitate study conduct. Lim-
ited data collection focussing on baseline patient characteristics,
potentially prognostic factors, major complications, outcome
parameters and on checking whether the study procedure was pur-
sued in accordance with protocol should be sufﬁcient to analyse
the results of the study, to answer questions posed in the objec-
tives and to identify new prognostic factors.
Presentation: Explanation of the study objectives, study design,
study procedures and the data collection process will largely
enhance comprehension of the study and will invite participation.
Clear oral communication is important to create correct under-
standing. The author will present this approach from educational
perspective.
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EX VIVO TREATMENT OF ALLOGENEIC LYMPHOCYTES WITH L-
LEUCYL-L-LEUCINE METHYL ESTER PREVENTS GRAFT-VERSUS-HOST
DISEASE IN HAPLOIDENTICAL MURINE MODEL
Varadi, G.; Hsieh, M.H.; Flomenberg, N.; Korngold, R. Jefferson Med-
ical College, Philadelphia, PA
L-leucyl-L-leucine methyl ester (LLME) is a lysosomotropic
agent that is taken up by cells through a saturable facilitated trans-
port mechanism. Once intracellular, LLME is converted to pro-
apoptotic (Leu-Leu)-OME metabolites through the acyl-trans-
ferase activity of dipeptydil-peptidase I (DPPI). LLME induces
programmed cell death of DPPI-expressing NK cells, monocytes,
granulocytes, the majority of CD8+ T cells, and a fraction of
CD4+ T cells. Graft-versus-host disease (GVHD), a major com-
plication of allogeneic hematopoietic stem cell transplantation, is
mediated by contaminating donor T cells present in the transplant
inoculum, which can also be beneﬁcial in enhancing engraftment,
in prevention of opportunistic infections, and in combating
leukemic relapse. Delayed lymphocyte infusion (DLI) was imple-
mented in an effort to balance some of these risk factors. In clini-
cal trials, while DLI was quite effective in treating leukemic
relapse, approximately one third of the patients still developed
severe GVHD. LLME has been previously shown to prevent
GVHD in animal conventional transplant models. In this study,
we sought to investigate the use of LLME in DLI in a haploiden-
tical murine model. LLME treated T cells were given as DLI two
weeks after hematopoietic stem cell transplantation. The LLME
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treated DLI resulted in reduced occurrence and severity of
GVHD while maintaining a signiﬁcant level of antileukemic activ-
ity. In an effort to further promote engraftment, antileukemic
responses and reduce the length of the immunosuppression while
preventing GVHD we transplanted the LLME treated lympho-
cytes together with the stem cells. The results clearly demonstrat-
ed that mice transplanted with LLME treated lymphocytes had a
100% survival as compared to those mice that received non
LLME treated lymphocytes. Transplantation of LLME treated
lymphocytes with stem cells can potentially provide a more target-
ed approach for preserving antileukemic activity and helping to
stabilize engraftment while reducing the occurrence of GVHD.
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DONOR CONDITIONING TO REDUCE RISK OF ACUTE GRAFT VERSUS
HOST DISEASE (AGVHD) USING PERIPHERAL BLOOD STEM CELLS
(PBSC) FOR MATCHED RELATED DONOR (MRD) ALLOGENEIC BONE
MARROW TRANSPLANTATION (ALLOBMT)
Vaughan, W.; Katz, R.; Salzman, D.; Tilden, A.; Lopez, R.; Carabasi,
M. U of AL at Birmingham, Birmingham, AL
From 2/98 through 5/00 59 adults (age 22-64, median 47) had
MRD alloBMT for malignant diseases using PBSC. GVHD pro-
phylaxis was CSA/Mtx with CSA/methylprednisolone substituted
for renal dysfunction (N=8). Donors received 10-16 µGm/Kg of
G-CSF for 4-5 days then large volume leukopheresis. Thirty-one
control patients conditioned with BuCy(2) or BuCyVP (7/31) plus
ATG received PBSC depleted of T-cells ex vivo using the CellPro
device. Twenty-eight patients conditioned with BuFludara (cohort
II) received PBSC not ex vivo T-cell depleted but from donors
given dexamethasone 10 mg/M2/dX3 beginning 2 days prior to
the collection in addition to the G-CSF. Distribution of age, diag-
nosis, GVHD prophylaxis, and time to ANC > 500/µL were simi-
lar. Six controls and 4 cohort II patients were inevaluable for
AGVHD due to early death (4) or withdrawal of GVHD prophy-
laxis to treat relapse (6). Controls received 2.2 to 23.4X105 (med -
7.4) CD3+ cells/Kg and cohort II received 6.3 to 70.8X107 (med -
24.5) CD3+ cells/Kg. Controls received 1.0 to 11.9X106 (med -
5.7) CD34+ cells/Kg, cohort II received 3.6 to 27.5X106 (med -
11.0) CD34+ cells/Kg. Within cohorts there was no correlation
between number of CD3+ cells infused and AGVHD nor between
the number of CD34+ cells infused and time to ANC > 500/µL.
Overall grade 2+ AGVHD occurred in 6 of 25 (24%) evaluable
controls and 7 of 24 (29%) evaluable cohort II patients. Two
patients in cohort II died of grade IV AGVHD. In this study the
AGVHD incidence and severity using dexamethasone-treated
PBSC donors and a BuFludara preparative regimen was only
slightly greater than that achieved with BuCy conditioning and ex
vivo T-cell depleted PBSC despite 300 times the CD3 cell dose.
The less toxic preparative regimen, removal of alloreactive T-cells
by dexamethasone, and/or the higher CD34 cell dose may explain
this result.
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VALIDATION OF A LIMITED SAMPLING STRATEGY (LSS) FOR PHAR-
MACOKINETICALLY DIRECTED DOSING OF HIGH-DOSE INTRA-
VENOUS BUSULFAN (BUSULFEX) IN BMT PREPARATIVE REGIMENS
Vaughan, W.; Carey, D.; Salzman, D.; Soong, S. Univ of AL at Birm-
ingham, Birmingham, AL
Variation in the area under the concentration/time curve (AUC)
for oral busulfan results in a substantial risk of over or under treat-
ment with excess risk of toxicity or relapse. Busulfex use reduces
this variability by eliminating variability in absorption. Variability
due to drug metabolism remains, but simpliﬁed pharmacokinetic
study may be employed to achieve a speciﬁc target AUC. Conven-
tional sampling strategies for determining AUC after oral admin-
istration use 12 samples over six hours to assure accurate tracking
of erratic absorption. With Busulfex there is no necessity for
drawing plasma levels during the infusion since busulfan pharma-
cokinetics are well described by single compartment, 1st order
elimination models. This eliminates the requirement for a second
iv access to avoid error due to contamination of the sample with
drug. In theory, only peak and trough levels should be necessary,
but to assure reliability for clinical decision-making, outlier values
must be able to be identiﬁed. This requires at least four samples.
We collected 11 samples from 13 adult patients and compared the
AUCs obtained using all samples versus only the 5 samples col-
lected hourly after the end of the infusion. The mean AUC calcu-
lation was 5% higher (1002 vs 956 µM-min) when only the small-
er number of post infusion samples were used and the CV was
substantially better (4.6% vs 8.2%). We now have used 5 sample
data to dose over 40 patients. To further validate this approach we
will present an analysis of pharmacokinetic data from 98 patients
in the Busulfex pivotal clinical trials. The AUCs based on all 11
samples from each patient will be compared to the AUC based on
the 5 post infusion samples. We predict this will conﬁrm compa-
rable reliability, and possibly superior accuracy, of Busulfex AUC
determination using 5-sample versus 11-sample testing while
reducing laboratory and nursing costs.
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DECREASED INCIDENCE OF CMV VIREMIA AFTER ALLOGENEIC
PERIPHERAL BLOOD STEM CELL TRANSPLANTS
Verma, A.; Morrow, M.; Devine, S.; Stevens, J.; Pursell, K.; Mihalov,
M.; Janda, W.; Peace, D.; Chen, Y.; Van Besien, K. University of Illi-
nois at Chicago, Chicago, IL
CMV infection can be detected by PCR, antigen-based or culture
methods. Using sensitive PCR, CMV viremia can be detected in up
to 60% of Bone marrow transplant recipients by day 100 and in up to
75% when CMV seronegative donor-recipient pairs (CMV-/-) are
excluded (Einsele et al Blood86:2815,1995). We evaluated the inci-
dence of CMV viremia in 52 consecutive allogeneic stem cell trans-
plant recipients using a sensitive PCR (8 CMV-/- patients were not
included). 17 patients (pts) had lymphoma, 28 had leukemia, 2 had
MDS, 2 had myeloﬁbrosis, 1 had aplastic anemia and 2 pts had sickle
cell disease. The median age was 46 (14-64). 48 patients received
unmanipulated stem cells from a matched sibling, 3 from a matched
unrelated donor and 1 received T-depleted stem cells from a haplo-
identical relative. Conditioning consisted of Fludarabine/thiotepa/
TBI in 26 pts, BEAM in 14, Cy/TBI in 2 and ﬂudarabine/melphalan
in 18 patients ( haplo-identical transplants and sickle cell patients also
received ATG 40 mg/kg). GVHD prophylaxis consisted of
tacrolimus and mini-methotrexate. No prophylactic ganciclovir was
given, but CMV viremia was treated with ganciclovir BID. No cases
of CMV pneumonia occurred, and the cumulative incidence of CMV
viremia was 35% ± 14% by day 100 and 38% ±15% by day 150.
Donor type, underlying disorder (leukemia vs lymphoma) and previ-
ous transplant were not associated with the risk for CMV viremia.
The cumulative risk for CMV viremia by day 150 was 62% ± 25% in
those receiving ﬂudarabine/melphalan conditioning vs 27 ± 16% in
pts receiving myeloablative regimens (P=0.019). In conclusion, the
risk for CMV viremia after allogeneic PBSCT is considerably lower
than after allo BMT. This may be related to more rapid immune
reconstitution. Surprisingly, the risk for CMV viremia appears high-
er after non-myeloablative ﬂudarabine/melphalan conditioning. This
may indicate more profound immunosuppresion.
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AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS CAN BE
SUCCESSFULLY TREATED USING LOW INTENSITY CONDITIONING
WITH FLUDARABINE AND MELPHALAN FOLLOWED BY ALLOGENEIC
STEM CELL TRANSPLANTATION
Verma, A.; Morrow, M.; Jessop, E.; Desai, R.; Huml, M.; Van Besien,
K.; Devine, S. University of Illinois at Chicago, Chicago, IL
Agnogenic myeloid metaplasia (AMM) with myelofibrosis is a
clonal hematopoietic disorder for which an allogeneic
hematopoietic stem cell (HSC) transplant is potentially curative.
Given the advanced age of most patients (pts) at diagnosis as
well as the indolent nature of the disease in some, many pts are
not considered candidates for standard myeloablative condition-
ing due to the anticipated toxicities. Here we report a series of
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four consecutive pts at our institution with AMM who received
an allogeneic HSC transplant following a low intensity regimen
consisting of fludarabine (F) and melphalan (M). All pts had
intermediate (N=3) or high (N=1) risk disease based on the crite-
ria of Dupriez (Blood 88:1013, 1996). The median age was 56
years (range 48-58). Conditioning consisted of F (25mg/m2 IV
on days -6 to -2) and M (70mg/m2 IV on days -3 and -2). All pts
received G-CSF mobilized peripheral blood stem cells from
HLA-identical siblings on day 0. The median CD34+ cell dose
was 5.9 x 106/kg. All pts engrafted, achieving an ANC>1,000/µL
on day +16 (range 12-20) and unsupported platelet count
>20,000/µL on day +14 (range 11-28). All have achieved red
blood cell transfusion independence. No pts experienced > grade
2 toxicity according to the criteria of Bearman. No pts devel-
oped grade II-IV acute GVHD. One of three evaluable pts has
developed limited chronic GVHD. With a median follow-up of
140 days (range 60-320), all pts survive with a Karnofsky per-
formance status of 100%, have achieved stable full donor
chimerism, and have experienced documented regression of mar-
row fibrosis and splenomegaly. Although follow-up is short,these
data are encouraging and suggest that a fludarabine and melpha-
lan based conditioning regimen is relatively non-toxic yet pro-
motes full donor chimerism in these pts. This regimen may
expand the application of allogeneic HSC transplantation to
older pts with AMM.
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CD8+ T CELLS CONTROL THE EXPANSION OF γ/δ+ T CELLS
Verneris, M.R.; Arshi, A.; Edinger, M.; Kornacker, M.; Baker, J.;
Negrin, R.S. Stanford University, Stanford, CA
Using both murine and human sources (spleen, blood, BM,
cord blood) we have previously reported conditions for the prop-
agation of large numbers of CD3+CD8+TCRα/β+ T cells which
co-express NK cell markers and mediate antitumor activity. Such
cells are generated by the timed addition of IFN-γ, α-CD3 and
IL-2 followed by 14-21 days of culture. To investigate the role of
the CD8 molecule in the recognition of tumor cells, we used
splenocytes derived from CD8-/- mice and found that signiﬁcant
numbers of CD3+CD4-CD8-TCRγ/δ+ cells expanded (>300X
expansion, ~100 x106/spleen). The expanded γ/δ T cells are mor-
phologically large, heavily granulated, with foamy cytoplasm.
They secrete signiﬁcant quantities of IFN-γ, little TNF-α and no
IL-4 or IL-10. Expanded γ/δ T cells mediate cytotoxicity against
a variety of both syngeneic and allogeneic tumor cell lines. To
conﬁrm the role of CD8+ cells in the inhibition of γ/δ T cells, we
performed similar studies using splenocytes derived from either
C57BL/6 or DBA mice. Depletion of CD8+ T cells led to the
expansion of large numbers of γ/δ T cells, indicating that CD8+ T
cells influence the homeostasis of γ/δ T cells. To establish
whether CD8+ cells inhibit γ/δ T cells through soluble mediators
or cell surface molecules, transwell experiments were performed.
These experiments showed that direct cell-to-cell contact is nec-
essary for inhibition. Given this, we investigated whether the
cytotoxic molecules FasL or perforin were responsible for CD8+
mediated suppression of γ/δ T cells. Using purified CD8+ cells
derived from gld or pfp mice, we found that neither molecule was
involved in the inhibition of γ/δ T cell growth. Taken together,
these results show that large numbers of ex vivo expanded γ/δ T
cells can be readily generated and that CD8+ T cells control the
expansion of γ/δ T cells through direct cellular interaction.
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A RANDOMISED, PROSPECTIVE COMPARISON OF ALLOGENEIC BONE
MARROW AND PERIPHERAL BLOOD PROGENITOR CELL TRANSPLAN-
TATION IN THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES
Vigorito, A.C.; Marques, J.F.; Aranha, F.J.; Eid, K.A.; Azevedo,
W.M.; Oliveira, G.B.; Correa, M.E.; Reis, A.R.; Miranda, E.C.; De
Souza, C.A. State University of Campinas, Sao Paulo, Brazil
We present the results of a prospective, randomised study com-
paring PBPC and BM focusing on engraftment, acute and chron-
ic GVHD and survival. Sixty patients with haematological malig-
nancies received HLA-identical sibling BM (group A) or PBPC
(group B). Evaluable patients were 29 (A) and 27 (B). Median age
was 36 (17-59) in A and 29.9 (7-51.5) in B. Conditioning regimen
was mainly Bu-Cy2; GVHD prophylaxis was CSA-MTX. PBPC
were harvested after 5 days of G-CSF 10mg/Kg/d. Median of
infused CD34+ cells were 3.96x106 /kg (1.19-17.55) and 5.12
x106/kg (1.25-71.61) for groups A and B, respectively (P=0.32).
Median of days for an ANC >0.5 x109 /L was 18 (13-30) in A and
15 (11-25) in B (P=0.02). Platelets >20 x109 /L occurred at +18
(10-40) in A and +12 (7-36) in B (P=0.001). Median days for dis-
charge were 27 (18-69) and 21 (16-42) for groups A and B,
respectively (P=0.01)The probability of ≥2 grade a-GVHD was
23% (A) and 26% (B) (P=0.53). The probability of extensive c-
GVHD was 61% and 77% in A and B, respectively (P= 0.05), fur-
thermore, all patientes in the PBPC group developed extensive
disease, while 6/11 (54.5%) in the BM group (P= 0.01). The esti-
mates of overall survival for A and B at 2000 days are 48% and
56% respectively (P=0.67); DFS at 2000 days are 50% and 60%
respectively (P=0.47). PBPC resulted in faster neutrophils and
platelets engraftment. The acute GVHD was similar in both
groups, but the severity of c-GVHD was higher with PBPC. No
differences in survival and DFS have been observed so far.
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HIGH RELATIVE RESPONSE OF MIXED LYMPHOCYTE CULTURE CAN
PREDICT CHRONIC GRAFT-VERSUS-HOST DISEASE IN HLA-IDENTICAL
SIBLING BMT
Vigorito, A.C.1; Visentainer, J.E.1,2; Lieber, S.R.1; Batista, S.C.1; Per-
soli, L.B.1; Aranha, F.J.1; Eid, K.A.1; Oliveira, G.B.1; Miranda, E.C.1;
De Souza, C.A.1 1. State University of Campinas, Sao Paulo, Brazil; 2.
State University of Maringa, Parana, Brazil
The purpose of this study was the evaluation the mixed leuko-
cyte culture (MLC) as an assay predictive of GVHD. From Sep-
tember 1993 to November 1999, 153 patients, 97 males, 56
females, median age 29 (3-59) years, were undergone BMT from
HLA-identical siblings. Acute-GVHD was observed in 26 of 128
(20.3%) and chronic GVHD in 54 of 114 (47.4%) evaluable
patients. For the analysis, one-way MLC assays were performed
by standard method. Results of MLC were expressed using the
relative response (RR) from donor against patient and ranged
from -47.0 to 40.7% (median 0.50%). The probability of develop-
ing GVHD was determined for patients with positive and nega-
tive MLC. There was not significant difference in incidence of
acute GVHD between the analysed groups. However, the inci-
dence of chronic GVHD was higher in recipients with RR≥4.5%
than in those with RR<4.5% (p= 0.0055). Using Cox proportional
hazards model, the relative risk of chronic GVHD for patients
with positive MLC (RR≥4.5%) was 2.54 (p=0.0019); for those
who received PBPC as grafting was 2.92 (p=0.0002) and for
patients who developed previous acute GVHD the risk was 2.27
(p=0.0361). When continuous RR values had been used, the rela-
tive risk of chronic GVHD increased 1.04 to each unit of RR
(p=0.0049); for those who received PBPC the risk was 2.56
(p=0.0011) and for patients who developed previous acute GVHD
the risk was 2.27 (p=0.0370). Our analysis showed that MLC was
not useful to predict acute GVHD, but MLC with RR≥4.5%
should be considered as a risk factor of chronic GVHD for HLA-
identical sibling recipients. Thus, MLC reactivity associated to
others risk factors can predict the development of chronic
GVHD, helping in the prevention and/or treatment of this late
complication of allogeneic BMT.
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VALACYCLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS
INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTAION: A
RETROSPECTIVE COHORT ANALYSIS
Vusirikala, M.; Morgan, D.S.; Wolff, S.N.; Stein, R.S.; Brandt, S.J.;
Greer, J.P.; Dummer, S.J.; Scheuning, F.G.; Goodman, S.A. Vander-
bilt University Medical Center, Nashville, TN
Cytomegalovirus (CMV) infection (reactivation) is frequently
encountered after allogeneic stem cell transplantation (SCT)
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and is associated with significant post-transplant morbidity and
mortality. Recent large prospective randomized studies using
Valacyclovir for the prevention of CMV infection in renal
transplant and AIDS patients have shown efficacy and safety.
The benefit of this approach of CMV prophylaxis has not been
reported in allogeneic SCT recipients. We hypothesized that
Valacyclovir may be useful in the prevention of CMV infection
after allogeneic SCT and performed a retrospective single cen-
ter study was to evaluate our treatment approach. We compared
a group of 31 patients who received Valacyclovir for CMV pro-
phylaxis with a matched cohort of 31 patients who did not
receive the drug or any other form of CMV prophylaxis. Vala-
cyclovir was used as primary prophylaxis in 12 patients and as
secondary prophylaxis (after a prior CMV reactivation was
effectively treated with either Ganciclovir or Foscarnet and
without CMV antigenemia at the start of Valacyclovir) in the
remaining 19 patients. The two treatment groups were well
matched for donor-recipient CMV serological-status and other
pre-transplant characteristics. No patients died within the first
100 days of transplant. CMV reactivation was detected by blood
antigenemia testing using a commercially available immuno-
flourescence assay for CMV early antigen pp65 on circulating
leukocytes. When used as primary prophylaxis, 3/12 Valacy-
clovir patients had CMV reactivation compared to 24/31 con-
trol patients (P < 0.001). For secondary prophylaxis, 5/19 Vala-
cyclovir patients reactivated compared to 16/24 control patients
(P < 0.05). Valacyclovir was well tolerated except for infrequent
and mild gastrointestinal side effects. Prophylaxis with Valacy-
clovir appears to be safe and efficacious in preventing both pri-
mary and secondary CMV reactivation after allogeneic SCT.
Larger prospective randomized studies will be required to con-
firm these observations.
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NON-MYELOSUPPRESSIVE “MICRO-CONDITIONING” INDUCES ORGAN
TRANSPLANT TOLERANCE AND CORRECTS HEMOGLOBINOPATHIES
Waller, E.K.; Adams, A.B.; Durham, M.M.; McKean, L.; Rees, P.;
Bingaman, A.W.; Middlesteadt, S.; Archer, D.; Pearson, T.C.; Larsen,
C.P. Emory University, Atlanta, GA
Stable donor hematopoietic chimerism eliminates the need for
chronic immunosuppressive therapy following organ transplan-
tation. Current experimental protocols to establish mixed
chimerism employ myelosuppressive conditioning or very large
“mega” doses of donor bone marrow. Using a single, low dose
of busulfan, costimulatory blockade (CB, anti-CD40L mAb and
CTLA4-Ig), and T-cell depleted bone marrow (TCD BM)
transplantation, we have created “costimulation chimeras” that
exhibit robust donor-specific tri-lineage tolerance (T, B, and
NK cells). Animals treated with busulfan doses of 20 mg/kg or
lower had no evidence of weight loss, hematopoietic toxicity,
GvHD, or other signs of ill health. The percentage of donor
cells in the peripheral blood on day +120 post-transplant among
allogeneic recipients treated with 20 mg/kg busulfan and corre-
lated directly with the engrafting dose of TCD BM (2x107 →
65%, 1x107 → 57%, 5x106 → 37%, 2x106 → 26%), and were
equivalent to the chimerism seen among mice receiving con-
genic TCD BM transplants following busulfan conditioning.
Co-stimulation chimeras had long-term (>250 days) acceptance
of skin allografts from the BM donor while rejecting third party
grafts. Thalassemic mice that received allogeneic transplanta-
tion after “micro-conditioning” showed normalization of ane-
mia and reticulocytosis without evident toxicity. The peripheral
blood of costimulation chimeras showed increasing numbers of
donor derived T-cells over time and deletion of the donor
superantigen reactive Vβ11+ and Vβ5+ CD4+ T cells by day 60.
Costimulation chimeras deleted Ly-49D+ NK cells that are
reactive towards the (donor) but not the b (host) haplotype.
Control groups (CB or TCD BM or busulfan alone) failed to
delete donor reactive Vβ11+ or Vβ5+CD4+ T cells or Ly-49D+
NK cells supporting both peripheral as well as thymic deletion
as a mechanisms for donor specific allograft tolerance.
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IL-17 INCREASES THE ENGRAFTMENT POTENTIAL OF HIGHLY PURI-
FIED CD34+ CELLS ON INDIVIDUAL STROMAL CELL COLONIES
Weiner, R.1; Alzobie, A.1; Schwartzenberger, P.2; Miller, A.1; Safah,
H.1; Rozans, M.1; Scher, C.1; Warrier, R.2; Kohls, J.2; La Russa, V.F.1
1. Tulane University Cancer Center, New Orleans, LA; 2. Louisiana
State University, Gene Therapy, New Orleans, LA
IL-17 is a novel cytokine produced by CD4+ T-cells and is
beleived to facilitate lympho-hematopoietic stem cell engraftment.
The number of blast cell colonies consisting of more than 50
blasts strongly adherent and nested to an individual stromal cell
colony was used to measure the engrfatment potential of highly
purified early hematopoietic CD34+ cells. Stromal-adherent
CFU-BLAST derived colonies were measured at weekly intervals
for 4 weeks post seeding of 1,500 puriﬁed (>95%)CD34+ cells per
individual stromal cell colony. The number (M+/-SEM)blast cell
nests of CD34+ cells were assessed on both pure fibroblast-like
stromal cell colonies, CFU-F derived and mixed stromal cell
colonies consisting of ﬁbroblast-like cells and adipocytes, believed
to be derived from multipotential stromal progenitors,CFU-FA.
Frequency of Blast cell colonies continuously increased similarly
per CFU-F or CFU-FA from week 1=1+/-0.3, week 2=2+/-0.5,
weeek 3=3+/-0.5, and week 4=3+/-0.4. In contrast, frequency of
blast cell colonies was significantly higher with IL-17: CFU-
BLAST/CFU-F at week 2=2+/-0.3, week 3=5+/-0.4,and week
4=5+/-0.6, and CFU-BLAST/CFU-FA at week 1=2+/-0.2 week
2=5+/-0.4, week 3=5+/-0.5, and week 4=6+/-0.3; (p=0.03 com-
pared to control). IL-17 expanded CFU-BLAST colonization of
CFU-F derived stromal cell colonies by 5X, and CFU-FA by 6X
after 4 weeks post seeding of 1,500 CD34+ cells. However, cumu-
lative production of CFU-BLASTS on both CFU-F and CFU-FA
were similar in contriol cultures; 8 CFU-BLASTS/CFUF or
CFU-FA. While IL-17 enhanced cumulative production to 13
CFU-BLAST/CFU-F(1.5X increase) and 17 CFU-BLAST/CFU-
FA (>2X increase). The engraftment potential indirectly measured
by frequency of CFU-BLASTS increased from 0.1% to 2.0%
when seeded on individual stromal cell colonies.
These data indicate that IL-17 enhances the engrfatment poten-
tial of early CD34+ cells. These data suggest that IL-17 may facil-
itate engraftment by targeting mesenchymal/stromal progenitor
derived “niches” to stimulate local expansion of early CD34+
hematopoietic stem cells.
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OUTCOME OF CHILDREN WHO UNDERGO STEM CELL TRANSPLAN-
TATION (SCT) FOR “LATE RELAPSE” OF ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL)
Weinstein, J.; Duerst, R.E.; Haut, P.; Venkateswaran, L.; Kletzel, M.
Children’s Memorial Hospital, Chicago, IL
Late relapse of ALL in childhood, defined as relapse > 24
months from diagnosis is uncommon, but has been treated tradi-
tionally with intensive conventional chemotherapy. We report our
experience for 12 patients (5M, 7F), with late relapse of ALL, who
underwent SCT in CR2 rather than further conventional
chemotherapy. Average age at diagnosis was 7.1 yrs (2-19, median
5) and at the time of SCT was 11 yrs (4.9-24, median 9.3) with
CR1 duration of 41 mo (28-57, median 38). Stem cell sources
were matched siblings (n=8), autologous peripheral blood cells
(n=2), unrelated umbilical cord blood cells (n=1) and a syngeneic
twin (n=1). The cytoreduction regimen was comprised of fraction-
ated total body irradiation (150 x 8 = 1200 cGy), etoposide (1000
mg/m2 infused over 24 hr) and cyclophosphamide (60 mg/kg x3).
Supportive care included G-CSF in 8 and GM-CSF in one
patient.
All patients engrafted with median time to an ANC > 500/ul of
14 days (10-52) and median time to an unsupported platelet count
of 20,000/ul of 28 days (13-168). Toxicities included febrile neu-
tropenia (n=10), bacteremia (n=1), acute graft-vs-host disease
(GVHD), (Grade II, n=1, Grade III, n=2). Mucositis was present
in all patients: Grade I, n=4; Grade II, n=6 and Grade III, n=2).
Multi-organ system failure was fatal in one patient. Three other
patients died from complications of aspergillus pneumonia (1),
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sepsis (1) and combined marrow and CNS recurrence (1). Event-
free-survival, with median follow-up of 33 mo (2-94) is 67%. We
conclude SCT is an effective form of therapy for ALL patients
suffering a “late relapse” of their disease. Additional follow-up will
be required to conﬁrm the efﬁcacy of this approach for consolidat-
ing a second remission of childhood ALL.
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IL-12 EXHIBITS DIVERSE ROLES IN ACUTE GVHD
Welniak, L.A.1; Blazar, B.R.2; Murphy, W.J.3 1. NCI-Frederick,
Frederick, MD; 2. University of Minnesota Cancer Center, Minneapo-
lis, MN; 3. SAIC-Frederick, Frederick, MD
Graft-versus-host disease (GVHD) remains a significant
cause of morbidity following allogeneic bone marrow trans-
plantation (BMT). The role of endogenous IL-12 is compli-
cated by the production of two separate biologically active
molecules from the subunits that comprise IL-12. IL-12 exists
as a heterodimer consisting of p35 and p40 chains, p40
homodimer has been reported to be an antagonist for the het-
erodimer. IL-12 knockout (KO) mice of either p35 or p40
chains were used as either donors and/or recipients in an allo-
geneic (total MHC mismatch) bone marrow transplant model
of GVHD. The p35 KO mouse can produce the p40 homod-
imer whereas the p40 KO mouse lacks both IL-12 and p40
homodimer. When IL-12 p35 KO mice were used as recipi-
ents, they succumbed quicker from acute GVHD (as deter-
mined by survival, weight loss, and histological assessment)
whereas the IL-12 p40 KO recipients demonstrated some pro-
tection from GVHD compared to control wild-type mice
recipients. Despite the absence of donor and recipient sources
of IL-12 in p35 KO recipients, serum IFN-γ was significantly
higher in p35KO recipients compared to IL-12 wild type
recipients on day 3 post-BMT. These results demonstrate that
the p40 homodimer in the p35 KO mice accelerates GVHD
whereas the total absence of IL-12 is mildly protective. The
results suggest that IL-12 heterodimer may have both
immuno-suppressive and immuno-stimulatory properties in
this murine model of acute GVHD.
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AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH
ACUTE MYELOGENOUS LEUKEMIA IN FIRST COMPLETE REMISSION
Zinke-Cerwenka, W.; Sormann, S.; Eibl, M.; Neumeister, P.;
Linkesch, W. Karl-Franzens University, Graz, Austria
Background: Early autologous stem cell transplantation (ASCT)
in patients with acute myelogenous leukemia (AML) is increasing-
ly used as post remission therapy in the last years.
Patients and methods: Seventeen patients (7 male, 10 female,
age: 18-69) were treated with idarubicin (12 mg/m2, d1-3), cyto-
sine arabinoside (200 mg/m2,d1-5) as induction and cytosine ara-
binoside (2000mg/m2, twice a day, d1-3), mitoxantrone (5
mg/m2,twice a day, d1-3)as continuous infusion for consolidation
therapy. The stem cell harvest was performed after the ﬁrst or sec-
ond consolidation therapy under stimulation with G-CSF starting
on day +7. The median CD34+ count was 6.1 x 106 cells/kg BW
(range 3.2-23). The mean time from diagnosis to ASCT was 6
(range: 4-12) months. Conditioning regimen consisted of fTBI (6
x 2 Gray) and cyclophosphamide (2 x 60 mg/kg BW).
Results: The median time to engraftment (ANC > 0.5 x 109 /L)
was on day +12. After a mean observation time of 21 months the 4
years probability of relapse-free survival (Kaplan-Meier) is 61%.
We conclude that early ASCT in first complete remission is an
effective treatment.
